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This thesis focussed on the immunobiology of colorectal cancer (CRC).  It explored 
the role of the γδ T cell ligand Endothelial Protein C Receptor (EPCR) in 
tumourigenesis, and subsequently characterised the relationship between           
intra-tumoural immunity and tumour genetics. In silico analyses and 
immunohistochemistry indicated EPCR was commonly overexpressed in epithelial 
cancers including CRC.  EPCR was upregulated due to gene amplification and DNA 
hypomethylation alongside neighbouring genes on chromosome 20q, a region 
previously implicated in tumourigenesis. These results clarify why EPCR is 
upregulated in diverse epithelial malignancies, with implications for EPCR-focussed 
clinical studies and understanding of γδ T cell immunity. 
TCGA analyses revealed that a novel immune signature, termed The Co-ordinate 
Immune Response Cluster (CIRC), comprising 28 genes, was co-ordinately regulated 
across CRC patients.  Four patient subgroups were delineated based on CIRC 
expression.  Microsatellite instability and POLE/POLD1 mutations were associated 
with high mutational burden and immune infiltration.  Immune checkpoint molecules 
were highly co-ordinated in expression.  RAS mutation was associated with lower 
CIRC expression. Further analyses revealed that RAS-associated 
immunosuppression was greatest in the most immunosuppressed transcriptional 
subtype, CMS2. These findings have implications for design of stratified 
immunotherapy approaches and highlight factors contributing to the particularly poor 
outcome of RAS mutant CRC. 
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1.1  Introduction 
This thesis explores the immunobiology of colorectal cancer (CRC).  CRC is the 
fourth commonest cancer in the UK and the second largest cause of cancer-related 
death [1].  Though there has been an increase in survival over the last 30 years, 5 
year survival for metastatic (stage IV) disease remains as low as 12% [2].  It 
therefore represents a significant challenge for both healthcare systems and for the 
research community.   
 
1.1.1 Colorectal Cancer Development 
CRC development follows a well characterised progression from normal colonic 
mucosa to adenoma to carcinoma, with known molecular aberrations responsible for 
each step (Figure 1.1).  This paradigm was first proposed by Fearon and Vogelstein 
[3].  
 
Mutation in the Adenomatous Polyposis Coli (APColi) gene is a key early step in 
CRC development [4].  This gene is crucial in the degradation of β-catenin, which is a 
component of the Wnt signalling pathway.  Wnts produced by stromal cells maintain 
the proliferating undifferentiated stem cell population at the base of colonic crypts 
(the functional subunits of the colon).  As stem cells migrate up the crypt, they 
receive fewer Wnt signals and therefore differentiate, cease proliferating and 
eventually apoptose.   Following APColi mutation, β-catenin levels remain high even 
in the absence of Wnt signalling, due to the decrease in its degradation.  Therefore 
cells with APColi mutation remain undifferentiated and do not migrate normally up the 
crypt.  This leads to the formation of an adenomatous polyp.  Mutations of APColi 
3 
 
may be inherited, causing familial adenomatous polyposis (FAP), a familial syndrome 
that leads to the development of a large number of colonic polyps.  However, the 
majority of CRCs are associated with a spontaneous mutation of APColi or another 















Figure 1.1  The genetic model for colorectal tumourigenesis (adapted from 
Fearon and Vogelstein [3]), showing the key mutations and abnormalities responsible 





Following APColi mutation and the development of an adenoma, further mutations 
occur which drive the progression to invasive carcinoma [3].  These can include 
mutations in the KRAS, NRAS, HRAS, PIK3CA, PTEN, BRAF, and TP53 genes.  
Biologically, CRCs are of one of two major subtypes – microsatellite unstable (MSI-H) 
and microsatellite stable (MSS) [5].  MSI-H tumours, as seen in the hereditary 
condition Lynch syndrome and in a proportion of sporadic tumours, are 
hypermutated.  This hypermutation is caused by defects in the DNA mismatch repair 
genes (including MLH1, MLH2 and MSH2).  Conversely, MSS tumours have low 
mutation rates but have a high degree of chromosomal instability, leading to 
aneuploidy and large gene copy number variations.  These two subtypes tend to 
have differing clinical courses.  MSI-H tumours tend to metastasise less frequently 
than MSS, and produce a stronger intra-tumoural immune response [5].  In addition, 
the overall patient survival is superior with MSI-H tumours.  However, patients with 
MSI-H tumours that recur have a poor prognosis [6, 7].   
 
The mutation profile of a tumour has implications not only for its progression but also 
for its sensitivity to emerging targeted therapies.  One particularly important pathway 
in this regard is the Epidermal Growth Factor Receptor (EGFR) pathway [8, 9] 
(Figure 1.2).  Mutations in the tyrosine kinases RAS and RAF can lead to constitutive 
activation of the pathway and MEK/ERK phosphorylation, even in the absence of 
EGFR activation by Epidermal Growth Factor (EGF).  This pathway is particularly 
important in cancer cell growth, and is therefore targeted in many emerging 
therapies.  Mutations within these genes have therapeutic implications.  For example, 
the EGFR monoclonal antibodies cetuximab and panitumumab are ineffective in 
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patients with RAS mutant tumours, as inhibition of EGFR alone fails to inhibit RAS 
signalling  [10].  
 
1.1.2 Management of colorectal cancer 
Currently, the management of CRC is dependent on the stage of disease at 
presentation, and whether the disease is colonic or rectal [11].  In brief, early stage I 
and II disease that is localised to the colon is usually treated solely with surgical 
resection.  Patients with stage III disease (with lymphatic metastases) may also 
require adjuvant (post-operative) chemotherapy for 6 months.  Finally, the treatment 
of patients with stage IV disease (distant metastases) is dependent on whether the 
intent is curative or palliative.  Curative intent may be feasible if the metastases are 
surgically resectable.  Otherwise, palliative treatment is offered which may consist of 
primary chemotherapy combined with targeted therapy, such as with EGFR 
monoclonal antibody therapy.   In contrast, rectal cancers may require preoperative 






Figure 1.2 EGFR pathways. Schematic of key EGFR-associated signalling 
pathways.  EGFR activation (by its cognate ligand epidermal growth factor (EGF)), 
leads to activation of key signalling cascades including the RAS-RAF-MEK-ERK and 
PI3K-AKT-mTOR pathways.  This leads to increased cell growth, proliferation and 
survival.  PTEN negatively regulates the PI3K-AKT-mTOR pathway.  In malignancy, 
mutations can occur in several of these genes, including EGFR, RAS, RAF, PI3K and 
PTEN, which can lead to constitutively active signalling in the absence of EGFR 
activation.     
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1.2  Cancer Immunology 
Cancer immunology is the study of the interactions of cancer cells and the immune 
system.  It is a rapidly developing field, and recent therapeutic advances have given 
hope that cancer immunotherapy will become a key treatment modality in a range of 
cancer types [12-16]. 
The immune system has long been perceived to play an important role in preventing 
the development of tumours – the concept of immunosurveillance  – where the 
immune system constantly surveys the body for developing tumours and eliminates 
them before they become clinically apparent [17, 18].  Immunosurveillance is thought 
to comprise three phases – the elimination phase, the equilibrium phase and the 
escape phase.  In the elimination phase, the immune system identifies and destroys 
cancerous cells.  In some cases, where elimination is not complete, this is followed 
by the equilibrium phase.  During this phase, the immune system maintains residual 
cancerous cells in a state of dormancy, which can persist for many years, such as in 
the case of the latent tumour cells that lead to recurrent or metastatic disease [19]. 
During this dormancy, the selection pressure created by the immune response 
encourages the growth of tumour cells that are able to avoid immune killing – a 
process also known as immunoediting [18].  This process may lead to the 
development of tumour cells that are resistant to the immune attack. These cells may 
then proliferate and dominate the tumour mass – the escape phase.  The concept of 
immunosurveillance remains controversial in the field [18].  However, it is clear that 
tumour cells escape immunity through several established mechanisms and 
potentially some unknown ones.  Some of the key mechanisms include down-
regulation of Class I MHC expression, repression of tumour antigen expression and 
9 
 
presentation, the release of suppressive cytokines (such as IL-10, TGF-β), and the 
repression of NKG2D ligands (to evade NK attack) [17].  Subsequently, the immune 
system may no longer effectively eliminate tumour cells.  Immunotherapy strategies 
need to overcome this loss of tumour immunogenicity – a challenge made 
considerably more difficult by the fact that tumour cells are effectively ‘altered self’, 
rather than foreign such as infectious pathogens. 
 
1.3  Cancer immunotherapy 
Cancer immunotherapy involves the harnessing of immunity for anti-cancer effect. 
Various approaches are in development, some of which are now used in patient care.  
Briefly, these include approaches that induce or increase neoantigen (mutated 
antigens) or tumour-associated antigen directed T cell responses (such as 
vaccination, chimeric antigen receptors (CARs) and adoptive T cell therapies), 
strategies that induce stimulatory signalling and proliferation (such as IL-4, GM-CSF 
and TNF-based (cytokine) therapies), modalities that utilise native or engineered 
viruses that kill cancer cells (oncolytic virus therapy) and finally methodologies that 
inhibit suppressive pathways or restore responses of exhausted/inactivated T cells 
through the inhibition of immune checkpoints (checkpoint blockade) [17, 20, 21].  In 
addition, conventional cytotoxic regimes may improve the anti-tumour immune 
response by releasing tumour neoantigens and modifying the immunosuppressive 





1.3.1 Adoptive cell therapy 
Adoptive cell therapy exploits the anti-tumour activity of lymphocytes to eradicate 
tumour cells [20].  It requires the isolation of lymphocytes from the patient’s 
peripheral blood, tumour tissue or draining lymph nodes, followed by ex vivo 
expansion and stimulation of the lymphocytes with a mixture of cytokines, followed by 
reinfusion back into the patient.   This approach expands tumour-specific T cells 
away from the immunosuppressive tumour microenvironment.  The lymphocytes 
reinfused are generally mixtures of CD4 and CD8 positive T cells.  It is often 
administered following lymphodepletion, which may improve the functionality of the 
infused T cells by eliminating immunosuppressive cells such as Tregs and myeloid-
derived suppressor cells [25].   
The key advantage with this strategy is that it enables the generation of a large 
number of high avidity T cells (avidity is the accumulated binding strength of the TCR 
with the peptide-MHC complex, determined by the accumulated strength of multiple 
individual interactions/affinities). Also there is no need to break tolerance against  
tumour antigens as is often the case with other approaches [20].  Disadvantages 
include the cost and time required to isolate and expand the T cell populations.  
Furthermore, the side effects, particularly with lymphodepletion, can be life-
threatening.   
In addition, this approach has been successful mostly in melanoma thus far.  
However, results in this tumour type have been promising, with high response rates 
and long-lasting tumour regression [26]. Additionally, a durable response was 
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obtained in a patient with cholangiocarcinoma on infusion of autologous mutation-
specific CD4+ cells which adopted a poly-functional Th1 phenotype [27]. 
 
1.3.2 Engineered T cell receptors and Chimeric Antigen Receptors 
There are two main strategies through which T cells are engineered to improve their 
anti-tumour activity.   The first is TCR engineering.  In this approach, the TCR α and 
β chains are designed or modified to increase the TCR’s antigen specificity and 
avidity [20].  The synthetic TCR is then expressed by the T cell [21].  
The second approach is the creation of chimeric antigen receptors (CARs).  CARs 
use a single-chain variable fragment (scFv) derived from the variable heavy and light 
chains of an antibody to target an extracellular antigen [21].  The advantage of this 
approach is that it can target antigens independently of the peptide-HLA complex 
[28].  CARs have evolved significantly since the generation of the initial functional 
CAR T cells.  T cell activation in the lymph node requires both ‘signal 1’, normally 
derived from the TCR-peptide-MHC interaction, and ‘signal 2’, by stimulation of CD28 
with B7 costimulatory molecules [20].  First generation CARs only provide activation 
of signal 1 to T cells [21].  Therefore, first generation CARs could lead to T cell 
anergy, due to repeated antigen stimulation without signal 2.  Second generation 
CARs address this by including an additional co-stimulatory domain that provides 
signal 2, such as the stimulatory domains of CD28 [21].  Third generation CARs 
include two co-stimulatory domains, such as CD28 and OX40.  Finally, ‘armoured’ 
CAR T cells include a further gene that provides the resulting T cell with a survival or 
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cytotoxicity advantage, or modulates the microenvironment.  This may include IL-12 
or CD40L.   
Responses have been seen with genetically engineered T cell therapies in various 
cancers.  However, the clinical use of highly avid TCRs have been associated with 
off-target effects on healthy tissues that express the same target antigen [20].   
 
1.3.3 Vaccination 
Vaccination in cancer includes preventative vaccines against cancer-causing 
infectious diseases such as Hepatitis B or the Human Papilloma Virus, and 
therapeutic vaccines which are being developed to treat cancers.  One of the main 
obstacles to the latter approach has been the identification of suitable antigens.   The 
ideal target antigens should be expressed at high levels in the target tumour in a high 
proportion of patients, and at low levels in normal tissue to minimise off-target effects 
[21].  In addition, the antigen should be important for the tumour’s growth or survival, 
to reduce the risk of immune escape due to downregulation of antigen expression 
[29].   
Suitable antigens may include tumour antigens, which are expressed at much higher 
levels in tumour tissue than normal tissue, such as NY-ESO-1, MUC-1 and CA-125 
[20, 21].  A further possibility is the targeting of neoantigens, which derive from the 
peptides encoded by tumour mutations.  An issue with this approach is that it is 
unclear to what extent neoantigens overlap between patients.  Therefore, efforts 
have been made to develop personalised vaccines, which target the specific 
neoantigens found in an individual patient’s tumour [16].  This requires genetic 
13 
 
sequencing of the patient’s tumour, in silico prediction of neoantigen-HLA binding, 
and then vaccine production – in this case a polytope mRNA vaccine (containing 5 
epitopes).  This approach is being investigated in an early phase clinical study.  In 
addition, both tumour antigens and neoantigens may be utilised in cell therapies.   
Dendritic cells (DCs) play a crucial role in vaccination approaches, which initial 
vaccine therapies did not fully exploit.  DCs, as professional antigen presenting cells, 
process the delivered antigens and present them upon Class II HLA molecules to 
CD4 T cells.  For this reason, attempts have been made to create DC-based 
vaccines, where DCs are isolated from patients and are loaded with antigens ex vivo 
[21].  One such DC vaccine, sipuleucel-T, has been associated with a 4-month 
median survival improvement in metastatic prostate cancer [30, 31]. 
 
1.3.4 Checkpoint blockade 
Of the various immunotherapies in development, checkpoint blockade has been the 
most successful thus far [14, 15].  The rationale of this therapy is to unleash pre-
existing anti-tumour responses.  CTLA-4, an inhibitory receptor expressed on T cells, 
prevents T cell activation by DCs through its interaction with the B7 co-stimulatory 
molecule, blocking the crucial ‘signal 2’ discussed above [20].  Ipilimumab, an anti-
CTLA-4 antibody, which has been approved for clinical usage in advanced 
melanoma, was a significant step forward for the field of immunotherapy.  This 
approval followed phase III trials that demonstrated significant prolongation of overall 
survival [12].  In addition, 20% of patients who survived went on to have long term 
durable benefit, which seems to be a particular strength of checkpoint blockade in 
14 
 
comparison to targeted therapies. However, response rates were low (12%), and a 
significant proportion of patients developed severe immune-related adverse events 
[21].  Of note, responses to this drug took longer to manifest than existing therapies, 
reflecting its mode of action.   
PD-1 is another inhibitory receptor expressed on T cells.  The ligands for PD-1, PD-
L1 and PD-L2, are expressed on tumour cells and antigen presenting cells [21].  The 
downstream signalling of PD-1, rather than preventing the activation of T cells like 
CTLA-4, inhibits T cell proliferation, cytokine release, and cytotoxicity [32, 33].  
Therefore, CTLA-4 regulates de novo immune responses, whereas PD-1 affects 
ongoing immune responses.  Two anti-PD-1 mAbs, pembrolizumab and nivolumab, 
have been approved for the treatment of advanced melanoma.  Clinical trials showed 
that up to 40% of patients with advanced melanoma had objective responses with 
these drugs – a considerable improvement over the 12% response rate observed 
with ipilimumab monotherapy [34, 35].  This included patients who previously had no 
response to ipilimumab.     
Nivolumab has also been approved for treatment of squamous-cell lung cancer 
refractory to platinum based therapy, based on a study showing a 3 month 
improvement on overall survival, and a 17% improvement in 2 year survival over 
those receiving docetaxel [15].  
A key improvement of PD-1 over CTLA-4 blockade is the toxicity profile.  The rates of 
severe toxicity were considerably reduced with PD-1 therapy [12, 14, 35], perhaps 
reflecting the benefit of specifically targeting cancer-induced immunosuppressive 
pathways rather than non-specifically activating the immune system [20]. 
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Monoclonal antibodies have also been developed against PD-L1 and PD-L2, which 
have shown responses in a range of human cancers [20].  In addition, other immune 
checkpoints such as TIM-3 and LAG-3 have also been targeted [21]. 
A key priority in the field is the development of biomarkers for these therapies.  
Currently, PD-L1 is used as a biomarker for PD-1 therapy.  However, patients with 
low PD-L1 expression can occasionally respond to PD-1 blockade, and conversely, 
patients with high PD-L1 expression may not respond [20], demonstrating that PD-L1 
may be a suboptimal biomarker. 
Due to these highly promising results, checkpoint blockade therapies are being 
investigated in a range of cancer types.  However, results in CRC have been 
relatively disappointing [14, 36], despite the fact that CRC is a tumour type where 





1.4  Colorectal cancer immunology  
Though immunotherapies have had limited success in CRC thus far, this disease has 
been the prototype cancer for studying the significance and the impact of tumour 
immunity and the tumour microenvironment [38].  Over a decade ago, multiple 
groups demonstrated that tumour infiltrating lymphocytes (TILs) are associated with 
improved prognosis in CRC [39-41].  Then, a seminal paper by Galon and colleagues 
in 2006 revealed that the density of TILs and the expression of certain immune-
related genes are of prognostic and predictive value in CRC [37].  The group 
identified a dominant cluster of genes for Th1 adaptive immunity, the expression of 
which were inversely associated with tumour recurrence.  Furthermore, 
immunohistochemstry analysis of CRC tissue microarrays revealed that densities of 
CD3, CD8, GZMB and CD45RO in the tumour core (CT) and invasive margin (IM) 
could stratify patients into groups with different disease-free survival and overall 
survival rates.  Combining the CT and IM scores increased the accuracy of the 
survival prediction.  CD3 density in these regions remained associated with overall 
survival after multivariate analysis adjusting for tumour and lymph node stage.  This 
led to the development of the ‘Immunoscore’, which is based on CD3 and CD8 
densities within the CT and IM, and is currently undergoing worldwide validation as a 
prognostic marker in CRC [38].  These two markers were selected as they are the 
two easiest membrane stains, and to avoid the technical difficulties with CD45RO 
and GZMB staining.  The aim of the validation is to ensure standardisation of the 
assay, which is crucial to ensure that this test can be applicable on a worldwide 
multicentre basis.  The relative simplicity of the test, requiring only two IHC stains, is 
likely to aid its implementation and reproducibility.  However, though it is prognostic 
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in CRC, and is potentially superior to the existing TNM classification in predicting 
outcome, it remains unclear how well it will predict responses to chemotherapy.  It is 
likely that this will be crucial in determining its clinical utility in the stratification of 
patients into treatment groups, rather than as an additional prognostic marker with 
only limited value.  This will be particularly relevant to Stage II patients, where the 
benefit of adjuvant chemotherapy is unclear [38].  Predicting which patients have a 
high recurrence risk could help target chemotherapy appropriately in this group. To 
determine its predictive value, clinical trials will likely be necessary. 
In their key 2006 paper, Galon and colleagues initially highlighted a cluster of 7 
genes that were correlated with disease-free survival [37] – TBX21/Tbet, IRF1, IFNγ, 
CD3z, CD8, granulysin and granzyme B.    Subsequently, they further confirmed that 
the Th1 genes, TBX21/Tbet, IFNG, IRF1 as well as STAT1 were all individually 
associated with disease-free survival [42]. Other independent immune gene 
predictors in this analysis included IL18RAP, ICOS, PD-L1, PD-L2 and PD-1.   
Additionally, the group found that patients with high expression of genes associated 
with Th1 T helper cells (TBX21/Tbet, IRF1, IL12RB2 and STAT4) exhibited 
prolonged disease-free survival, whereas those with high expression of Th17-
associated genes (RORC, IL17A) had a poor prognosis [43].  This highlights the 
potential significance of Th1 CD4 cells, alongside the previously discussed cytotoxic 
CD8 cells, in mediating effective anti-tumour immunity.  
Despite the known impact of immunity on patient outcome in CRC, the factors that 
determine a patient’s immune phenotype are still unclear.  These are likely to include 
tumour, host and environmental factors [44].  Within tumour and host factors, few 
systematic analyses have investigated the somatic and germline molecular drivers of 
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immune infiltration.  Although microsatellite unstable (MSI-H) cancers are known to 
be associated with increased TIL density [5, 45-50], the nature of the immune 
infiltration and the molecular drivers of the immune phenotype in microsatellite stable 
(MSS) CRCs are poorly understood. In particular it is unclear whether defined 
molecular subsets (such as RAS mutant, BRAF mutant, PIK3CA mutant, quadruple 
wildtype (BRAF, PIK3CA, NRAS, KRAS all wildtype)) are associated with high or low 
immune infiltration.  In addition, in both MSI-H and MSS cancers the extent to which 
therapeutically targetable inhibitory immune checkpoint receptors are represented 
are unclear and is of substantial interest, particularly considering recent checkpoint 
blockade failures in colorectal cancer [13, 14]. Given the prognostic and predictive 
relevance of CRC immunophenotype, a clearer understanding of the link between 








1.5 EPCR and the immune recognition of cancer  
As discussed above, the conventional adaptive immune response plays an important 
role in preventing the development and progression of cancers.  However, the role of 
the unconventional immune response has yet to be fully explored.  Recently, γδ T 
cells, an unconventional T cell subset, have been suggested to correlate closely with 
prognosis across different cancers [51].  γδ T cells are less well understood than 
conventional αβ T cells and are thought to have an innate-like function similar to NK 
cells [52].  One of the primary aims of this project is to determine the significance of 
Endothelial Protein C Receptor (EPCR), a γδ T cell ligand, in epithelial 
tumourigenesis.  EPCR had no known immunological role until a recent study by the 
Willcox and Déchanet-Merville groups [53], who aimed to identify possible ligands for 
the γδ T cell receptor.   γδ T cells have important roles in bacterial and viral infection.  
However, they are also thought to be important in cancer immunosurveillance.  Mice 
deficient in γδ T cells have increased rates of carcinogenesis.  Expansion of this set 
of T cells in blood is associated with better outcome in cancer in humans [54].  As γδ 
T cells are not MHC/HLA-restricted, the HLA haplotype of patients is not relevant.  
This makes them attractive for potential immunotherapies.  Early stage clinical 
studies involving γδ T cells in cancer have shown promising results [54-57].  
However, the manner in which the Vδ2-negative γδ T cell receptor (TCR) in particular 
recognises infected or transformed cells had not been determined.   
The work stemmed from a patient who underwent lung transplantation and 
developed acute cytomegalovirus (CMV) infection whilst on immunosuppressive 
medication.  In this patient, a γδ clone with a specific TCR called LES had expanded 
and comprised 40% of blood γδ T cells and 20% of all blood T cells.  It had 
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previously been suggested that Vδ2-negative γδ T cells could recognise CMV 
infected cells and tumour lines [58].  Therefore, the authors hypothesised that the 
TCR of the LES clone recognised a ligand present on both CMV infected cells and 
transformed cells.   
The group created cDNA from the LES TCR’s Vγ4 and Vδ5 chains, and induced 
expression of this TCR in JRT3 cells (which lack a TCR).  These cells now reacted to 
several cancer cell lines (including HT29) and CMV infected cells.  Antibodies were 
produced against the LES TCR’s ligand by immunising mice with HT29 colorectal 
cancer cells.  One antibody, 2E9, stained all LES targets, including the tumour lines, 
after which it also inhibited all LES recognition.  To identify the ligand of 2E9 (2E9L), 
the group immunoprecipitated proteins from 2E9L positive cells (including HT29 and 
HeLa).  They separated the proteins with SDS-PAGE and then trypsinised the 2E9 
reactive band.  Using mass spectrometry, they were able to identify the protein as 
EPCR.   
The group confirmed that EPCR and 2E9L were the same.  EPCR antibodies 
prevented 2E9 binding in previously positive cells.  Using surface plasma resonance, 
the group were able to confirm direct and specific binding between EPCR and 2E9.  
Through mutational analysis, they identified specific binding sites.  Significantly, 
EPCR did not have an antigen-presenting role like MHC but directly bound to the 
TCR.  However, EPCR alone was necessary but insufficient for TCR activation. 
In view of the role of γδ T cells in cancer immunosurveillence, the discovery of EPCR 
as a ligand in a specific subset was significant.  EPCR is not upregulated upon CMV 
infection, but EPCR’s upregulation on various tumour lines [59] suggested the 
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possibility that it may have relevance for γδ T cell recognition of cancer as part of a 
“multimolecular stress signature”.  This highlighted the role of EPCR in tumorigenesis 
as an interesting avenue to explore.   
 
1.6   EPCR structure and signalling 
 
EPCR is a type I transmembrane protein with 20% homology to MHC class I and 
CD1 (Figure 1.3), though it lacks an α3 domain [60].  It was initially described in 
relation to Protein C (PC), an important modulator of coagulation [61].  EPCR 
increases the conversion of the zymogen PC to Activated Protein C (APC), and is 
also a receptor for both PC and APC.  APC cleaves coagulation factors V and VIII 











Figure 1.3 The structure of a) EPCR and b) CD1d [62, 63].  The α1 and α2 
platforms are highly homologous. The α3 domain of CD1d has been omitted for 
clarity.  The lipids within the binding grooves are P-Phosphatidylmethanolamine or 
phosphatidylcholine (EPCR) and α-galactosylseramide (CD1d).  





1.7 EPCR’s role in blood coagulation 
EPCR’s most significant role is in preventing the excess clotting of blood.  Seegers 
and collaborators initially identified autoprothrombin II-A, now termed Protein C, in 
the 1960s [64].  The discovery of PC partially explained the remarkable capacity of 
the haemostatic system to clot in areas of endothelial injury but maintain sufficient 
flow elsewhere.  Esmon and colleagues at the University of Oklahoma (USA) have 
made significant contributions to the understanding of PC and its pathways, and have 
expanded the known roles of PC from the inhibition of clotting factors to the wide 
range of functions known today.   It became apparent that whilst PC activation 
requires thrombin, the rate of activation with thrombin alone is insufficient for effective 
coagulation modulation [65].  Esmon postulated that there could be an important 
cofactor in the vascular endothelium.  Prior to this, endothelium was thought to only 
play a passive role in clotting.  This was confirmed by perfusing an isolated rabbit 
heart’s coronary arteries with thrombin and PC.  When both of these were perfused, 
the effluent from the heart possessed anticoagulant activity.  Without perfusing 
through the vessels, the thrombin and PC failed to produce anticoagulant activity.  
When the perfusate contained only thrombin, the effluent failed to activate PC.  This 
experiment was crucial in demonstrating that the endothelium was central to the 
prevention of potentially harmful clotting.   
It took several more years for the group to identify EPCR [61], and demonstrate that 
it directly activates PC.  In the interim period, a study suggested that PC protected 
against E. coli septicaemia in baboons [66].  Therefore, it seemed increasingly likely 
that PC affected inflammation and intracellular signalling via an unknown receptor.  
The Esmon group showed that APC bound to Human Umbilical Vein Endothelial 
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Cells (HUVECs) [61].  From here, the group were able to determine the likely final 
primary structure of the APC-binding protein, which they termed Endothelial Protein 
C Receptor.  They correctly predicted that it was a type 1 transmembrane protein, 
with 4 glycosylation sites in the extracellular domain and a short cytoplasmic tail. This 
cytoplasmic tail is significant in the cellular distribution of EPCR [60]. Interestingly, the 
sequence of EPCR is highly homologous to the CD1 family (Figure 1.3). Esmon and 
colleagues did make an astute observation that CD1d promotes T cell responses, 
and therefore EPCR could interact in some manner with the immune system.  
Although EPCR lacks the α3 domain of CD1, the α1 and α2 domains are highly 
analogous.  The binding of PC to HUVECs was compared to several other cell lines 
[61].   Esmon noted that the osteosarcoma cell line HOS and the epidermoid 
carcinoma line HEph-2 both bound to APC, albeit much more weakly than the 
HUVEC line.  The HOS line and the monocyte cell line U937 both had low levels of 
detectable EPCR mRNA.   These findings may have been the earliest indications of 
EPCR expression in cancers.  However, clearly the emphasis of Esmon’s work was 
to investigate the receptor structure and function in terms of coagulation and 
inflammation, perhaps explaining why EPCR’s expression in those cancer cell lines 
was not investigated further.  Esmon correctly suggested that EPCR would be 
involved in intracellular signalling, and that the EPCR/APC complex might activate 
other proteins.  However, at that stage, it was not linked directly to protease activated 
receptor 1 (PAR1), a type of proteolytically-activated receptor that was identified later 
[67].  Thus, although it was clear that EPCR significantly augmented the activation of 
PC, the intracellular signalling initiated as a result of EPCR activation was poorly 
understood.   
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1.8    Protease Activated Receptors and EPCR signalling 
Protease activated receptors (PARs) are group of receptors activated by proteolytic 
cleavage, and are crucial for EPCR-mediated signalling.  The first to be described 
was PAR1, which is activated by thrombin and factor X [67].  The Ruf group utilised 
PAR1 deficient murine fibroblasts to determine whether APC had proteolytic activity 
upon PARs [68].   PAR1 deficient fibroblasts were responsive to APC only when 
EPCR was co-expressed with a PAR.   PAR1 cleavage-blocking antibodies 
prevented APC-induced intracellular signalling but not that induced by the direct 
PAR1 agonists.  Blocking PAR1 also inhibited any PAR2 signalling.  This was 
evidence that the APC/EPCR complex activated PAR1 by proteolytic cleavage.  This 
work provided the important insight that PC mediated intracellular effects, including 
anti-apoptotic and anti-inflammatory effects, are entirely dependent on PAR1 
activation.  Gene induction by APC and direct PAR agonists was highly concordant.  
Anti-apoptotic genes that were upregulated by APC included the Bcl-2 related protein 
A1 and inhibitor of apoptosis protein 1 (IAP1).  Other upregulated genes include 
negative regulators of multiple pro-inflammatory pathways, including mitogen 
activated protein kinase (MAPK) and the nuclear factor kappa B (NF-κb) pathways.  
The gene profile matched closely with the expression profile of PC defined in an 
earlier study [69].  The Ruf group’s work substantially progressed the understanding 
of PC function by linking EPCR and PC to PAR1, a receptor that can initiate a 
diverse set of intracellular pathways. 
Grinnell and collaborators utilised RNA microarrays to identify the broad range of 
genes modulated by APC [69].  However, the group did not link APC’s effects with 
EPCR or PAR1, as this was established subsequently [68].  Yet, the work by Grinnell 
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was the earliest evidence that the PC/APC/EPCR pathway had a significant impact 
on gene transcription, independently of APC’s inhibition of thrombin production, and 
explained the in vitro and in vivo results found in the sepsis setting, where APC was 
found to have an anti-inflammatory effect  [66, 70, 71].  The genes regulated by APC 
were related to inflammation, apoptosis, cell survival and cell adhesion (which is 
significant in early cancer metastasis [72]).  The inflammatory gene NF-B2 was 
downregulated by APC.  Genes related to cell adhesion included intracellular 
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and E-
Selectin. Two pro-apoptotic genes were downregulated by APC – calreticulin and 
TRPM-2.  Anti-apoptotic genes that were upregulated included A1 and IAP.   All of 
these genes have potential relevance in the cancer setting, although APC and EPCR 
were not thought to be relevant in cancer at that time. Physiologically produced PC 
could increase cell and organ survival.  In vitro assays using Staurosporine (an 
apoptosis inducer) confirmed that recombinant APC (rhAPC) reduced the proportion 
of cells undergoing apoptosis, as confirmed by caspase-3 staining.  This effect was 
dose dependent, which in light of the now known signalling pathway, suggests 
progressively greater EPCR and PAR1 signalling with higher doses of APC.  With 
this work, APC’s potential as an anti-inflammatory and anti-apoptotic agent were 
substantiated with transcriptional data. 
Other than A1 and IAP, other pro- and anti-apoptotic proteins have been found to be 
modulated by EPCR, including Bax and Bcl-2 [73].  Cheng and collaborators 
investigated the effects of APC in ischaemic brain injury.  Hypoxia induced apoptosis 
in endothelial cells through an increase in p53 and subsequent alteration of the 
Bax/Bcl-2 ratio.  APC produced a cytoprotective effect in hypoxic conditions by 
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reducing p53 (by 77% in 2 hours) and altering the Bax/Bcl-2 ratio to reduce 
apoptosis.  APC reduced TUNEL and caspase-3 (a key executioner caspase) 
staining.   This was independent of thrombin effects.  PAR1 and EPCR-blocking 
antibodies completely inhibited this effect, but non-blocking EPCR antibodies did not 
prevent the effect.  IAP or A1 expression was unaltered, which differs from Joyce’s 
findings in HUVECs [69].  The finding that APC/EPCR/PAR1 can modulate p53 is 
particularly significant with regard to cancer.  p53 is a well-described and crucial 
tumour suppressor protein.  EPCR reducing p53 activity could potentially affect 
apoptosis in cancer.  Therefore it is feasible that EPCR expression on cancer cells 
could confer an intrinsic advantage on them. 
In addition to reducing apoptosis, Xue et al. provided in vitro evidence that EPCR 
activation can induce cellular proliferation [74].  After demonstrating EPCR 
expression in skin keratinocytes using immunohistochemistry, they established that 
APC stimulation of keratinocytes causes phosphorylation of ERK2.  This 
phosphorylation was dependent on both EPCR and PAR1, as confirmed by the lack 
of phosphorylation when using blocking antibodies.  ERK2 is an example of a 
mitogen-activated protein kinase (MAPK), which is important in growth factor 
signalling via the EGFR pathway.  The discovery that EPCR activation leads to 
MAPK phosphorylation suggests that it could have a role in cell proliferation in 
endothelium and skin.  Alongside the anti and pro-apoptotic genes that are regulated 
by EPCR [69], this is another mechanism by which EPCR could encourage 
uncontrolled growth in cancer.   
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Several EPCR-activated pathways overlap with pathways known to be important in 
cancer, including the ERK pathway.  Figure 1.4 provides a summary of EPCR-










Figure 1.4 PC induced signalling pathways (adapted from Thiyagarajan et al. 2007 
[75]).  
The thrombin/thrombomodulin (TM) complex presents PC to EPCR.  PC is then 
activated (APC). APC inactivates factors V and VIII.  In addition the APC/EPCR 
complex cleaves PAR1, a G-protein coupled receptor.  This leads to activation of 
phospholipase C.  Inositol triphosphate (IP3) mediates influx of calcium, causing 
activation of kinases and phosphorylation of ERK (green arrows).  This induces 
expression of pro-proliferative genes in the nucleus.  Additionally, PAR1 activation 
downregulates p53 and alters the Bax/Bcl-2 ratio, thus inhibiting apoptosis (yellow 
arrows).  PAR1 also mediates APC’s anti-inflammatory effect through downregulation 





1.9     The study of EPCR in cancer 
1.9.1  In vitro studies 
The earliest evidence that EPCR may have a role in cancer came from Fukudome 
and collaborators in 2001 [76]. The group approached their work on the basis of PC’s 
and EPCR’s anticoagulant activity.  Their initial aim was to explain the coagulopathic 
state in cancer.  Around the same period, other groups were investigating EPCR and 
APC’s anti-inflammatory effects [68-70].  Using techniques including 
immunohistochemistry and western blotting, the Fukudome group determined that 
EPCR was expressed on a range of glioblastoma and haematological cancer cell 
lines.  Importantly, they demonstrated that PC activation was inhibited by an EPCR-
blocking antibody, but not by an antibody that allowed EPCR/PC binding.  Positive 
EPCR staining was demonstrated on paraffin-embedded sections of invasive ductal 
breast carcinoma (96% of samples).  The group postulated that the high frequency of 
EPCR expression in these aggressive cancers may have benefitted tumour 
progression.  Yet at the time very few viable explanations for this observation could 
be provided.  Nevertheless, by closely scrutinising for factors that explained 
coagulopathy in cancer, the group identified aberrant expression of EPCR, a protein 
that we now know has pleiotropic effects [69]. 
The Scheper group suggested that EPCR may have a role in chemoresistance [59].  
The group generated a panel of antibodies against proteins highly expressed in multi-
drug resistant (MDR) cancer cell lines.  One of these antibodies, LMR-42 mAb 
(monoclonal antibody), reacted with a protein that was induced by selecting 
doxyrubicin resistant cancer cell lines.  The group noted that LMR-42 mAb reacted 
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with several MDR lines, but not their parental lines nor non-cancer cell lines.  The 
highest expression was in cell lines most poorly responsive to chemotherapy.  Of 
note, the commonly used HCT116 colon cancer line was strongly positive.  IHC 
staining with the antibody was positive on endothelium and some cancer tissue.  The 
group deduced through sequence analysis that LMR-42 was identical to EPCR.  This 
work demonstrated that EPCR was associated with chemoresistance, without 
providing a mechanistic explanation for this effect.  EPCR expression was a stable 
trait in these cells even after several weeks without doxyrubicin treatment, and was 
therefore not transiently induced by the chemotherapy.  The group suggested that 
EPCR might provide a coagulation-free environment, but this cannot fully explain its 
effects, especially in view of these cell line studies, where coagulation does not 
occur.  Therefore, this work gives a strong indication that EPCR is important 
potentially in cancer and may have relevance to chemotherapy treatment, but does 
not provide a mechanism of action.   
A study from the University of Carolina (USA) was the first to investigate the role of 
EPCR in cancer cell migration and invasion [72].  Around this time, evidence was 
accumulating that APC increased migration in endothelial cells [77] and keratinocytes 
[74]. This group used a transwell assay system to investigate migration in endothelial 
cells (HUVECs) and breast cancer cell lines (MDA-MB-231 and MDA-MB-435).  APC 
was found to increase breast and endothelial cell migration and invasion by 125-
375%.  This effect was dose dependent.  PC did not have the same effect.  Anti-
EPCR and anti-PAR1 antibodies both attenuated migration and invasion. The anti-
EPCR antibody inhibited production of APC, but EPCR was also noted to be crucial 
to APC’s effects on migration.  As the effect was seen both in endothelial cells and 
32 
 
cancer cells, it suggested that a common APC/EPCR/PAR1 mediated pathway was 
present in both cells.  APC was not itself a chemotactic agent.  This suggests that the 
pathway increases invasion and chemotaxis towards other chemotactic factors, 
which may have relevance in early metastasis.  The group could not fully explain the 
mechanism of the increased migration and invasion.  They suggested that APC’s 
protease activity was crucial, both in the activation of PAR1 (intracellular signalling) 
and perhaps in the activation of extracellular matrix proteases, as had been shown 
previously [74].  This paper brought developments of EPCR understanding in the 
endothelial setting to cancer.   
 
1.9.2 In vivo and clinical studies 
Several groups have performed in vivo studies into EPCR’s role in various cancers, 
but clinical data are limited.  A key study by a group based at the University of 
Navarra (Spain) extensively investigated EPCR’s role in cancer metastasis using in 
vivo models [78].  Building on previous findings relating APC/EPCR to apoptosis, cell 
survival and migration, the group sought to determine if EPCR expression aids the 
metastatic process in lung cancer.  They identified an adenocarcinoma cell line 
(A549) that expressed EPCR based on flow cytometry.  APC was able to induce 
intracellular signalling via EPCR, leading to phosphorylation of ERK and Akt.  They 
therefore established that key EPCR-relevant pathways in endothelial cells were also 
functional in this tumour cell line.  On microarray analysis, the genes upregulated by 
APC treatment included several that have previously been identified [69], and as 
expected had anti-apoptotic and cyto-protective roles.  EPCR expression was 
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knocked down in A549 cells using shRNA (small hairpin RNA).  Rather than 
proceeding with in vitro assays, the group utilized these knockdown cell lines in an in 
vivo mouse model of lung cancer.  Controls or shRNA treated A549 cells were 
injected into Athymic nude-Foxn1nu mice and subsequent development of bone 
metastases was assessed.  The key finding was that the shRNA group of mice 
developed significantly fewer hind limb bone metastases.  Similar results were 
obtained by inoculating mice with control A549 cells and then regularly injecting them 
with EPCR-blocking antibodies.  Antibody administration significantly decreased the 
metastatic tumour burden.  Taking a non-EPCR expressing parental A549 line and 
inducing EPCR expression (using viral vectors) increased the development of 
metastasis in this mouse model.  Administration of EPCR-blocking antibodies 
ameliorated this effect.  This is strong evidence that EPCR has an important role in 
metastasis development. 
Anton and collaborators also made attempts to characterise EPCR’s expression in a 
cohort of lung cancer patients (n=295).  These patients underwent standard 
treatment, i.e. surgery with or without adjuvant chemotherapy.  EPCR expression 
was determined post-operatively by immunohistochemistry.  Pathologists blinded to 
the details of each case scored each patient’s EPCR expression.  The group 
performed a multivariate Cox regression analysis to determine the relationship 
between EPCR expression and progression, recurrence, chemotherapy response 
and survival.  In multivariate analysis, high EPCR expression was associated with a 
shorter time to progression (TP, P=0.021), suggesting that EPCR could be an 
independent predictor of disease progression.  There was no significant relationship 
with overall survival.  However, when only the stage I patients (those with cancer 
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confined to the lung) were analysed, high EPCR expression significantly correlated 
with disease progression (p<0.001) and decreased survival (p<0.05). When stage I 
patients were removed from the overall analysis, no significant correlations were 
observed in the stage II-IV patients alone.  This analysis suggests that EPCR may be 
important in the development of early metastasis rather than in the continued growth 
of established metastases.   
Another important finding in this study relates to patient stratification and prediction of 
chemoresponsiveness, which are both increasingly important in cancer.  Patients 
with stage I cancer were grouped according to whether they had adjuvant 
chemotherapy post-surgery or not.  In patients with low EPCR expression, 
chemotherapy was not associated with any change in disease progression or 
survival.  In contrast, for patients with high EPCR expression, chemotherapy was 
associated with decreased progression and increased survival.  This suggests that 
EPCR expression could be used to predict chemotherapy response, as well as 
serving as a prognostic marker for early stage patients.  This would require validation 
in prospective trials.  Overall however, this work has progressed the understanding of 
EPCR’s role in cancer through a multi-faceted approach, and makes the protein a 
strong candidate for investigation in a range of cancers.  It also demonstrates its 
possible clinical uses as a predictive and prognostic biomarker, or in the modulation 
of EPCR to control disease. 
An earlier study by Bezuhly et al. [79] led to observations that were contrary to the 
work published by Anton et al, albeit in a different tumour type.  The group aimed to 
relate endothelial EPCR activity with melanoma liver and lung metastases.  Bezuhly 
and colleagues examined whether APC, with its established anti-inflammatory 
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activity, could reduce adhesion molecule expression and therefore metastasis 
development.  APC decreased both adhesion and migration significantly in in vitro 
models.  However, this effect was lost at the higher doses of APC, for reasons that 
were unclear.   
The group used a mouse model in which endothelial EPCR was overexpressed 
(Tie2-EPCR).  These mice and WT mice were inoculated with the melanoma cells.  
Two weeks later, surviving mice were sacrificed and spleen and liver were taken for 
analysis.  In the two week period, 4/10 of the WT mice died, but all of the Tie2-EPCR 
mice survived.  The liver and lungs had significant reductions in tumour nodules in 
the Tie2-EPCR mice respectively.  qRT-PCR revealed that P-selectin and TNF were 
significantly reduced in the EPCR overexpressing mice, suggesting that a reduction 
in adhesion molecule expression accounted for the decreased metastases.   Injecting 
APC in WT mice led to a less marked but still significant reduction in tumour nodule 
development.  Therefore in this study, EPCR expression limited metastasis. The 
group did not perform any experiments where EPCR expression was reduced, to 
assess whether the opposite effect occurred.   
This study contradicts Anton’s findings, where reducing EPCR in lung cancer cells 
using shRNA reduced the development of bone metastases, as did an EPCR 
blocking antibody.  There are several possible reasons for this discrepancy.  The 
metastatic sites investigated differ, and it is possible that crucial pathways vary in 
different anatomical sites.  The B16-F10 melanoma line is a mouse cancer line, 
whereas the A549 lung cancer line is a human line. The melanoma line did not 
express EPCR, whereas the lung cancer line did.  This means that the anti-human 
antibodies used in the Anton study only targeted the engrafted cancer, whereas in 
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the Bezuhly study the anti-mouse antibody only targeted the endothelium.  Therefore 
the different findings may arise from inherent differences in the biology of different 
tumour types, and also in the specific targeting of EPCR in cancer or in endothelium.  
The effects of EPCR may be context dependent. 
Schaffner, Esmon and colleagues investigated the relevance of EPCR expression in 
stem cell-like cancer cell (CSC) populations [80].  CSCs are postulated to be 
important in cancer chemoresistance, recurrence and metastasis.  They may have 
the ability to differentiate into all the cell types within a cancer.  Previous work had 
shown that EPCR is expressed in aggressive breast cancer CSCs [81].  Schaffner 
and colleagues confirmed EPCR’s importance in breast cancer CSC niches and 
investigated its consequences in breast cancer in vitro and in vivo models.  Like 
Beaulieu and colleagues [72], this group utilized the breast cancer cell line MDA-MB-
231.  However, they selected a highly aggressive triple-negative (oestrogen receptor, 
progesterone receptor, Her2/neu negative) derivative line by using cells that were 
passed through mouse mammary fat pad.  They separated the derived cells into 
EPCR+ and EPCR- cells using fluorescence-activated cell sorting (FACS).  Similarly 
to previous groups [69, 78], they extracted RNA and performed microarray analyses 
to determine differential gene expression.  In addition to genes previously described 
such as MAPK1/ERK2 [69], markers associated with CSCs were overexpressed in 
EPCR positive cells.  These included ALDH1B1 and ALDH1A3, and integrins 4 and 
6. 
The group used a polyoma middle T (PyMT) mouse model that spontaneously 
develops breast cancer in a fashion similar to the clinical scenario.  They were able 
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to breed these mice with EPCRlow/low mice to produce an EPCR deficient model for 
breast cancer.  These EPCRlow/low mice had a significantly smaller tumour burden and 
increased survival over the experimental period compared to controls.  However, the 
group took further steps to ensure that only the EPCR gene was differentially 
expressed, by breeding PyMT EPCRflox/flox mice.  EPCR deletion led to an increase in 
survival and decrease in tumour load.   
Two findings from these experiments were particularly important.  Firstly, EPCR 
expression in the cancer cells rather than the host determined outcome.  Secondly, 
the tumours resulting from high EPCR-expressing cell xenografts mostly contained 
cells that were EPCR negative.  This demonstrates that the EPCR cells either 
reduced EPCR expression or differentiated into other cell types, as would be 
expected from CSCs.  The EPCR-expressing cells may therefore have an increased 
capacity to initiate tumour growth.  This initiating capacity was reduced by using 
blocking antibodies that were injected alongside cancer cells in one experiment and 
intra-peritoneally in another.  In the intra-peritoneal group, mice were administered 5 
injections of blocking antibody (or control) over 14 days.  In both experiments, the 
blocking antibodies were associated with decreased tumour growth and burden. 
This study demonstrated that EPCR may have broad relevance across epithelial 
cancer groups.  The work links EPCR to the stem-cell like phenotype and attempted 
to identify the source of ligands in the tumour environment.  The group discussed the 
possibility of therapeutic EPCR blockade.  The safety of latter approach has not been 
explored, though the Schaffner group note that no adverse effects have been 
observed in animal models.  This point should be treated cautiously, as there are 
EPCR-associated examples such as APC in sepsis where animal models did not 
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reveal the serious complications of treatment [66, 70, 71, 82], and the universal 
expression of EPCR on endothelium could be a major obstacle.  
Keshava and colleagues investigated EPCR expression in mesothelioma and their 
results were seemingly contradictory to what has been observed in other cancers 
[83].   Their work was centred on Tissue Factor (TF), an important factor in the 
extrinsic coagulation pathway that, like EPCR, has been linked to poor outcomes in 
cancer.  In investigating TF, they also studied EPCR, due to their shared pathways.  
In vitro, the group found that a more aggressive mesothelioma cell line (REN) did not 
express EPCR, whereas EPCR was present in less aggressive lines (MK9 and MS-
1).  This is contrary to the results in other cancers [78, 80].  In their xenograft models, 
REN cells that had been treated with a pZeoSV plasmid containing human EPCR 
cDNA were injected into mouse pleural cavities.  The EPCR cDNA decreased tumour 
growth and burden significantly.  The Keshava group found that apoptosis markers 
(TUNEL) were increased in the tumours with increased EPCR expression, which 
again differs from the known actions of EPCR and PAR1 [69].  Conversely, grafting 
EPCR shRNA-treated MK9 and MS-1 cells significantly increased tumour growth and 
burden, but only when TF was overexpressed concurrently.  There was no effect 
observed on parental MK9 and MS-1 cells that were treated with the shRNA.  
The authors acknowledged that their findings differ from others groups, and 
suggested that this may be due to the particular cell types that they have used or the 
particular environment of these mesotheliomas.  The biology of these cancers may 
differ.  Like EPCR, TF (in complex with FVIIa and Xa) activates PAR1 [67].  The 
group noted that PAR1 activation can be pro or-anti apoptotic depending on the 
amplitude and duration of the signal [73, 84, 85].  In the presence of TF mediated 
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activation of PAR1, EPCR may have a pro-apoptotic/anti-proliferative effect.  This 
study demonstrates the complexity of these signalling pathways, where EPCR may 
have distinct effects in different cancer types.   
A French group, Ducros and collaborators, investigated EPCR’s potential role as a 
biomarker and in cancer associated coagulopathy [86]. The group obtained blood 
samples from 79 patients with ovarian cancer. They found that soluble EPCR 
(sEPCR) correlated closely with CA-125, the established ovarian tumour marker.   
The group also found that sEPCR and membranous EPCR were expressed in the 
ascitic fluid of these patients.  The study is most notable for its extensive genotyping.  
They sequenced the sEPCR from ovarian cancer patients and membranous EPCR 
from several cancer lines, including ovarian (OVCAR-3), lung (A549), colorectal (HT-
29) and breast (MDA-MB-231) lines.  The group detected 13 single nucleotide 
polymorphisms (SNPs), which were consistent with established SNPs in endothelial 
EPCR.  Cells carrying haplotype A3 shed a higher quantity of sEPCR into their 
growth medium.  This is consistent with work suggesting that the A3 haplotype in 
cancer patients is associated with higher levels of sEPCR, which is associated with 
increased venous thrombosis [87].  The mechanism of this effect is thought to be due 
to sEPCR binding with PC in blood, leading to less APC production by endothelial 
EPCR.    This study demonstrates that EPCR may be a potential biomarker for at 
least one type of cancer, and may be predictive for the development of 
thromboembolism.  Potentially, sEPCR measurement could allow more appropriate 
and personalised thromboprophylaxis.   
It is evident that recently there has been increasing interest in EPCR’s role in cancer.  
The recent finding that it can act as a γδ TCR ligand suggests possible interaction 
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with anti-tumour immune responses.  The tumour biology of EPCR therefore 
becomes very relevant.  However, several key questions remain unanswered.  The 
majority of these studies have investigated EPCR-intrinsic functions, and have not 
investigated the wider biological context of EPCR dysregulation.  Though many 
studies have utilised mouse models, there are very few that have investigated EPCR 
in the human setting [78, 86].  Furthermore, there have been diverse effects of EPCR 
in different tumours, and the reason for this has not been explored.  The breadth of 
its expression in different cancers also needs to be determined.  In view of its 
recently discovered function as a γδ T cell ligand, it is now increasingly crucial to 





1.10 Project aims  
 
Emerging immunotherapies such as checkpoint blockade are now impacting on 
patient care.  However, the results have been variable in different cancer types [13, 
14].  Responses to checkpoint blockade have been linked to genetic factors [88], and 
though genetics and immunity are both relatively well understood, the link between 
the two is less well characterised.  CRC is a good model to develop this 
understanding, as it has well defined molecular subtypes with variable mutation rates 
and immune infiltration (which has been linked to patient outcome [37]).  To 
understand why immunotherapies have had limited success thus far in CRC, I shall 
investigate the genetic and pathological factors that impact on the immune 
microenvironment (Chapter 4).  This could potentially enable better targeting of 
existing immunotherapies, and could facilitate the development of novel approaches.  
To characterise immunity in different patient groups, I shall establish a gene 
expression signature for the immune microenvironment.  In addition, I will explore the 
immune microenvironment of the key RAS mutant subgroup of patients (Chapter 5). 
In addition, I shall explore the role of the γδ T cell ligand EPCR in colorectal 
tumourigenesis (Chapter 3).  The known functions of EPCR have expanded since its 
discovery.  Initially significant mainly for its role as an anti-coagulant factor, it is now 
implicated in inflammation and potentially immunity as a γδ T cell ligand.  There is 
also growing evidence that EPCR has a role in tumourigenesis.  Since this project 
was conceived, EPCR has been studied in a range of tumour types.  However, it has 
not as yet been investigated in CRC, the third commonest cancer in this country and 
the second most common cause of cancer-related death.  In view of the well-
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established developmental pathway and pathological characterisation of CRC, this 
tumour type is a promising model in which to explore the role of EPCR in 
tumourigenesis.  Therefore, I shall investigate the extent and mechanism of EPCR 
expression and its impact in CRC, both in vitro and in a clinical cohort, to determine 
























2.1 Bioinformatic analyses 
2.1.1 EPCR bioinformatics 
EPCR mutation, methylation, copy number and expression data were retrieved from 
the The Cancer Genome Atlas (TCGA) project via the cBioportal tool [89-92].   
Pathological and clinical data were also downloaded.  Cancer cell line encyclopaedia 
[93] data were retrieved using the CCLE portal and cBioportal.  Oncomine 
(Compendia Bioscience) was used for analysis and visualization of EPCR expression 
in multiple tumour types [94]. 
Data were tabulated and analysed with The Integrative Genomics Viewer [95] and 
Excel (Microsoft Corp.).  Pearson correlations were performed when the data 
distributions were parametric, and Spearman when they were non-parametric.  
Significance tests were performed in Minitab (Minitab Inc.) using T-tests for 
parametric data and Mann-Whitney U for non-parametric data.  Normality of 
distributions were confirmed using the Anderson-Darling Test. 
2.1.2 Immunity bioinformatics 
2.1.2.1 Gene identification 
Genes associated with innate and adaptive tumour immunity in cancer [37, 42] and 
genes relevant to established colon cancer pathways were shortlisted as initial 
genes.  This list was expanded using molecular network pathway analysis (using 
cBioportal) [89, 90, 92].  This revealed further molecules and genes with known 
genetic, pathway and functional associations with the initial genes.  Genes revealed 
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through this approach were screened for inclusion into the final gene list based on 







































2.1.2.2 Data extraction 
Normalised Agilent microarray and RNAseq z-score data for initial genes and 
mutation data for TP53, KRAS, BRAF, NRAS, HRAS, PIK3CA and PTEN were 
extracted from The Cancer Genome Atlas (TCGA) colorectal dataset [91] using the 
cBioportal tool [89, 90, 92].  Where expression data were unavailable, genes were 
excluded from the analysis.  Clinical data for these patients were retrieved from the 
TCGA portal (https://tcga-data.nci.nih.gov/tcga/) and were tabulated with genetic 
data.   
2.1.2.3 Data analysis 
Data were tabulated in Excel (Microsoft Corp.) and unsupervised two-dimensional 
hierarchical clustering was performed using MeV (Dana-Farber Cancer Institute, 
Boston, MA, USA) and the Pearson correlation.  Patient and gene clusters were 
identified by varying gene-tree distance-thresholds and visual analysis.  Normality of 
distributions was confirmed with the Anderson-Darling test.  Pearson Coefficient of 
determination (R2) values were calculated in Excel and Minitab (Minitab Inc.) to 
investigate correlations in gene expression.  Gene expression was correlated against 
beta actin as a control gene.  T tests were performed for univariate analyses of 
normally distributed data, and Mann Whitney U tests for non-normally distributed 
data.   Multivariate linear regression analyses of gene expression against mutations 
in key tumour associated genes (P53, KRAS, BRAF, NRAS, HRAS, PI3KCA, PTEN) 
were completed in Stata 12.2 (Statacorp.).  For two by two comparisons, a Chi 
squared test was used; if any groups contained less than 5 values, the Fishers Exact 
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test was used in preference.  MEK activation signature data were retrieved for the 
TCGA dataset from the authors [16] and statistical analyses were performed in Excel.      
2.1.2.4 Mutation rate analysis 
Mutation rate and number data for 12 TCGA cancer types, including CRC, produced 
by Kandoth et al. [96] were downloaded from the Synapse platform 
(https://www.synapse.org/, Sage Bionetworks).  Expression data for CIRC genes 
were extracted using cBioportal, and were combined with mutation data in Excel.  
CIRC expression was calculated for each case, and correlations with mutation rate 
were made both by mutational group comparisons and Pearson and Spearman tests.  
Graphs were produced in Excel and Minitab. 
2.1.2.5 Neoantigen analysis 
Neoantigen analysis was undertaken in collaboration with Sebastian Boegel and 
Ugur Sahin (TRON, University of Mainz, Germany).  Full CRC TCGA RNAseq data 
and sequencing data were used.  Initially, the number of non-synonymous single 
nucleotide variations (nsSNVs) was determined per patient.  Using RNAseq, the 
number of reads per mutation was calculated to determine whether the neoantigen 
was expressed.  HLA-type was predicted from RNAseq data using seq2HLA and 
HLA-binding predictions were made using the IEDB MHC binding prediction 
algorithm v2.9 (consensus method), as described by Boegel et al. [97, 98].  A cutoff 
for strong binding (and thus “likely immunogenic”) was 1.0. This approach was used 
to determine how the strength of neoantigen binding to HLA and the total number of 
neoantigens related to CIRC expression in TCGA patients. 
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From the total neoantigen data, the number of neoantigens per case and top rank 
neoantigen data were calculated and combined with CIRC expression in Excel, and 
correlation tests were performed.  Individual analysis of RAS-associated neoantigens 
were performed by extracting RAS neoantigen data from total neoantigen data for all 
cases and determining the number and frequency of these neoantigens as well as 
binding strength in each case. 
2.1.2.6 Cancer cell line encyclopaedia analysis 
CIRC microarray z-score data for 51 colorectal cell lines were retrieved from the 
CCLE database using cBioportal.  These were combined with mutation data for 
KRAS, NRAS, HRAS, BRAF, PIK3CA and PTEN.  Mean expression of the CIRC and 
key immune genes in each mutational subtype were calculated, and significance 
testing was performed using T-Tests for one by one comparisons.   
2.1.2.7 Consensus Molecular Subtypes (CMS) analysis 
Consensus molecular subtype (CMS) data were obtained from the Colorectal Cancer 
Subtyping Consortium through the Synapse platform (https://www.synapse.org/, 
Sage Bionetworks). 
These data were utilized to perform intra-CMS group analysis of RAS mutation and 
CIRC.  In addition, RNAseq data were downloaded for the extended TCGA RNAseq 
dataset and the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) dataset.  
Single sample enrichment of pathways was assessed using the Gene Set Variation 
Analysis (GSVA) algorithm [99].  Data from TCGA were downloaded as level 3 
processed data; genes with no variation were removed, and remaining genes 
expression values were log2 transformed.  CMS labels for these datasets were 
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downloaded from Synapse at https://www.synapse.org/crcsc.  Immune cell type gene 
sets used in this analysis are described in Bindea et al. [100].  Differential enrichment 
using KRAS mutation status within and across CMS groups was tested using the 
Wilcoxon rank sum test, and corrected for multiple testing using Benjamini-Hochberg 
procedure. 
 
2.2 Specimen collection 
 
2.2.1 EPCR specimens 
Patient tumour and serum specimens were collected from the University of 
Birmingham Human Biomaterials Resource Centre (HBRC) (ethical approval HBRC 
11-058).  Survival analysis utilised tumour samples from the MRC COIN study 
(ISRCTN27286448), under ethical approval 13/WM/0339 [10].  All patients had 
provided consent for use of their tissue.  Specimens were cut to a thickness of 4 
microns.  
2.2.2 RAS cohort specimens 
2.2.2.1 Sample size calculation and sample collection 
To determine the required sample size, a power calculation was performed using 
Altman’s nomogram.  This confirmed that a total of 100 samples (50 RAS mutant, 50 
RAS wildtype) were required for a power of 80%, a significance level (α) of 0.05 and 
a minimum detectable standardised difference of 0.55.   This power provided an 80% 
probability of detecting a difference between the RAS mutant and wildtype groups if 
one existed.  The significance level was the threshold below which the null 
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hypothesis (that there was no difference between the RAS mutant and wildtype 
groups) would be rejected, in this case corresponding to a p value <0.05.   
The specimens were selected to represent the range of RAS mutations observed in 
the original TCGA microarray data set.  The final cohort comprised 28 RAS 
G12D/G13D mutants (24.3%), 38 RAS non-G12D/G13D mutants (33.0%), and 49 
RAS wild types (42.6%).  Therefore, there were 66 RAS mutants and 49 RAS 
wildtypes (total = 115).  Samples were obtained from the completed CRUK Stratified 
Medicine Programme One pilot study and CRC patients from the Queen Elizabeth 
Hospital, Birmingham.  These patients had their RAS mutation status determined as 
part of their routine clinical workup.  Samples were collected under ethical approval 
HBRC 14-205 (Sponsor: University of Birmingham).  
2.2.2.2 Sample processing 
Suitable formalin-fixed, paraffin-embedded (FFPE) blocks were identified from 
pathology reports and were retrieved and processed at the HBRC biobank.  Twenty 
sections of 4 micron thickness were cut from each block and were mounted onto 
slides for staining.  Additionally, six 10 micron scrolls were cut from each block and 






2.3.1 EPCR and PAR1 immunohistochemistry 
2.3.1.1 Immunohistochemistry protocol 
Paraffin-embedded colorectal cancer sections and matched adjacent normal sections 
were deparaffinised and heat-induced epitope retrieval (HIER) was performed by 
adding the slides (in a slide rack) to a tray containing Novocastra Epitope Retrieval 
Solution pH8 (Leica, RE7116), which was incubated in a water bath heated to 97°C 
for 40 minutes. Slides were then washed twice (5 minutes per wash) in diluted DAKO 
wash buffer (S3006, containing 0.05 mol/L Tris/HCl, 0.15 mol/L NaCl, 0.05% Tween 
20 at pH7.6).  A hydrophobic mark was drawn around the tissue section using a 
DAKO Delimiting pen (DAKO, S2002).   Two to three drops of dual endogenous 
enzyme inhibitor were applied (component of Dako Envision Detection System 
peroxidase/DAB, Rabbit/Mouse kit, K406511-1).  Slides were then washed twice as 
above.  Non-specific binding was blocked by adding 100μl of 1% normal goat serum 
(NGS) (50μl concentrated NGS diluted in 5000μl of antibody diluent), with 30 minute 
incubation at room temperature (RT). Primary antibody was then added immediately 
after tipping off the NGS without washing the slides - 100μl 1:75 mouse anti-human 
EPCR antibody (R&D Systems, clone 304519, targeting human EPCR Ser18-
Ser210, mouse anti-human), diluted with antibody diluent (DAKO, S0809). The slides 
were incubated with the primary antibody overnight at 4°C. Slides were then washed 
three times with wash buffer and incubated for 30 minutes with 4 drops of polyclonal 
anti-mouse secondary antibody (Dako, component of Envision Detection System) at 
RT.  Slides were then washed three times with wash buffer as above.  Peroxidase 
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activity was revealed by adding 100μl diaminobenzidine (DAB – component of Dako 
Envision Detection System) for 5 minutes at RT.  The slides were counterstained with 
haematoxylin (100%, for 40 seconds) and were then washed under warm running tap 
water for 2 minutes.  Slides were dehydrated in 70% ethanol for 2 minutes, then 
100% industrial methylated spirit (IMS) for 2 minutes, and were then added to 
Histoclear for 2 hours at RT (Fisher Chemical).  Coverslips were mounted using 2-3 
drops of DPX (National Diagnostics), and were left to dry overnight.  Guidance on 
antibody optimisation was provided by a histopathologist (Dr Philippe Taniere, Queen 
Elizabeth Hospital, Birmingham). Controls that omitted the primary antibody were 
also performed to rule out non-specific binding of the secondary antibody.   For PAR1 
IHC the same protocol was used with a primary antibody that targeted PAR1 (NBP1-
71770, clone N2-11 Novus Biologicals), at a dilution of 1:100. 
2.3.1.2 EPCR immunohistochemistry scoring 
EPCR-stained slides were imaged on a Vectra 2.0 (Perkin Elmer) system using 
custom imaging algorithms developed on Inform software (Perkin Elmer).  Analysis of 
slides was performed on Inform software, using trained tissue and cell segmentation 
algorithms that were validated by a histopathologist (Dr Philippe Taniere).  Staining 
intensities were determined on a per cell basis, and H-scores were created by the 
Inform software.  H scores were calculated by the following formula:  [1 x (% cells 
with weak staining) + 2 x (% cells with moderate staining) + 3 x (% cells with heavy 
staining)].  This produced a score ranging from 0 to 300.  Tumour region and Stroma 
region H-scores across all slides were collated and compared using the unpaired T 




COIN study slides were stained for EPCR at the HBRC biobank using a Bondmax 
Autostainer.  The primary antibody (R&D systems, clone 304519) incubation time 
was 10 minutes at a dilution of 1:200. Antigen retrieval was performed at pH9.  
Stained slides were scanned using a Leica SCN400 slide scanner.  Scanned slides 
were analysed on Definiens Tissue Studio software.  Tumour regions of each slide 
were manually identified, and trained segmentation algorithms were used to separate 
epithelium and stromal regions.  Quantification of EPCR staining was performed on a 
regional basis, with the software quantifying the percentage of pixels that had strong 
staining, moderate staining, weak staining or no staining in each area. These data 




2.3.2 RAS cohort immunohistochemistry 
2.3.2.1 Immunohistochemistry protocol 
Immunohistochemical staining was performed using a Leica Bondmax autostainer.    
Clinically validated (IVD-CE) antibodies were chosen where available (Table 2.2).  
Otherwise, knockdown/knockout validated antibodies were selected.  If these were 
not available, in-house validation was performed, as described below. 








CD4  Leica 4B12 Prediluted, 
ready to 
use 
30 pH9 IVD-CE 
(clinically 
validated) 
CD8 Leica 4B11 Prediluted, 
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use 






























Abcam CR3/43 1:100 20 pH6 In-house 
 
Table 2.2 List of antibodies.   
*CST antibody validation includes western blot analysis, staining of paraffin-
embedded cell pellets with known expression, the use of blocking peptides, and the 




Initial staining conditions and concentrations were based on vendor 
recommendations, and were iteratively optimised in conjunction with a 
histopathologist (Dr Philippe Taniere).  
2.3.2.2 RAS cohort Immunohistochemistry scoring 
After staining of the CRC sections for the markers above, slides were scanned at 40x 
magnification using a Leica SCN400 slide scanner.  Scanned slides were digitally 
analysed using Definiens Tissue Studio software.  Analysis algorithms were created 
and optimised for each individual marker.  Regions of interest (ROIs) were created in 
the tumour regions of each slide, in order to enable an inter-tumoural analysis.  All 
tumours were digitally segmented into tumour epithelium and stroma regions using 
trained segmentation algorithms.  Depending on the marker type, staining was 
quantified on a per cell basis or on an area basis.  Class II HLA alone was quantified 
using the area method as the staining was strong and therefore the Definiens 
software could not reliably identify haematoxylin-stained nuclei (which is necessary 
for cell based scoring).  Percentages of cells or pixels with high, medium, low or no 
immunoreactivity were quantified in each region.  This produced either histological 
scores for cell-based scoring, which is a function of the number and intensity of 
immunoreactive cells as described above, or percental scores for area-based 
scoring, which is a function of the number and intensity of positive pixels on the 
scanned specimen.  Thresholds for negative/low, low/medium and medium/high were 
set to maximise the dynamic range of results between samples and to reduce false 
positive results (Table 2.3).  Haematoxylin thresholds (the staining intensities at 
which haematoxylin was recognised) were set individually and differed for each 
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antibody due to differences in DAB staining.  Haematoxylin thresholds were set to 








































0.02 0.25 0.60 1.00 
 
Table 2.3 Definiens scoring method and thresholds for each marker 
After analysis, segmentation was manually validated for each slide.  Analysis was 
performed using Excel (Microsoft Corp) and Minitab (Minitab Inc).  The normality of 
the distribution of Histological scores in each group (RAS mutant or RAS wildtype) 
was determined by performing the Anderson-Darling test.  All data were non-
parametrically distributed.  Therefore, for one by one comparisons, Mann Whitney U 





2.3.2.3 HLA Class II antibody validation 
To validate the HLA class II mAb (Anti-HLA DR + DP + DQ antibody [CR3/43] 
(ab17101)) (Abcam) a stably CIITA (Class II major histocompatibility complex 
transactivator) lentiviral transduced HEK293T cell line was used.  The parental 
HEK293T and K562 cell lines served as negative controls.  Expression of MHC class 
II was initially confirmed by flow cytometry.  Cells were then pelleted by centrifugation 
and fixed in 10% formaldehyde.  The pellets were embedded into paraffin blocks and 
cut into 4µm sections and mounted onto glass slides.  Immunohistochemistry was 
performed on those sections using the Leica Bond-RX automated platform.  Images 
of the sections were scanned using a Leica SCN400 Slide scanner (Figure 2.1). 
Flow cytometry was performed.  Cells in the cell suspension were counted and the 
volume containing 1 x 105 transferred to a 96-well plate.  Cells were then pelleted by 
centrifugation and re-suspended in 1:50 dilution of BioLegend allophycocyanin 
(APC)-conjugated anti-human HLA-DR (clone L243) (BioLegend).  A further two wells 
were used for isotype control (BioLegend APC Mouse IgG1 isotype) and negative 
control (MACS buffer). The cells were incubated with the antibody for 30 minutes at 
4°C. They were then washed with MACS buffer and fixed in 2% paraformaldehyde 
(PFA).  Flow cytometry was performed on a BD LSR II Flow Cytometer running the 
BD FACSDiva software (BD Biosciences). Flow cytometry demonstrated high levels 
of MHC class II in transfected cells in comparison to complete lack of expression in 










Figure 2.1 HLA Class II antibody validation.  The left panel shows staining of the 
parental HEK293T cell line, and the right panel shows the Class II HLA-expressing 
transfected HEK293T cell line. 




2.4 Survival analyses 
2.4.1 EPCR survival analysis 
Clinical data for the patients in the COIN study were obtained from the MRC under 
REC approval 13/WM/0339.  Data obtained included treatment arm (chemotherapy 
or chemotherapy plus cetuximab), demographic details including age and sex, 
clinical data including WHO performance status, number of metastases, timing of 
metastases, site of primary (within colorectum), serum carcinoembryonic antigen 
(CEA), microsatellite status and mutation status for key genes including KRAS, 
BRAF, NRAS and PI3K.  Survival data included 12-week response, best response, 
death, censored time to death, progression and censored time to progression (PFS 
time). 
The median EPCR percental score was used to categorise patients into EPCR high 
and low groupings.  Additionally, a separate analysis was performed for the top 20% 
of EPCR expressors against the bottom 20%.  Statistical modelling was performed 
using Stata 12.1 (Stata Corp).  Both the prognostic and predictive analyses utilized 
the Cox proportional hazards model, and adjusted for factors that significantly 
associated with PFS to p<0.05.  The proportional hazards assumption was tested by 
calculating Schoenfeld residuals (estat phtest).  
Stata commands: 
stset pfstime, failure(pfsstatus) 
estat phtest 
stcox i.factorx -  (for each factor) 
xi:stepwise, pr(0.05):stcox factor x factor y i.EPCRfactor   
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sts graph, by(factorx) 
 
2.4.2 RAS cohort survival analysis 
Clinical data for the patient cohort were extracted from patient notes.  Clinical 
information included patient age, gender, ethnicity, tumour stage, RAS mutation 
status and overall survival.  Microsatellite status data (as determined by fragment 
analysis) were added, as were the results of IHC scoring. Using Stata, survival 
analysis was performed (Cox regression) as above to determine the association 




2.5 shRNA transfection 
5 clones of EPCR shRNA (Sigma MISSION lentiviral pLKO.1-puro transduction 
particles) and 1 control shRNA (Sigma MISSION pLKO.1-puro Control high titre 
transduction particles - SCH001H) were obtained from Sigma (Table 2.4).   
 






















Table 2.4 shRNA clone IDs. 
1.6x104 HCT116 cells or HT29 cells were plated in each well of a 96 well plate and 
grown to 70-80% confluence in Dulbecco’s Modified Eagle Medium (DMEM) with 
10% Foetal Calf Serum (FCS). The media was removed, and 110μl media and 
hexadimerine bromide (polybrene, final concentration 8μg/ml) was added to each 
well.  shRNA lentiviral particles were added to appropriate wells at multiplicity of 
infections (MOIs) of 5, 1.5 and 0.5.  Cells were incubated with shRNA for 20 hours at 
37 with 5% carbon dioxide. The media containing lentivirus was then removed, and 
fresh media was added (120μl per well), and cells were incubated for a further 24 
hours.  Triplicate wells for each lentiviral construct and control were used.  The media 
was then removed from wells, and fresh media containing puromycin (1μg/ml) was 
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added, which was used to select shRNA transfected cells, as the shRNA construct 
contained a puromycin resistance gene.  A puromycin titration curve was previously 
produced to determine the minimum concentration that caused complete cell death 
after 3-5 days (1μg/ml).  Puromycin-containing media was replaced every 3-4 days 
until resistant colonies could be identified.   Colonies were expanded into a 12 well 
plate.  All 5 constructs and the controls for MOI 5 and MOI 0.5 were expanded.  They 
were subsequently expanded into 6 well plates, and then into 10cm culture dishes. 
EPCR expression was quantified with flow cytometry.  Maintenance of EPCR 
knockdown throughout the experimental period was confirmed with flow cytometry 
after completion of assays. 
EPCR-overexpressing HT29 cells were a generous gift from Julie Dechanet-Merville 
(University of Bordeaux, France). 
 
2.6 Flow cytometry 
2.6.1 EPCR cell line expression 
After incubation of HCT116 and HT29 cells with shRNA, media were removed from 
the wells and cells were washed with PBS buffer.  Cells were trypsinised with 500μl 
trypsin for 2 minutes at 37°C.  Trypsin was neutralised with media, and 500μl of cell 
suspension were aliquoted into flow cytometry tubes.  These were centrifuged and 
the supernatant was discarded.  EPCR (anti-human EPCR APC, eBioscience, clone 
RCR-227) and isotype control (Rat IgG1 K Isotype Control APC, eBioscience, clone 
eBRG1) antibodies were diluted with MACs buffer (5μl EPCR antibody in 50μl MACs 
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buffer per test, 0.83μl isotype control antibody in 66.6μl MACs buffer per test).  MACs 
buffer comprised 1 x PBS (pH 7.2) + 2nM EDTA + 0.5% BSA.  Cells were suspended 
in 50μl of diluted antibody, and the tubes were incubated in a dark ice box for 30 
minutes.  MACs buffer was then added to the tubes using transfer pipettes, cells 
were centrifuged, and the supernatant was discarded.  The cells were resuspended 
with MACs buffer, and were again centrifuged.  Supernatant was discarded, and cells 
were resuspended in MACs buffer.  The cells were fixed with 250μl of 1% PFA, and 
were stored at 4°C until analysis.  Cells were analysed on an Accuri C6 or LSR II (BD 
Biosciences) flow cytometer using standard protocols, and data were analysed using 
FlowJo and Excel. 
2.6.2 EPCR expression in mast cells 
The human Mast Cell (MC) line HMC-1.1 (V560G) [101] was cultured in IMDM with 
10% FBS.  Human Lung Mast Cells (HLMCs) were isolated from healthy lung 
obtained at surgery using anti-CD117-coated Dynabeads at ∼99% purity [102].  
HLMCs were cultured in DMEM (Dulbecco's Modified Eagle Medium) supplemented 
with 10% FCS, and cytokines (100 ng/ml SCF, 50 ng/ml IL-6, and 10 ng/ml IL-10) as 
described previously [103]. HMC-1 cells and HLMCs were stained with 2E9 antibody 
(1µg/mL) [53] which recognises EPCR protein or stained with IgM isotype control. 
Cells were indirectly labelled with FITC (Dako) and analysed by one-colour flow 
cytometry on a FACSCanto (BD Biosciences).  
EPCR expression was then confirmed on lung FFPE tissue using IHC.  Briefly, 10 nM 
citrate buffer was used for antigen retrieval on 4 µm sequential paraffin sections, 
followed by immunostaining with mouse anti-human EPCR monoclonal antibody 
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(R&D systems, clone 304519, 10 µg/mL) and  mouse anti-human tryptase (DAKO, 
clone AA1, 0.1 µg/mL).  Sections were counterstained with Mayer’s haematoxylin. 
 
2.7 MTT assays  
HCT116 and HT29 shRNA EPCR knockdown cells were cultured in DMEM with 10% 
FCS. Equal numbers of cells (4x103) were plated in each well of a 96 well plate.  
Cells were incubated at 37C with 5% carbon dioxide.  After 48 hours of incubation, 
chemotherapy drugs were added to the plates (either 5-Fluorouracil (5FU) or 
epirubicin) in concentrations determined by serial dilution (5FU - 0 to 256 μM, 
epirubicin – 0 to 8 μM).  After a further 48 hours of incubation, 10μl MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5mg/ml in PBS) was added to 
each well and after 2 hours cells were lysed with 50μl DMSO and absorbance was 
calculated using a Victor plate reader at 490nm for 0.1 seconds.  Colour intensity 
was normalised against controls untreated with chemotherapy.  All experiments were 
performed in triplicate.   
 
2.8 BrdU assays 
Assays were performed using the BrdU (bromodeoxyuridine) cell proliferation ELISA 
kit (Roche).  Cells were plated and treated with epirubicin or 5FU as with the MTT 
assays above.  After 48 hours of incubation, cells were labelled with 10μl per well of 
BrdU labelling solution and incubated for 4 hours at 37°.  The media was then 
removed and the plate dried with absorbent paper.  Cells were then denatured by 
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incubation with 200μl FixDenat solution for 30 minutes at RT.  Cells were incubated 
with 50μl Anti-BrdU-POD antibody solution for 90 minutes at RT (100μl per well) and 
then washed with wash buffer.  The wash buffer was then removed and absorbent 
paper was used to remove excess wash fluid.  This was repeated a further two times.  
100μl of substrate solution was added to each well, and plates were incubated for 15 
minutes at RT and were then analysed on a Victor plate reader at 405nm for 0.1 
seconds.  Colour intensity was normalised against untreated controls. 
 
2.9 Migration assays 
70-80% confluent EPCR-perturbed and control HCT116 and HT29 cells were serum-
starved by incubation in serum-free medium (DMEM) for 24 hours.  600μl of DMEM 
with 10% FCS was added to the wells of a 24 well plate.  2x105 cells in 100μl serum-
free DMEM were added to a Corning Transwell insert (Sigma, pore size 0.4 µm). The 
insert was then added to a well of the 24 well plate.  Cells were incubated from 3 - 48 
hours.  The cells on the lower side of the Transwell insert were fixed with 30% 
methanol and stained with 2% crystal violet for 2 hours at 4°C.   The Transwell 
inserts were removed and the upper side of the membrane was cleaned with a cotton 
bud to remove the non-migrated cells.  The inserts were photographed with a light 
microscope and camera in 5 set regions (upper left, upper right, lower left, lower right 
and centre) using Axiovision software (Carl Zeiss).  Cells were counted and analysed 
using Excel (Microsoft Corp).  The Mann-Whitney U test was used to compare 




2.10 Invasion assays   
70-80% confluent EPCR-perturbed and control HCT116 and HT29 cells were serum-
starved as with the migration assays.  Cells were suspended at 1.0 x 106 cells/ml in 
serum-free DMEM. 250μl of this cell suspension (containing 2.5 x 105 cells) was 
added to a QCM cell invasion assay insert (Millipore).  The insert was then added to 
a well of a 24 well plate that contained DMEM with 10% FCS.  Cells were incubated 
for 24-48 hours at 37°C and 5% CO2.  The cells and media from the top side of the 
insert were removed by pipetting out the remaining cell suspension.  The cells on the 
lower side of the insert were then detached by incubation for 30 minutes at 37°C with 
cell detachment solution (component of Millipore QCM cell invasion assay kit).  The 
insert was removed and detached cells were lysed and fluorescently labelled with 
200μl lysis buffer/dye solution (CyQuent GR Dye 1:75 with 4x lysis buffer, 15 minute 
incubation at RT).  200μl of the mixture was transferred to a new plate.  The wells 
were read with a fluorescent plate reader (Victor) using the 480/520 nm filter set.  
Results were analysed in Excel (Microsoft Corp). 
2.11 Activated Protein C ERK phosphorylation  
Activated Protein C (APC, Sigma) was added at a concentration of 180nM to 
confluent HCT116 cells after 24 hours of serum starvation.  APC was added for 2 
minutes, 5 minutes or 10 minutes, with or without prior 30 minute incubation with 
EPCR function-blocking antibodies (RCR-252, Novus Biologicals, 20μg/ml) after 
which cells were lysed with sodium dodecyl sulfate (SDS) containing phosphatase 




2.12 Western blotting 
Western blotting for ERK and pERK was performed using HCT116 cell lysates with 
Biorad TGX precast gels (Miniprotean TGX precast gel 12% 10 wells).  The transfers 
from gels onto membranes were performed using the Biorad Trans-blot Turbo system 
(using Biorad Transblot Turbo transfer pack PDVF midi).  After blockade with 3% 
BSA in TBST, separate membranes were incubated with primary antibody 
(ERK/pERK, New England Biolabs PhosphoPlus (Thr202/Tyr204) Antibody Duet 
(4370S + 4695S)) overnight at 4°C (pERK antibody 1:2000 dilution, ERK antibody 
1:1000 dilution, both into 20ml diluent (TBST with 5% BSA and 0.01% sodium 
azide)). Membranes were then incubated with goat anti-rabbit horseradish 
peroxidase (HRP) conjugated secondary antibodies (1:20000 dilution, 1μl antibody 
diluted in 20ml BSA).  Development was completed with an EZ-ECL kit (Biological 
Industries) and images of membranes were taken using the ChemiDoc MP system 
(Biorad).  Images were analysed using Image Lab 4.1 (Biorad).   
Western blotting was also performed to determine whether PC and APC were 
present in culture media (DMEM) or HCT116 cell lysate or supernatant.  Exogenous 
APC (Sigma), was used as a positive control in this analysis.  The western blotting 
protocol was as described above, except that a protein C primary antibody (clone 
NBP1-58065, Novus Biologicals, 1:1000 dilution) was used.  This antibody detected 
both PC and APC, as it targeted the light chain of PC from amino acids 1 to 236, 






HCT116 cells were treated with APC after 48 hours of serum starvation.  Optimal 
APC concentrations and treatment durations were determined by assessing APC-
induced expression changes of 4 genes (NFkB2, PCNA, BCL2A1, EFNA1, which 
were chosen based on previous findings in endothelium [69]) using quantitative real 
time polymerase chain reaction (qRT-PCR) (probes from Invitrogen (Table 2.5)).   
Genes Probe IDs NCBI reference Sequence 
NFkB2 Hs01028901_g1    NM_001077494.2 
PCNA Hs00427214_g1 NM_002592.2 
BCL2A1 Hs00187845_m1 NM_004049 
EFNA1 Hs00358886_m1 NM_004428.2 
 
Table 2.5 Taqman Probe IDs  
APC concentrations of 22.5nM, 45nM, 90nM and 180nM and treatment durations of 
24 and 48 hours were tested, based on a previous microarray study [69]. RNA was 
extracted from APC-treated cells using the RNeasy Plus Kit (Qiagen), as per the 
manufacturer’s instructions, alongside negative controls.  Reverse transcription was 
performed using the superscript VILO cDNA synthesis kit (Life Technologies), as per 
the manufacturer’s instructions.  qPCR was performed using a Sensimix II probe kit 
(Bioline) on a ABI 750 qPCR machine (Applied Biosystems).  The following program 
cycle was used: 50°C for 2 minutes; 95°C  for 10 minutes; (95°C for 15 seconds; 
60°C for 1minute) x 40.  Data were analysed in Excel.  The mean cycle threshold 
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values (Ct) were calculated using triplicate reactions, and were normalised against 
18S controls to calculate gene expression. A concentration of 180nM for 24 hours 
was associated with maximal alteration in gene expression.   
RNA was extracted from cells treated with 180nM APC for 24 hours using the 
RNeasy Plus Kit (Qiagen) alongside negative controls.  Extracted RNA purity and 
concentration was confirmed using a spectrophotometer (NanoDrop 3300, Thermo 
Scientific).  RNA was sent for two-colour Agilent Microarray analysis at the Functional 
Genomics Facility at the University of Birmingham, using Agilent SurePrint G3 
Human Gene Expression v3 8x60K Microarrays.  Three experimental replicates were 
performed.  A minimum of two technical replicates were performed for each 
specimen.  APC treated cells were assigned to Cy5 and controls to Cy3.  Differential 
gene expression data was produced in R using the Limma package (Bioconductor) 
after ‘Loess’ normalisation [104-106].  Genes with a Bayes factor greater than 5 or an 
adjusted p value of<0.05 (Benjamini and Hochberg’s method) were considered for 
further analysis. Further analysis was completed using DAVID [107, 108] and GSEA 
[109, 110].  
Limma commands for microarray analysis: 
library (limma) 
targets <- readTargets("Targets.txt") 
RG <- read.maimages(targets, path=".", source="agilent.median") 
RG <- backgroundCorrect(RG, method="normexp", offset=16) 
MA <- normalizeWithinArrays(RG, method="loess") 
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noControls <- MA$genes$ControlType == 0 
MA2 <- MA[noControls,] 
MA.avg <- avereps(MA2, ID=MA$genes$ProbeName) 
design <- modelMatrix(targets, ref="Control") 
fit <- lmFit(MA2, design) 
fit2 <- eBayes(fit) 
output <- topTable(fit2, adjust="BH", coef="Test", number=100000) 
write.table(output, file="Results.txt", sep="\t", quote=FALSE) 
 
2.14 sEPCR ELISA 
EPCR ELISA was performed using a Human EPCR ELISA kit (Elabscience, E-EL-
H0065).  Serum from 21 early stage (Dukes A or B) and 19 late stage (Dukes C or D) 
CRC patients were obtained from the HBRC biobank.  Reference standards were 
created with serial dilution.  100μl of serum or standard was added to a well of the 
ELISA plate which was then incubated at 37°C for 90 minutes.  The solution was 
removed, and 100μl of EPCR biotinylated detection antibody was added and 
incubated for 60 minutes at 37°C.  Each well was aspirated with wash buffer (350μl 
per well).  The wash buffer was removed at each step by patting the plate dry on 
absorbent paper.  The wells were washed three times in total.  100μl of HRP 
conjugate solution was added to each well and the plate was covered and incubated 
for 30 minutes at 37°C.  The wells were washed five times as above.  90μl of 
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substrate solution was added to each well. The plate was sealed and incubated in 
darkness at 37°C for 15 minutes.  The reaction was terminated by adding 50μl of 
Stop solution (containing sulphuric acid) to each well.  The optical density was 
measured on a Victor plate reader at 450nm.  Results were analysed on Excel. 
2.15 CEA ELISA 
CEA ELISA was performed using a CEA human ELISA kit (Abcam, ab99992).  
Reference standards were created with serial dilution.  100μl of serum or standard 
was added to a well of the ELISA plate which was then incubated at RT for 150 
minutes.  Each well was aspirated and washed four times with wash buffer (300μl per 
well).  The wash buffer was removed at each step and the plate dried using 
absorbent paper.  100μl of biotinylated CEA detection antibody was added and 
incubated for 60 minutes at RT.  The wells were washed four times as above.  100μl 
of HRP-streptavidin solution was added to each well and the plate was covered and 
incubated for 45 minutes at RT.  The wells were washed four times as above.  100μl 
of substrate solution was added to each well. The plate was sealed and incubated in 
darkness at 37°C for 30 minutes.  50μl of Stop solution was then added to each well 
to terminate the reaction.  The optical density was measured on a Victor plate reader 







2.16.1 RNA extraction 
RNA was extracted from 3 FFPE scrolls per tumour using the Purelink FFPE total 
RNA isolation kit (Invitrogen) as per the manufacturer’s instructions.  After extraction, 
the samples were treated with 1μl/sample DNAse (DNase I Amplification Grade, 
Thermo Fisher (1 unit/μl)) to eliminate any extracted DNA.  The RNA concentration 
was determined using the Qubit RNA Broad Range assay kit (Life Technologies), as 




2.16.2 Truseq panel 
A custom Illumina Truseq library/panel was designed in collaboration with Dr Andrew 
Beggs.  This panel targeted the genes in Table 2.6.  The genes selected included the 
28 genes in the CIRC metagene, a host of additional immune-related genes, and 
genes associated with the Dry et al MEK signature.  The CIRC and Dry et al MEK 
signature are described in chapter 4. 
ALOX5AP ELF1 ICOS MAP2K3 
BIN2 ETV4 IDO1 NCKAP1L 
BNIP3 ETV5 IFNG ORM1 
CCL18 EVI2A IGHA1 PDCD1 
CCL5 EVI2B IGLL1 PDCD1LG2 
CD247 FOXP3 IL10 PHLDA1 
CD274 FXYD5 IL10RA PIAS1 
CD4 GNLY IL12A PROS1 
CD48 GZMH IL12B PTPRC 
CD53 GZMK IL17A S100A6 
CD74 HAVCR2 IL18 SASH3 
CD80 HLA-A IL18RAP SERPINB1 
CD8A HLA-B IL6 SLCO4A1 
CIITA HLA-C IRF1 SOCS1 
CSF1R HLA-DMA ITGB2 SPRY2 
CTLA4 HLA-DMB JAK2 SRGN 
CXCL10 HLA-DOA KANK1 STAT1 
CXCL11 HLA-DPA1 LAG3 TBX21 
CXCL13 HLA-DPB1 LAPTM5 TRIB2 
CXCL9 HLA-DQA2 LAT2 VEGFA 
CYBB HLA-DRA LCP2 WAS 
DOCK2 HLA-DRB1 LGALS3  
DUSP4 HLA-DRB5 LST1  
DUSP6 ICAM1 LZTS1  
 




Figure 2.2 contains a summary of the library preparation workflow.  In brief, 400ng of 
the RNA extracted from each tumour was used for the protocol.  The RNA was 
reverse transcribed into first strand cDNA using Protoscript II reverse transcriptase 
and random primers.  The Oligo pool was then hybridised to the cDNA.  This 
hybridized an oligo pool containing upstream and downstream oligos specific to the 
targeted regions of interest to the cDNA samples and bound them to paramagnetic 
streptavidin beads.  The bound oligos were then washed, extended and ligated.  This 
removed unbound oligos from cDNA.  A DNA polymerase extended from the 
upstream oligo through the targeted region, followed by ligation to the 5’ end of the 
downstream oligo using a DNA ligase.  This resulted in the formation of products 
containing the targeted regions of interest flanked by sequences required for 
amplification.  Then PCR amplification was performed, amplifying the extension-
ligation products using primers that added index sequences for sample multiplexing.   
The resultant output was cleaned using AMPure XP beads, to purify the PCR 
products from the other reaction components.   The library was then pooled and 
quantified.  This combined, quantified, denatured, and diluted equal volumes of 
library in hybridisation buffer in preparation for sequencing. The sequencing was 










Figure 2.2 Summary of RNAseq library preparation workflow.  
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2.17 Microsatellite status 
DNA was extracted from one FFPE scroll per tumour using the Maxwell RSC DNA 
FFPE kit (Promega) as per the manufacturer’s instructions.  DNA concentration was 
determined using the Qubit dsDNA BR assay kit (Life Technologies). 
Microsatellite status was determined with a protocol adapted from Buhard et al. [111].  
This technique uses a refined version of the ‘Bethesda panel’ of five markers for the 
analysis of MSI.  The Bethesda panel includes two mononucleotide (BAT-25 and 
BAT-26) and three dinucleotide (D5S346, D2S123, and D17S250) repeats.  Tumours 
with instability at two or more of these markers are defined as being MSI-H, whereas 
those with instability at one repeat or showing no instability are defined as MSI-low 
and MSS tumours, respectively.   
Extracted DNA from tumour samples underwent polymerase chain reaction (PCR) 
with the reagent volumes in Table 2.7. 




Primer Mix 0.6 
MyTaq 0.2 
Sample (DNA) 1.0 
 
Table 2.7 Microsatellite status PCR reagents 
PCR reaction conditions were 95°C for 2 minutes, then 33 cycles of 95°C for 15 
seconds, 55°C for 15 seconds and 72°C for 50 seconds.  Successful amplification 
was confirmed by running the product on an agarose gel. 
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Fragment analysis was conducted on an Applied Biosystems 3730 DNA analyser set 
to run in ‘fragment analysis’ mode.  1µl sample (from a 1/100 dilution of PCR 
product), 9µl of formamide and 1µl LIZ-600 size standard (Applied Biosystems) were 
loaded onto each well of the plate.  Sizes of microsatellite markers were determined 



















3.1.1 The physiological role of EPCR 
Endothelial protein C receptor (EPCR) is a type I transmembrane protein that is 
homologous to Major Histocompatibility Complex (MHC) molecules.  It was initially 
described as a receptor for Protein C (PC), which is crucial in the down modulation of 
blood coagulation [61].  EPCR increases the conversion of the zymogen PC to 
Activated Protein C (APC), and is a receptor for both PC and APC.  In endothelium, 
APC cleaves factors V and VIII, which is central to its anti-coagulative effect [60].  In 
addition to coagulation, EPCR expression on endothelium is known to play important 
roles in inflammation, apoptosis and cell proliferation [69, 73, 74, 112].   APC binding 
to EPCR initiates intracellular signalling and alters gene transcription [69].  This 
signalling is dependent on Protease-Activated Receptor 1 (PAR1).  Downstream 
effects of PAR1 activation include ERK and Akt phosphorylation and subsequent 
alteration in the expression of inflammatory genes [69, 74].  Pro and anti-apoptotic 
proteins such as Bax and Bcl2, as well as p53, are modulated by PAR1 cleavage 
[73].  Subsequently, it is thought that APC/EPCR, through cleavage of PAR1, has 
anti-inflammatory and anti-apoptotic effects [113].     
3.1.2 EPCR as a ligand for γδ T-cells 
EPCR has been shown to be upregulated in various cancer cell lines [59].  Moreover, 
work in our laboratory has highlighted EPCR as a direct ligand for Vδ2-negative γδ T-
cells [53], the predominant tissue subset of these unconventional T cells.  γδ T cells 
are able to recognise ‘altered self’, by detecting upregulation of host components via 
germline-encoded receptors (eg NKG2D) or potentially via the γδ TCR, in either 
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microbial or non-microbial stress. EPCR is a direct ligand for the Vγ4δ5 LES TCR, 
originally isolated from a patient with acute CMV.  EPCR, expressed on endothelial 
cells infected by CMV in vivo, was not upregulated by CMV infection, but TCR 
recognition of EPCR in the context of a CMV-induced ‘multimolecular stress 
signature’ was sufficient to induce LES recognition of target cells.  LES was able to 
recognise various cell lines expressing EPCR in an EPCR-dependent manner.  
These studies highlighted the possibility that EPCR might act as a signal of epithelial 
tumourigenesis to γδ T cells.  To understand this more fully, a greater knowledge of 
EPCR’s role in epithelial tumourigenesis was required.  I therefore sought to 
understand the extent and significance of EPCR’s expression in epithelial cancers, 
the cellular mechanisms of its expression, and its functional significance in 
transformed tumour cells.  EPCR-associated signalling pathways have potential 
relevance in cancer, overlapping with key proliferative and apoptotic pathways in the 
tumour setting, raising the possibility that dysregulated EPCR expression on 
transformed epithelial tissue may directly effect similar mechanisms to promote 
tumour cell survival and growth. 
3.1.3 EPCR in cancer 
Recently, there has been increasing interest in EPCR’s potential role in the epithelial 
tumour setting.  However, there have been conflicting results in different tumour 
types.   A number of studies suggest that EPCR expression increases tumour cell 
survival.  In mouse xenograft models of lung cancer, treatment with EPCR-blocking 
antibodies reduces metastatic tumour burden [78].  Knockdown of EPCR in a gastric 
cancer cell line suppresses cell proliferation and migration [114].  In breast cancer, 
EPCR is a marker of cancer stem cell-like populations, which are thought to have a 
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high tumour-initiating capacity, and in vivo EPCR blockade attenuates tumour growth 
[80].  Conversely, mouse melanoma studies suggest that APC treatment and 
endothelial EPCR overexpression are associated with decreased metastasis 
development in this tumour type [79].  Additionally, in in vivo models of 
mesothelioma, EPCR knockdown significantly increases tumour growth and burden 
[83].   
These opposing results demonstrate that there is ambiguity regarding EPCR’s 
significance in the cancer setting, with varying effects in different tumour types.  
However, there are clearly suggestions that EPCR is clinically relevant.  Significantly, 
EPCR has been shown to be a marker of chemoresistance in tumour cell lines [59],  
including colorectal cancer cell lines such as HCT116.  Furthermore, EPCR 
expression is predictive for chemotherapy response in early stage non-small cell lung 
cancer [78].  Finally, in ovarian cancer, serum EPCR expression is correlated with the 
tumour marker CA-125, suggesting possible clinical relevance as a biomarker [86].  
The role of EPCR in CRC, a tumour type with high mortality and prevalence [1], has 
not been explored, and in view of the well-established developmental pathway and 
pathological characterisation of CRC, this tumour type is a promising model in which 
to clarify the role of EPCR in tumourigenesis.  
3.1.4 Chapter aims 
In this chapter, I have characterised EPCR expression in CRC, and have provided 
potential explanations into the mechanisms of its expression.  The role of APC 
induced signalling on ERK and gene transcription has been explored.  Furthermore, I 
have shown that EPCR has a modest impact on tumour cell chemosensitivity and 
82 
 
influences migration.  Finally, utilizing cancer tissue from the MRC COIN clinical trial 
[10], which investigated the efficacy of EGFR monoclonal antibody therapy in 
metastatic colorectal cancer, I provide insights into EPCR’s likely clinical relevance.  
The data provide a compelling mechanism for EPCR expression in multiple epithelial 
tumour settings, and suggest that its upregulation could represent a wider 
dysregulation of chromosome 20q.  These findings have implications for 
understanding the clinical significance of EPCR in different tumour settings.   
Furthermore, they highlight that single γδ TCR ligands may have the potential to 







3.2.1 EPCR mRNA expression in multiple cancer types 
The Oncomine database, which enables comparative analysis of gene expression in 
tumours versus normal tissue, was interrogated to determine EPCR expression in 
multiple tumour types [94].  EPCR was upregulated in tumour versus normal in 126 
separate datasets and downregulated in 50 datasets, which included 21 different 
cancer types.  Of all cancer types, colorectal cancer had the highest level of EPCR 
overexpression, and the most datasets in total in which EPCR was overexpressed 
(Table 3.1).  In CRC, across 9 separate non-overlapping datasets, EPCR was 
significantly overexpressed (p <0.0001).   This suggested amongst all tumours, 
colorectal cancer had one of the highest and most consistent levels of EPCR 
upregulation.   
Interestingly in certain cancer types, particularly ovarian cancer, EPCR was amongst 
the most downregulated genes.  This highlights that the expression of EPCR is highly 




Analysis type by cancer Cancer vs. 
normal 
Bladder cancer 4  
Brain and CNS cancer 13  
Breast Cancer 3 9 
Cervical Cancer 3  
Colorectal cancer 22  
Oesophageal cancer 8 2 
Gastric cancer 8  
Head and Neck cancer 14  
Kidney cancer 9 1 
Leukaemia 8 1 
Liver cancer 4 2 
Lung cancer  5 
Lymphoma 11 1 
Melanoma  2 
Myeloma 1  
Other cancer 12 4 
Ovarian cancer  10 
Pancreatic cancer 5  
Prostate cancer  9 
Sarcoma 2 4 
 
Percentile of underexpressed genes 
containing EPCR 
 Percentile of overexpressed genes 
containing EPCR 
1% 5% 10%  10% 5% 1% 
       
 
Table 3.1 ONCOMINE expression data – number of datasets in which EPCR is significantly 
differentially expressed in cancer versus normal to p<0.0001.  Cell colour is determined by the highest 




3.2.2 EPCR expression in colorectal cancer 
To confirm EPCR’s upregulation in colorectal cancer, sections from 30 colorectal 
cancers and adjacent normal regions were stained for EPCR using 
immunohistochemistry.   The primary EPCR antibody was validated using a HCT116 
EPCR knockdown cell line, and endothelium acted as a positive control (Figure 3.1).  
In addition, a control was performed with the primary antibody omitted (data not 
shown).     
Stained sections were imaged on the Vectra platform and were analysed using 
Inform software (Figure 3.2 and 3.3).  Segmentation and scoring algorithms were 
validated by a Histopathologist.  This confirmed that EPCR reactivity was higher in 
tumour regions compared to normal regions (p<0.0001).  Reactivity was measured 
using the H-score, which is a function of reactivity intensity and percentage coverage.  
The mean H score in tumour regions was 244.2 (standard error 5.03), versus 87.6 
(standard error 10.43) in normal regions.  EPCR reactivity was observed in the 
cytoplasm and membrane compartments.  Intense reactivity of what appeared to be 
mast cells (as confirmed by a Histopathologist) was observed throughout tissue 
sections (Figure 3.2D).  Collaborative studies by Professor Peter Bradding confirmed 
EPCR expression on mast cells (Figure 3.4).  This is the first report of 








Figure 3.1 Validation of EPCR antibody. 
a) IHC staining of wild type HCT116 cells with anti-EPCR antibody. 
b) IHC staining of EPCR shRNA knockdown HCT116 cells with anti-EPCR 
antibody. 








Figure 3.2 Scanned image of EPCR-stained CRC section. 
a) Whole slide scanned image of CRC region surrounded by normal colonic 
mucosa.  
b) 5x magnified image of tumour with adjacent normal colonic mucosa 
c) 20x magnified image of tumour region, demonstrating strong EPCR 
staining 









Figure 3.3 Digital software analysis of EPCR-stained CRC section. 
a) Area for digital analysis with Inform software (20x magnification) 
b) Image a) with Inform tissue-segmentation through trained automated 
algorithm.  Red=epithelium, green=stroma, yellow=background 








Figure 3.4 EPCR expression on mast cells. 
  
a) Flow cytometry demonstrating EPCR protein expression on mast cells using 2E9 
antibody  
b) Flow cytometry data are presented as percentage of 2E9+ cells of the total cell 
population using the Overton method [115] for Human Mast Cell line 1 (HMC-1) and 
Human Basophil and Lung Mast Cell line (HLMC) 
c) and d) Sequential sections demonstrating co-localisation of EPCR to tryptase 




3.2.3 The association between EPCR expression in colon cancer and gene 
amplification and hypomethylation 
To determine the possible mechanisms of EPCR overexpression, I utilised public 
bioinformatic genomics and transcriptomics datasets [91].  The EPCR gene 
(PROCR), though rarely mutated in any cancer type, was frequently amplified (Figure 
3.5).  In the CRC TCGA dataset, gene amplification was significantly associated with 
increased mRNA expression (p<0.05).  Overall, there was a strong correlation 
between PROCR copy number and mRNA expression (Spearman rho = 0.325, 
p<0.00001) (Figure 3.6A).  In the same dataset, the chromosomal unstable (CIN) 
group of cancers had a significantly higher EPCR expression than the non-CIN group 
(p<0.01).  Despite this, some EPCR overexpressors were of the non-CIN 
microsatellite unstable (MSI) hypermutated subtype.  These tumours were mostly 
diploid, thus gene amplification could not account for overexpression.  I therefore 
suspected that epigenetic factors were also important in determining EPCR 
expression.  Indeed, there was a strong inverse correlation between PROCR 
promotor methylation and gene expression across the entire patient dataset 
(Spearman rho -0.59, p<0.001) (Figure 3.6 B, C).  When copy number data were 
combined with methylation data, it became clear that hypomethylation played a key 
role in determining expression across all patient groups (Figure 3.7).  Patients that 
overexpressed EPCR had significantly lower methylation than those that did not 
(p<0.001).  Amplification and hypomethylation when combined associated with the 
highest expression.  Having established that EPCR is overexpressed in a large 
number of colorectal tumours, and the likely mechanism, the wider genomic context 








Figure 3.5 PROCR amplification, deletion and mutation rates across a range of 
cancer types and databases [89, 92].  The number above each bar represents the 






Figure 3.6 The association between EPCR expression and PROCR gene 
amplification and hypomethylation in the TCGA CRC dataset (n=195) 
a) PROCR copy number versus mRNA expression 
b) Variation in PROCR copy number and promotor methylation with mRNA 
expression  
c) Heatmap showing correlation between PROCR mRNA expression, promotor 








Figure 3.7 Relationship between PROCR methylation, GISTIC copy number 
scores and expression.  GISTIC (Genomic Identification of Significant Targets in 
Cancer) scores of 0 (blue) represent tumours with diploid PROCR copy number, 
scores of 1 (green) represent tumours with low level gains in PROCR copy number, 
and scores of 2 (red) represent tumours with high level amplification of PROCR copy 
number.  The upper box highlights patient group with low methylation and highest 
expression.  The lower box highlights most highly methylated patients, who have low 




3.2.4 The association between EPCR expression and chromosome 20q 
amplification 
To determine whether PROCR was co-expressed with other genes, I explored TCGA 
expression and genetic data. The majority of genes whose expression correlated 
most closely with PROCR were located in the same chromosomal region - 
chromosome 20q (Table 3.2).   
On an individual patient basis, PROCR gene amplification was frequently associated 
with amplification of all genes in chromosome 20q (Figure 3.8).  Across the entire 
195 patient cohort, the copy numbers of the majority (99.42%) of genes located on 
chromosome 20q were positively correlated with PROCR copy number (Figure 3.9A), 
whereas a significantly smaller proportion of 20p genes were correlated (36.90%, 
p<0.05 (chi-squared)).  In addition, the expression of a high proportion (53.80%) of 
20q genes were positively correlated with PROCR expression, though the 
correlations were not as strong as those seen with copy number (Figure 3.9C).  A 
significantly smaller proportion of 20p genes were correlated in terms of expression 
(13.72%, p<0.05 (chi-squared)).  Finally, 55.33% of chromosome 20q genes 
correlated with PROCR in terms of promotor methylation.  However, a similar 
proportion of 20p genes were also correlated in terms of methylation (51.30%, 
p=0.47, chi-squared) (Figure 3.9B).  This suggests that whilst PROCR copy number 
and expression co-regulation are a 20q regional phenomenon, regulation of 
methylation is less region-specific. 
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Across the entire colon cancer dataset, chromosome 20q was amongst the most 
frequently amplified chromosomal regions (Figure 3.10).  Additionally, 20q was 
amplified across a range of cancer types, including several in which EPCR has been 
shown to be expressed, including melanoma [79], gastric cancer [114] and lung 
squamous cell cancer [78] (Figure 3.10). These data suggest that EPCR may be a 
marker of tumours with chromosome 20q amplification, which are known to have 










HM13 0.45 20q11.21 
PDRG1 0.44 20q11.21 
C20ORF24 0.43 20q11.23 
PSMA7 0.43 20q13.33 
TPD52L2 0.43 20q13.33 
TRPC4AP 0.43 20q11.22 
MRGBP 0.43 20q13.33 
ADRM1 0.42 20q13.33 
BRI3 0.42 7q21 
EIF6 0.41 20q11.22 
ATP6V1F 0.41 7q32.1 
EFNA2 0.41 19p13.3 
SSUH2 0.41 3p25.3 
NDRG3 0.4 20q11.23 
RHOD 0.4 11q13.2 
EDEM2 0.39 20q11.22 
ACTR5 0.39 20q11.23 
DYNLRB1 0.39 20q11.22 
CEBPA 0.39 19q13.11 
FAM96B 0.39 16q22.1 
UQCC1 0.38 20q11.22 
PIGU 0.38 20q11.22 
ROMO1 0.38 20q11.22 
AHCY 0.38 20q11.22 
NEU1 0.38 6p21.33 
TOMM34 0.38 20q13.12 
TCFL5 0.38 20q13.33 
RPS21 0.38 20q13.33 
TLDC2 0.37 20q11.23 
 
Table 3.2 Genes most highly co-expressed with EPCR in TCGA CRC dataset, 











Figure 3.8 Copy numbers of chromosome 20 genes in 195 TCGA colorectal 
cancer patients.  Genes are organised by chromosomal location (20p is left, 20q is 
right).  Each individual horizontal coloured line represents a patient.  Blue represents 
loss of gene, red represents gain of gene and white represents no change in copy 
number.  The location of PROCR is indicated by the arrow. 









Figure 3.9 PROCR correlations with chromosome 20 genes.   
Pearson correlations for PROCR gene (A) copy number, (B) methylation and (C) 
expression with genes on chromosome 20, arranged by chromosome region.  
PROCR is located on 20q11.2 (boxed). Red lines represent the thresholds of 










Figure 3.10 Genomic copy number variations across a range of cancers.   
Red represents gene and chromosome amplification.  Blue represents deletion of 
genes and chromosomes.  Chromosomes are ordered from 1 to 23,X,Y. 
Chromosome 20q is one of the most frequently amplified regions in colon cancer and 
across a range of cancer types (colon adenocarcinoma, breast adenocarcinoma, 
lung squamous cell cancer, gastric adenocarcinoma and melanoma TCGA data). 





Carvalho et al. previously identified 3 regions, called ‘smallest regions of overlap’ 
(SROs), of chromosome 20q that are commonly amplified in CRC [117].  PROCR is 
located within the first of these (SRO 1) which spans 32-36 Mb.  The group identified 
7 putative oncogenes located on 20q based on upregulation on carcinomas versus 
adenomas, association with 20q amplification, and correlation between copy number 
and gene expression.  Of these 7 genes, 6 significantly correlated with EPCR 
expression (Table 3.3).  Furthermore, EPCR expression was significantly correlated 
with 13/13 potential ‘cancer initiating genes’ located on 20q identified by Tabach et 
al. [116].  Finally, PROCR was significantly correlated with a gene that was 
previously ranked first in a microarray-based CIN signature (TPX2) [118], reinforcing 






C20orf24 20q11.22 0.989164 0.227405 0.498511 
AURKA 20q13.2 0.907967 0.009653 0.239549 
RBM38 (RNPC1) 20q13.32 0.928319 0.21619 0.053815 
NELFCD (TH1L) 20q13 0.901242 0.155924 0.334379 
ADRM1 20q13.33 0.920162 0.295276 0.454516 
MRGBP 
(C20orf20)  
20q13.33 0.909783 N/A 0.409151 
TCFL5 20q13.3-qter 0.909783 0.214221 0.364161 
 
Table 3.3 Correlation of the Carvalho et al. putative chromosome 20q 
oncogenes and PROCR.  Table values for copy number, methylation and 
expression are Pearson scores (R) versus PROCR in the TCGA CRC dataset.  
P<0.05 where R>0.1405, highlighted red. 
 
Having established that EPCR upregulation correlates with regional dysregulation, I 
then sought to understand the significance of EPCR expression in tumourigenesis. 
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3.2.5 EPCR expression in colorectal cancer cell lines 
Using the Cancer Cell Line Encyclopaedia [93], in silico analyses of EPCR 
expression in multiple colorectal cancer cell lines were performed to inform in vitro 
studies.  5 cell lines were selected which were predicted to have high EPCR 
expression (HCT116, HT29, RKO, COLO320 and SW480).  EPCR expression was 
confirmed with flow cytometry (Figure 3.11).  All CRC carcinoma cell lines that were 
tested expressed EPCR.  Both HCT116 and HT29 cell lines had high expression, 
and these lines were chosen for further in vitro studies as they represent the two 
main biological subtypes of CRC (MSI-H and CIN respectively).  EPCR expression 
was also investigated in adenoma cell lines.  The AA/C1 adenoma line exhibited low 
expression (Figure 3.11 F,G), but its malignant derivative AA/C1 10C had higher 





Figure 3.11 Expression of EPCR on colorectal cancer cell lines.  Expression of 
EPCR on a) Colo320, b) RKO, c) SW480, d) HT29 and e) HCT116 cells by flow 
cytometry. Expression of EPCR on f) AA/C1 non-tumourigenic adenoma cells or g) 
the tumourigenic AA/C1/10C derivative.  Isotype control staining is shown in grey and 





3.2.6 Exogenous Activated Protein C (APC) induction of ERK phosphorylation 
in colon cancer cells 
ERK is a key MAP kinase that mediates several of the downstream effects of EGFR 
and RAS signalling, as well as other pathways [10, 119].  APC treatment of vascular 
endothelial cells has been shown to induce ERK phosphorylation [120].  Therefore, I 
wanted to investigate whether EPCR-mediated signalling could induce ERK 
phosphorylation in the CRC setting, as this could have implications for the effects of 
EPCR upregulation on tumour cells.  HCT116 cells were therefore treated with 
exogenous Activated Protein C (APC) to determine whether APC could induce ERK 
phosphorylation in this colorectal cancer cell line (Figure 3.12).  Treatment of serum-
starved HCT116 cells with APC for 2-10 minutes was associated with an increase in 
ERK phosphorylation.  This increase was inhibited by EPCR-blocking antibodies, 







Figure 3.12 Western blotting investigating the effect of APC on ERK 
phosphorylation.  
a) Western blotting for pERK and Total-ERK of lysates from serum-starved 
HCT116 cells that had been treated with APC for 5 minutes.  Negative controls 
were serum starved only.  Positive controls were treated with 50% FCS for 10 
minutes. 
b) Western blotting after pre-treatment with EPCR-blocking antibody.  The 
protocol was otherwise identical to a), and was performed in parallel. 




3.2.7  Detection of EPCR-related proteins in CRC  
APC is produced through the activation of Protein C (PC), via EPCR [75].  To 
determine whether HCT116 cells produce endogenous PC, serum-starved HCT116 
cells were lysed and western blotting for PC was performed (Figure 3.13).  A faint 
band for PC was observed in the cell lysate, but no signal was detected in the 
supernatant or media.  This suggests that these cells can produce PC endogenously, 
and therefore autocrine EPCR-mediated PC activation may be possible.   
To determine if Protease-Activated Receptor 1 (PAR1) (which is crucial for EPCR-
mediated signalling [75]) is present in primary CRC tissue, exploratory 
immunohistochemistry was performed on 10 CRC cases.  This demonstrated PAR1 
immunoreactivity in cancer cells (Figure 3.14) in all cases.  The presence of PAR1 













Figure 3.13 Detection of Protein C in HCT116 cell lysate.  The anti-Protein C 
antibody detects both Protein C (62 KDa) and Activated Protein C (APC, 21 KDa).  
Exogenous APC was used as a positive control.  A faint band was detected in the 60-
65KDa range in the HCT116 lysate, suggestive of the presence of PC.  Lysis of 
HCT116 cells and western blotting for APC were performed in triplicate.  The faint 










Figure 3.14 PAR1 immunohistochemistry in (A) CRC and (B) normal colon.  
In addition, controls were performed with the primary antibody omitted (data not 




3.2.8 Microarray analysis 
After establishing that APC can induce ERK phosphorylation in HCT116 cells, I 
wanted to determine the effect of APC treatment on gene transcription. Optimal APC 
concentrations and treatment durations were determined by assessing APC-induced 
expression changes of 4 genes (NFkB2, PCNA, BCL2A1, EFNA1, which were 
chosen based on previous findings in endothelium [69]) using qRT-PCR.   A 
concentration of 180nM for 24 hours was associated with maximal alteration in gene 
expression.  Therefore, serum-starved HCT116 cells were treated with 180nM APC 
for 24 hours.  RNA was extracted from both APC-treated cells and control cells for 
two-colour Agilent microarray analysis.  Differential gene expression was determined 
using the R Limma package.  There was strong overlap between the three 
experimental replicates, with over 400 genes with differential gene expression across 
all three replicates.  Table 3.4 shows genes with significant differential expression 
(Bayes factor > 5).  Within the list of differentially expressed genes, a high proportion 
were ribosomal.  Gene groupings were investigated by gene set enrichment analysis 
(GSEA) (Table 3.5, Figure 3.15).  Several gene groupings were enriched, a large 
proportion of which were associated with gene transcription.  Additionally, several 
gene sets associated with epidermal growth factor (EGF) signalling were enriched, 
consistent with the ERK phosphorylation data.  Finally, a gene set containing genes 
upregulated by thrombin signalling in HUVEC cells was significantly enriched, 





Gene ID Gene name LogFC (Fold 
Change) 




RPL13A ribosomal protein L13a 0.729831 1.32E-09 5.04E-05 11.4789 
RPS2 ribosomal protein S2 0.75432 2.37E-09 5.04E-05 11.07495 
RPS21 ribosomal protein S21 0.64925 7.57E-09 8.69E-05 10.22977 
RPL38 ribosomal protein L38 0.640211 8.88E-09 8.69E-05 10.10872 
RPS20 ribosomal protein S20 0.56367 1.23E-08 9.05E-05 9.857144 
RPL12 ribosomal protein L12 0.589346 1.61E-08 0.000105 9.647333 
RPL26 ribosomal protein L26 0.527112 2.52E-08 0.000119 9.293517 
RPS27 ribosomal protein S27 
(metallopanstimulin 1) 
0.569845 2.63E-08 0.000119 9.257807 
EEF1A1 eukaryotic translation 
elongation factor 1 alpha 1 
0.687543 3.33E-08 0.000125 9.067365 
RPL23 ribosomal protein L23 0.691122 3.35E-08 0.000125 9.06284 
RPL8 ribosomal protein L8 0.581833 3.41E-08 0.000125 9.047782 
RPL35A ribosomal protein L35a 0.614064 3.76E-08 0.00013 8.96871 
RPL31 ribosomal protein L31 0.484977 7E-08 0.000188 8.453052 
TACSTD2 tumor-associated calcium 
signal transducer 2 
0.505105 8.88E-08 0.000226 8.251977 
RPL37A ribosomal protein L37a 0.457551 9.24E-08 0.000226 8.218734 
UBC ubiquitin C 0.505567 1.26E-07 0.000286 7.951056 
RPL32 ribosomal protein L32 0.44282 1.27E-07 0.000286 7.948702 
KITLG KIT ligand 0.430458 1.36E-07 0.000289 7.885965 
RPS18 ribosomal protein S18 0.430622 1.38E-07 0.000289 7.876527 
DUT dUTP pyrophosphatase -0.4403 1.79E-07 0.000357 7.648652 
GIPR gastric inhibitory polypeptide 
receptor 
0.665148 2.49E-07 0.000421 7.360759 
RPS8 ribosomal protein S8 0.49689 2.51E-07 0.000421 7.35272 
RPL7A ribosomal protein L7a 0.431458 2.9E-07 0.00046 7.224366 
RPS13 ribosomal protein S13 0.366457 4.07E-07 0.00052 6.922628 
CLK1 CDC-like kinase 1 -0.38066 4.25E-07 0.000532 6.882765 
RPL17 ribosomal protein L17 0.377933 4.57E-07 0.000555 6.818574 
ING3 inhibitor of growth family, 
member 3 
0.367639 5.26E-07 0.000596 6.692568 
RPL3 ribosomal protein L3 0.446173 6.22E-07 0.000629 6.540546 
RPS7 ribosomal protein S7 0.413569 8.01E-07 0.000677 6.309131 
SLC1A3 solute carrier family 1 (glial 
high affinity glutamate 
transporter), member 3 
0.36994 9.43E-07 0.000693 6.159936 
LCN2 lipocalin 2 (oncogene 24p3) 0.483695 9.43E-07 0.000693 6.159605 
MT2A metallothionein 2A 0.448027 9.86E-07 0.000695 6.118647 
RPL10A ribosomal protein L10a 0.373973 9.91E-07 0.000695 6.113851 
ANXA2 annexin A2 0.352575 1.02E-06 0.000695 6.089494 
C10orf10 chromosome 10 open reading 
frame 10 
0.396982 1.07E-06 0.000716 6.040645 
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HNRPH2 heterogeneous nuclear 
ribonucleoprotein H2 (H') 
0.348645 1.17E-06 0.000757 5.958679 
ARHGEF15 Rho guanine nucleotide 
exchange factor (GEF) 15 
0.451955 1.24E-06 0.000776 5.910181 
RPL36A ribosomal protein L36a 0.459017 1.27E-06 0.000784 5.886451 
RPS16 ribosomal protein S16 0.587827 1.33E-06 0.000806 5.841946 
RPS3A ribosomal protein S3A 0.38013 1.42E-06 0.000822 5.782664 
RPL34 ribosomal protein L34 0.401456 1.5E-06 0.000845 5.732861 
ATF6 activating transcription factor 
6 
0.330841 1.52E-06 0.000846 5.71839 
FAU Finkel-Biskis-Reilly murine 
sarcoma virus (FBR-MuSV) 
ubiquitously expressed (fox 
derived); ribosomal protein 
S30 
0.402734 1.54E-06 0.000846 5.70528 
BRP44L brain protein 44-like 0.389064 1.68E-06 0.000881 5.624935 
RPL13 ribosomal protein L13 0.526131 1.85E-06 0.000946 5.534252 




0.379488 1.85E-06 0.000946 5.533545 
EIF4A3 eukaryotic translation 
initiation factor 4A, isoform 3 
-0.33887 1.92E-06 0.000947 5.501359 
DHTKD1 dehydrogenase E1 and 
transketolase domain 
containing 1 
0.364546 1.94E-06 0.000951 5.489604 
FAM49B family with sequence 
similarity 49, member B 
0.396678 1.97E-06 0.000955 5.477903 
RPS26 ribosomal protein S26 0.454294 2.2E-06 0.001032 5.372796 
RPL30 ribosomal protein L30 0.362797 2.21E-06 0.001032 5.367476 
HRASLS5 HRAS-like suppressor family, 
member 5 
0.456289 2.25E-06 0.001032 5.351502 
TAPBP TAP binding protein (tapasin) 0.312637 2.26E-06 0.001032 5.349157 
CNOT7 CCR4-NOT transcription 
complex, subunit 7 
0.352376 2.27E-06 0.001032 5.344529 
RASD1 RAS, dexamethasone-induced 
1 
0.525178 2.31E-06 0.00104 5.326405 
FKSG30 actin-like protein 0.315158 2.43E-06 0.001081 5.279509 
SSBP4 single stranded DNA binding 
protein 4 
-0.36137 2.67E-06 0.001143 5.192159 
SPATA22 spermatogenesis associated 
22 
0.446524 2.86E-06 0.001206 5.125614 
RPLP0 ribosomal protein, large, P0 0.376217 2.87E-06 0.001206 5.121352 
DTL denticleless homolog 
(Drosophila) 
-0.32126 2.91E-06 0.001212 5.10953 
RPL10 ribosomal protein L10 0.320072 2.97E-06 0.001219 5.091869 
RPS19 ribosomal protein S19 0.349232 2.97E-06 0.001219 5.090609 
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GJB3 gap junction protein, beta 3, 
31kDa (connexin 31) 
0.307522 3E-06 0.001225 5.08002 
RPS12 ribosomal protein S12 0.319493 3.07E-06 0.001242 5.059895 
HMBS hydroxymethylbilane 
synthase 
-0.31278 3.12E-06 0.001242 5.044439 
DUSP1 dual specificity phosphatase 1 0.395831 3.12E-06 0.001242 5.043594 
ATAD4 ATPase family, AAA domain 
containing 4 
0.375962 3.15E-06 0.001242 5.034235 
TES testis derived transcript (3 
LIM domains) 
0.428908 3.27E-06 0.001244 5.000888 
 
Table 3.4 Genes differentially expressed after APC treatment of HCT116 cells 
(Bayes Factor >5).  Log FC shows fold change (base 2) in APC-treated cells versus 
controls.  A logFC of 0 therefore represents equal expression in the APC-treated and 
control cells, >0 represents higher expression in the APC-treated cells, and <0 

















REACTOME_PEPTIDE_CHAIN_ELONGATION 83 0.830811 0 0 958 
REACTOME_INFLUENZA_VIRAL_RNA_ 
TRANSCRIPTION_AND_REPLICATION 
97 0.791672 0 0 958 
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_ 
PROTEIN_TARGETING_TO_MEMBRANE 
106 0.767984 0 0 958 
KEGG_RIBOSOME 85 0.838541 0 0 958 
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_ 
REGULATION 
91 0.791225 0 0 958 
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED 
_BY_THE_EXON_JUNCTION_COMPLEX 
102 0.748643 0 0 958 
REACTOME_TRANSLATION 131 0.695274 0 0 958 
REACTOME_INFLUENZA_LIFE_CYCLE 130 0.687707 0 0 958 
BILANGES_SERUM_AND_RAPAMYCIN_SENSITIVE_GENES 61 0.72625 0 0 958 
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX 
_AND_SUBSEQUENTLY_THE_43S_COMPLEX 




43 0.737235 0 0 958 
CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP 44 0.714276 0 0 958 
REACTOME_METABOLISM_OF_MRNA 202 0.517838 0 0 958 
FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_UP 50 0.642381 0 0 1173 
NAGASHIMA_EGF_SIGNALING_UP 52 0.629965 0 0 2671 
PECE_MAMMARY_STEM_CELL_DN 128 0.529283 0 0 1489 
REACTOME_METABOLISM_OF_RNA 245 0.453754 0 0 958 
NAGASHIMA_NRG1_SIGNALING_UP 160 0.485804 7.41E-05 0.001 2099 
CHASSOT_SKIN_WOUND 10 0.878359 2.08E-04 0.003 1642 
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_ 
DN 
63 0.526858 3.91E-04 0.006 886 
HOLLEMAN_ASPARAGINASE_RESISTANCE_B_ALL_UP 22 0.674004 3.73E-04 0.006 551 
REACTOME_OLFACTORY_SIGNALING_PATHWAY 102 0.474621 5.87E-04 0.01 3844 
REACTOME_METABOLISM_OF_PROTEINS 382 0.395476 8.40E-04 0.015 2516 
UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN 34 0.597898 8.05E-04 0.015 4451 
TIEN_INTESTINE_PROBIOTICS_6HR_UP 50 0.533304 0.00148 0.028 1092 
HSIAO_HOUSEKEEPING_GENES 363 0.389684 0.00247 0.049 1536 
LEE_LIVER_CANCER_HEPATOBLAST 15 0.701492 0.00248 0.051 3202 
AMIT_EGF_RESPONSE_40_HELA 39 0.545263 0.00395 0.083 2970 
YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP 46 0.535978 0.00390 0.085 1692 
BILANGES_SERUM_RESPONSE_TRANSLATION 33 0.579625 0.00436 0.099 1489 
 
Table 3.5 Top 30 gene sets in Gene Set Enrichment Analysis of APC-treated 







Figure 3.15 Gene set enrichment analyses. Enrichment plots for gene sets: 
a) Nagashima EGF signalling up 
b) Zwang EGF persistently up 
c) Amit EGF response 40 Hela 
d) Uzonyi response to leukotriene and thrombin 
These enrichment plots rank all genes (bottom section) in order of most 
overexpression after APC treatment to most underexpression.  0 represents equal 
expression after treatment.  The black vertical bars (middle section) represent genes 
from the relevant gene set. The green line (top section) represents the running 
enrichment score for the gene set as the analysis walks down the ranked list, 
increasing the running-sum statistic when a gene is in a gene set and decreasing it 
when it is not.  As the peaks of these green lines occur towards the left 
(overexpression) side of the gene list, these gene sets are highly enriched. 
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3.2.9 EPCR shRNA knockdown assays  
Having established that EPCR signalling can induce ERK phosphorylation and alter 
gene transcription, I wanted to determine whether the functional effect of EPCR 
provided any benefit to tumour cells.  Previous work had demonstrated that EPCR is 
a marker of chemoresistant cell lines, including HCT116 [59].  To further examine the 
effect of EPCR expression on chemosensitivity, EPCR expression was knocked 
down in HCT116 cells using shRNA (Figure 3.16).  Two shRNA constructs were 
chosen that induced high (clone 969 – 90-95%) and medium (clone 379 – 60-70%) 
levels of knockdown.  EPCR knockdown significantly reduced the effectiveness of 
5FU and epirubicin in MTT and BrdU assays (Figure 3.17 A,B).  
Transwell assays were performed to determine how EPCR expression affected 
cellular migration.  Over 48 hours, HCT116 cells with high EPCR knockdown had a 
significantly higher rate of migration than control cells (p<0.001) or medium-level 
EPCR knockdown cells (p<0.001) (Figure 3.17C).  However, no significant 
differences between the groups were observed in QCM invasion assays (Figure 
3.17D).  
To determine whether the effect of EPCR perturbation was similar in a MSS/CIN cell 
line, the experiments were repeated in HT29 cells.  In HT29 cells, EPCR knockdown 
did not have any consistent effect on MTT and BrdU chemosensitivity assays (Figure 
3.17 A,B).  In comparison to the HCT116 cells, the effect of the chemotherapy drugs 
was significantly smaller in both the control and knockdown cells.  However, as with 
HCT116 cells, high EPCR knockdown (>95%) correlated with an increase in cellular 
migration in the Transwell assay (p<0.01) (Figure 3.17C).  No difference was 
observed with knockdown in QCM invasion assays (Figure 3.17D).  Both total cell 
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migration and invasion were less in the HT29 cells compared to the HCT116 cells.  
HT29 EPCR overexpression (to over 600% of wild type HT29) did not consistently 
affect chemosensitivity, migration or invasion.  These data suggest that the effect of 
EPCR on chemosensitivity may differ in different cell lines, though the effects on 










Figure 3.16 shRNA EPCR knockdown in HCT116 cells. 
a) Flow cytometry data confirming knockdown of EPCR expression with 
shRNA (vector 969) compared to control cells. 
b) EPCR expression in wild type cells and shRNA transfected cells (vectors 







Figure 3.17 Functional assays after shRNA EPCR knockdown in HCT116 cells.  
a) MTT scores for control and shRNA knockdown (clone 969) HCT116 and 
HT29 cells after treatment with 5FU (32μM), shown as a percentage of 
control cells (cells untreated with chemotherapy). 
b) BrdU scores for control and shRNA knockdown (clone 969) HCT116 and 
HT29 cells after treatment with 5FU (32μM), shown as a percentage of 
control cells (cells untreated with chemotherapy). 
c) 48 hour Transwell migration assay – Number of cells that migrated through 
Transwell membrane for each clone in five assessed regions. 
d) 48 hour QCM invasion assay. 
Asterixes represent statistical significance of EPCR-low cells versus control cells 




3.2.10 Serum sEPCR correlation with CEA and clinical stage 
Serum soluble EPCR (sEPCR) has previously been shown to correlate with the 
ovarian tumour marker CA-125 in ovarian cancer [86].  To investigate whether 
sEPCR may increase with clinical stage or correlate with the colorectal tumour 
marker CEA in CRC patients, exploratory experiments were performed on serum 
retrieved from 21 patients with early stage colorectal cancer (Duke Stage A-B) and 
19 patients with late stage disease (Duke Stage C-D).  ELISAs for sEPCR and CEA 
were performed.  Neither sEPCR nor CEA were significantly higher in patients with 
lymph node or distant metastases versus patients with localised disease (p=0.371 
and 0.593 respectively) (Figure 3.18).  There was a trend towards a correlation 
between sEPCR and CEA, but this did not reach significance (Spearman Rho=0.271, 
p=0.091).  These studies were exploratory and underpowered, and further 
experiments with a sufficient numbers of samples will be required for confirmation of 















3.2.11  EPCR expression and chemotherapy or cetuximab responsiveness 
Previous studies have indicated that EPCR is a marker for chemoresistant cell lines 
[59], and conversely its expression may predict chemotherapy responses in early 
stage lung cancer [78].  Furthermore, I have shown that EPCR perturbation can 
marginally affect CRC cell line chemosensitivity. Therefore I wanted to determine 
whether EPCR could affect chemosensivity in CRC patients. In addition, having 
established that EPCR can mediate APC-dependent ERK phosphorylation on CRC 
cells, I was also interested in the potential impact of EPCR upregulation on clinical 
responses to EGFR monoclonal antibodies (mAbs) in CRC patients.  Patients with 
RAS mutation do not respond to EGFR mAbs due to ‘bypass signalling’ resulting 
from constitutively active MEK/ERK signalling [10].  As EPCR-mediated signalling 
induces ERK phosphorylation, I hypothesised that EPCR could also act as a bypass 
signalling pathway in an analogous manner.  
To determine whether EPCR expression is associated with chemotherapy or EGFR 
monoclonal antibody (cetuximab) responsiveness in CRC, 153 CRC tumour samples 
from the MRC COIN study [10] were stained for EPCR using immunohistochemistry.  
Of these, 71 were from the chemotherapy arm, and 82 were from the chemotherapy 
plus cetuximab arm.  These slides were analysed using Definiens Tissue Studio 
software.  Percental scores for EPCR were calculated for each slide.  Survival 
analyses were performed using the Cox proportional hazards model, adjusting for 
factors that significantly associated with progression-free survival (PFS) to p<0.05 
(KRAS mutation status and MSI status).  No significant difference in PFS was 
observed between EPCR high and low cases (divided by median EPCR expression) 
across all patients (Figure 3.19) or when both treatment arms were analysed 
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individually.  No difference in PFS was observed when the top and bottom 20% of 
EPCR expressors were compared.  Finally, EPCR did not predict for survival in either 
treatment arm after exclusion of RAS mutant cases.  These data suggest that EPCR 






Figure 3.19 Kaplan-Meier curves for progression free survival in EPCR high 
and low patients.  Patients have been separated by median EPCR expression in: 
a) Tumour epithelium 
b) Tumour stroma 
 
The blue lines represent low EPCR expression, and the red lines represent high 




3.3 Discussion  
 
EPCR, a receptor with anti-apoptotic and proliferative effects [69, 73, 74], is known to 
be expressed on various cancer cell lines [59, 72].  I have demonstrated, using 
robust digital immunohistochemistry algorithms and bioinformatic analyses, that 
EPCR is aberrantly expressed in colorectal cancer tissue, with expression being 
higher in cancer regions compared to normal regions in all cases tested. 
 
Though EPCR expression has been investigated in various epithelial cancers, the 
mechanism of its upregulation has previously been unclear, and EPCR upregulation 
has not previously been linked to chromosome 20q amplification and promotor 
hypomethylation.  20q amplification occurs as a result of chromosomal instability 
(due to the loss of the CIN suppressor genes of Chr18q [121]) and occurs frequently 
in malignant transformation.  The phenomenon occurs in multiple cancer types [116, 
117, 122-124], and there is in vitro evidence that it occurs early in the natural history 
of transformation, promoting cancer initiation independently of other chromosomal 
abnormalities [116].  20q amplification has been correlated with poor prognosis, 
aggressive tumour phenotype, progression, and metastasis formation, and Tabach et 
al. suggest that 20q amplification plays a causative rather than a bystander role in 
the process of tumourigenesis [116].  In colorectal cancer, 20q amplification has 
been associated with the progression of colonic adenomas into malignant 
carcinomas [117, 122, 125], and occurs in over 65% of CRC cases.  Carvalho et al. 
confirmed that 20q amplification occurs in under 20% of non-progressed adenomas, 
but in over 60% of progressed adenomas [117]. This is consistent with my in vitro 
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findings, which demonstrated poor expression of EPCR in the adenoma cell line 
AA/C1.   However, the AA/C1 10C derivative, a malignant variant of the AA/C1 cell 
line, had higher EPCR expression [126].   EPCR expression correlates strongly with 
6/7 of the Carvalho et al. putative oncogenes and 13/13 of the Tabach et al. ‘cancer 
initiating genes’, all located on chromosome 20q [116, 117].   It is therefore possible 
that the characteristics of EPCR-expressing tumours may be a result of both EPCR 
and of co-expression of local genes on 20q.  Previous studies have confirmed EPCR 
expression in breast cancer, ovarian cancer and lung cancer, but these studies have 
not related EPCR expression to chromosomal amplification or hypomethylation [78, 
80, 86].  Significantly, all of these tumour types are associated with 20q amplification.  
I have shown that EPCR expression should be taken in the context of this 
phenomenon, as 20q amplification is itself is associated with an aggressive and 
invasive phenotype [72, 78, 116, 117].    
 
Though amplification of genes on 20q was uniform, promotor methylation was less 
co-ordinated, suggesting that this important epigenetic control mechanism may be 
one factor which accounts for the relatively greater variability in gene expression 
compared to copy number across the chromosomal region.  Other epigenetic control 
mechanisms may explain the minority of cases where copy number and methylation 
status do not predict EPCR expression.   
 
I then investigated the implications of aberrant EPCR expression on the functional 
phenotype of CRC cells, following studies highlighting EPCR’s effects on cancer cell 
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migration, invasion and proliferation in different tumour settings [72, 78, 79, 83]. 
While the results establish that EPCR, via APC binding, can stimulate ERK signalling 
and elicit changes in gene transcription (as is the case in endothelial cells), the in 
vitro functional assays failed to identify compelling evidence that overexpression of 
EPCR per se might provide functional advantages for CRC cells.  Interestingly, in 
both HCT116 and HT29 cells, EPCR expression appeared to decrease migration in 
in vitro assays.  Furthermore, EPCR had variable effects on cancer cell phenotype 
across cell lines: specifically, it increased chemosensitivity of HCT116, consistent 
with a report that higher EPCR expression was associated with superior 
chemotherapy response in early stage lung cancer [78]. In contrast, no 
chemosensitivity effects were observed in HT29 cells, and no effects on invasion 
were observed in either cell line. However, an important limitation of these 
experiments and of approaches highlighting both beneficial and detrimental effects of 
EPCR perturbation in animal models [78, 79, 83, 114] is that they primarily address 
EPCR-intrinsic effects on cancer development, and typically focus on a small number 
of cell lines.  My findings underline that the effects of EPCR upregulation on cancer 
cells may be heavily dependent on biological context, including the exact cancer cell 
line and potentially upregulation of functionally important neighbouring genes co-
amplified on chromosome 20q.  This demonstrates the need for models that 
represent the variety of biological variants observed in the clinical scenario.   
 
Increased migration rates were observed in HCT116 and HT29 shRNA EPCR 
knockdown cells.  As a potential inhibitor of migration, EPCR may impact on 
metastasis development. The migration data are contrary to the data observed in 
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breast cancer cells by Beaulieu and collaborators [72], who demonstrated that APC 
increased chemotaxis in a dose-dependent manner.  However, rather than altering 
Activated Protein C (APC) concentrations as in Beaulieu’s study, I perturbed EPCR 
directly.  In addition, in lung cancer, EPCR knockdown decreased the development of 
bone metastases in a mouse xenograft model [78].  However, in mesothelioma, 
EPCR expression has been observed to suppress tumourigenicity and growth [83], 
which is consistent with my findings.  As with chemosensitivity, it is possible that 
EPCR’s effect on migration is variable in different tumour types, depending on the 
specific context of its expression.   
 
Treatment of HCT116 with EPCR’s natural ligand APC induced ERK 
phosphorylation, which was inhibited by EPCR blockade.  Consistent with this, 
microarray analysis of APC-treated cells showed an increase in ribosomal RNA 
expression, which is a known effect of ERK phosphorylation [127].  An increase in 
cellular proliferation due to APC may explain why EPCR knockdown decreases 
chemosensitivity in these cells, as tumour cells that divide more rapidly are more 
sensitive to chemotherapy [4].  Multiple gene sets associated with EGF signalling 
were enriched, consistent with the suggestion that APC induces ERK 
phosphorylation through EPCR-mediated signalling.  Additionally, a gene set 
associated with thrombin signalling was enriched.  Thrombin in complex with 
thrombomodulin, in the endothelial setting, presents PC to EPCR, activating PC [75].  
This enrichment therefore suggests that the effects of APC signalling on gene 




Analysis of samples from the MRC COIN study did not reveal any association 
between EPCR expression and progression free survival in advanced CRC within the 
chemotherapy or chemotherapy plus cetuximab arms.  There is a need for the 
identification of predictive biomarkers for EGFR monoclonal antibody therapy in 
metastatic CRC, as thus far, no predictive biomarkers have been identified in RAS 
wildtype patients.  As EPCR mediates ERK phosphorylation, it could potentially have 
acted as an additional bypass pathway during EGFR inhibition with cetuximab, 
similar to RAS mutation.  However, survival analysis of EPCR stained specimens did 
not show any association with PFS.  Less than half of RAS wild type patients 
respond to EGFR monoclonal antibody therapy, and the response rate is only 
approximately 15% higher than with chemotherapy treatment alone [128].   Therefore 
there remains a considerable need to identify predictive biomarkers that will enable 
improved targeting of this therapy and to prevent toxicity in patients who will not 
derive benefit.  Additionally, as EPCR is a marker for chemoresistant cell lines [59], 
and has been linked to chemotherapy responses in early stage lung cancer [78], I 
wanted to determine whether there was any association with PFS in CRC.  No 
significant relationship with PFS was found, suggesting that the impact of the EPCR-
high phenotype is insufficient to impact on chemosensitivity. 
 
Previous work in our laboratory has demonstrated that EPCR is a ligand for a specific 
Vδ2-negative clone of the γδ T-cell receptor [53].  EPCR is constitutively expressed 
on endothelium.  In this context γδ T-cells detect CMV via a multimolecular stress 
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signature.  In epithelium however, where EPCR is not normally expressed, EPCR 
could act as bona fide marker of cellular stress as it is likely to be consistently 
upregulated in multiple transformed tissues.  Therefore EPCR could represent a 
molecular exemplar of how γδ T-cells can recognise stress in different settings. 
Further work is required to determine whether EPCR expression in epithelial tumours 
is relevant to γδ T-cell responses. 
 
EPCR may not be an attractive therapeutic target in CRC due to physiological 
expression throughout the vasculature and its variable effect on cancer cells.  The in 
vitro and microarray data, taken together with the bioinformatics analysis and survival 
data, suggest that EPCR does not have a substantial impact on tumour phenotype.  
The analyses therefore raise the possibility that the EPCR-high phenotype may be 
due to regionally co-expressed genes, rather than EPCR itself.  Work by Tsafrir et al. 
has shown that 20q amplification is absent in normal colonic mucosa, occurs at low 
levels in adenoma, becomes more frequent as disease advances, and is found in the 
majority of metastatic samples [125].  As the group note, such wide scale 
chromosomal changes are likely to lead to the expression of genes which in 
themselves do not confer a selective advantage.  EPCR may be such a bystander 
gene.  However, EPCR may have value as a surrogate marker of 20q amplification.  
Furthermore, there have been suggestions that EPCR could predict for thrombotic 

















In addition to investigating the role of EPCR, a ligand for unconventional T cells, I 
wanted to explore how conventional adaptive immunity could be used to stratify CRC 
patients.  Patient stratification involves the grouping of patients for specific 
interventions or treatments.  Bowel cancer treatment is currently stratified mainly by 
clinical stage and tumour site [11] as discussed in the thesis introduction.  However, 
molecular stratification is becoming increasingly significant in clinical management.  A 
key example of this, as highlighted in the previous chapter, is the mutation status of 
RAS, which is crucial in the prediction of EGFR mAb treatment responses [10].  
Furthermore, stratification based on the mutation status of multiple genes is being 
investigated in multiple tumour types.  In a key CRC stratified medicine clinical trial 
(FOCUS4 [129]), patients are stratified and recruited into specific treatment arms on 
the basis of their BRAF, KRAS, NRAS, PIK3CA and PTEN mutation status.  In terms 
of immunological stratification, a tumour’s microsatellite status affects patient 
survival, potentially due to differences in immune infiltration [5].   
The extent of immune infiltration is now emerging as another key stratifier.  The 
density of tumour infiltrating lymphocytes (TILs) and the expression of certain 
immune-related genes are of prognostic and predictive value in colorectal cancer 
(CRC) [37, 38, 42, 100, 130].  A worldwide task force is attempting to validate the 
‘immunoscore’, an immunohistochemistry based scoring system centred on CD3 and 
CD8 density conceived by Galon and collaborators [38, 42].  TNM staging, when 
combined with immunoscore (TNM-I), is more prognostically accurate than traditional 
TNM staging alone [37, 130].  Whilst the simplicity of this scoring system will likely be 
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beneficial for clinical implementation, it is limited in the biological insights it can 
provide into the immune microenvironment in CRC.  For instance, it does not 
incorporate key molecules, such as CD4, cytokines, class II molecules and inhibitory 
molecules, which are likely to play important roles in the tumour microenvironment.  
Furthermore, the factors that determine a patient’s immune microenvironment are still 
unclear.  These are likely to include tumour, host and environmental factors [44].  
Within tumour and host factors, few systematic analyses have investigated the 
somatic and germline molecular drivers of immune infiltration.  Although microsatellite 
unstable (MSI-H) cancers, which represent approximately 15% of colorectal cancers 
and have a superior prognosis [46], are known to be associated with increased TIL 
density [5, 45-50], the nature of the immune infiltration and the molecular drivers of 
the immune phenotype in microsatellite stable (MSS) CRC are poorly understood. In 
particular it is unclear whether defined molecular subsets (RAS mutant, BRAF 
mutant, PIK3CA mutant, quadruple wildtype (BRAF, PIK3CA, NRAS, KRAS all 
wildtype)) are associated with high or low immune infiltration.  In addition, in both 
MSI-H and MSS cancers the extent to which therapeutically tractable inhibitory 
immune checkpoint receptors are represented are unclear and is of substantial 
interest, particularly considering recent checkpoint blockade failures in colorectal 
cancer [13, 14]. Given the prognostic and predictive relevance of CRC 
immunophenotype, a clearer understanding of the link between immunophenotype 
with tumour genotype is crucial. 
To explore the determinants of immune phenotype I carried out a bioinformatic 
analysis of CRC data in The Cancer Genome Project (TCGA). These analyses 
defined a co-regulated cluster of immune related genes with a distinct Th1 bias, 
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expression of which defines four patient subgroups.  Subsequently, the determinants 
of the immune response in colorectal cancer were explored.  The findings have 
implications for our understanding of the immunobiology of colorectal carcinogenesis, 
and provide a potential framework for the development of stratified immunotherapy 





4.2.1 Co-ordinate expression of immune response-related genes in colorectal 
cancer 
I interrogated expression of immune response-related genes in the colorectal cancer 
(CRC) dataset in The Cancer Genome Atlas (TCGA).  This dataset includes a total of 
195 patients with complete transcriptomic, mutation and clinical data.  Preliminary 
analyses focussed on an larger initial gene group (Table 4.1) that was based partly 
on previous studies on bio-molecular networks incorporating immune genes linked 
with disease-free survival in CRC [37, 42, 100].  These included those associated 
with Th1 subset function (STAT1, IRF, IFNG, TBX21, IL18RAP, ICOS, GNLY), 
certain chemokines (CX3CL1, CXCL9, CXCL10), adhesion molecules (ICAM and 
MADCAM) and an array of class II genes.  I also included a number of immune 
checkpoint genes (PD-1, PD-L1, PD-L2, LAG3, TIM3, CTLA-4), two of which (PD-L1 
and PD-L2) were previously associated with outcome [42].  Finally, the initial gene list 
was supplemented with class I genes, additional class II genes and genes involved in 
T cell activation.  I also included NKG2D ligands (including ULBPs) and the γδ T-cell 











































Unsupervised two-dimensional hierarchical clustering was performed to assess the 
extent to which gene expression was co-ordinate or independent across the patient 
cohort. Visual analysis of the clustering highlighted a 28-gene subset (Table 4.2) 
which formed a clear gene grouping, expression of which was co-ordinately regulated 
(Figure 4.1).  Gene-tree analysis of the dendrogram confirmed the validity of this 
grouping, identifying a subset of 24 highly co-ordinated genes (distance threshold 
0.46) predominantly associated with Th1 immunity, including numerous class II MHC 
loci, and inhibitory molecules targeted in checkpoint blockade strategies.  This 24-
gene block was identical to my 28-gene cluster other than the absence of three 
additional class II MHC loci (HLA-DRB5, HLA-DQA2 and HLA-DQA1) and one 
additional inhibitory molecule (HAVCR2 (TIM3)), all of which correlated closely with 
the 24-gene block and were positioned directly adjacent on the gene cluster 
dendrogram.  I therefore proceeded with the 28-gene cluster as it formed a clearly 
co-ordinated block on visual and correlation analysis.  This grouping was termed the 





Figure 4.1 Two-dimensional hierarchical clustering reveals a closely co-ordinated immunological gene expression 
cluster – The Co-ordinate Immune Response Cluster (CIRC). Clustering was performed by gene expression (rows) and 
patients (columns) using the Pearson algorithm.  Yellow represents high gene expression, black represents intermediate gene 
expression and blue represents low gene expression.  The red box shows a group of closely associated genes (the CIRC) that 



































Table 4.2 Genes within the co-ordinate immune response cluster (CIRC).  These 




Of the 28 genes in the CIRC, 20 have previously been associated with outcome 
based on experimental data [37, 42, 100].  I have shown here that these prognostic 
immune response genes are highly co-ordinately expressed in CRC and correlate 
with other biologically associated genes including HLA-DQA1, HLA-DRB5, HLA-
DPB1, LAG3, TIM3, CTLA4 and CCL5.  The degree of correlation between immune 
checkpoint receptor/ligand gene expression was notable (Table 4.3).  Particularly 
striking was the correlation between PD1 and LAG3 (r2=0.62, Figure 4.2).  CTLA4 
and PD1, both key targets of checkpoint blockade therapy, were also correlated 
(Figure 4.3).  Beta actin acted as a control in this analysis (Figure 4.4). 
  
CTLA4 PD-1 PD-L1 PD-L2 TIM3 LAG3 Beta Actin 
  
CTLA4 PDCD1 CD274 PDCD1LG2 HAVCR2 LAG3 ACTB 
CTLA4 CTLA4 X 0.36 0.42 0.35 0.35 0.42 0.04 
PD-1 PDCD1 0.36 X 0.45 0.31 0.45 0.62 0.04 
PD-L1 CD274 0.42 0.45 X 0.48 0.5 0.51 0.07 
PD-L2 PDCD1LG2 0.35 0.31 0.48 X 0.49 0.31 0.08 
TIM3 HAVCR2 0.35 0.45 0.5 0.49 X 0.52 0.06 
LAG3 LAG3 0.42 0.62 0.51 0.31 0.52 X 0.03 
Beta Actin ACTB 0.04 0.04 0.07 0.08 0.06 0.03 X 
  
Table 4.3 R2 values correlating expression of inhibitory molecules in colorectal 









Figure 4.2 Significant correlation between LAG3 and PDCD1 (PD1) expression.  
Pearson correlation analysis indicates the inhibitory molecules LAG3 and PDCD1 










Figure 4.3 Significant correlation between CTLA4 and PDCD1 (PD1) expression.  
Pearson correlation analysis indicates the inhibitory molecules CTLA4 and PDCD1 











Figure 4.4 Correlation between ACTB (Beta Actin) and PDCD1 (PD1) expression 






Given the Th1 bias of the cluster I performed separate unsupervised hierarchical 
clustering analysis of Th2 cytokines IL-2, IL-3, IL-4, IL-5 and IL-6 and transcription 
factor GATA3, revealing that these genes were excluded from the CIRC.  I also noted 
that the Th17 cytokine IL-17A was also excluded from the cluster (Figure 4.1).  The 
exclusion of these genes confirmed that the CIRC was a Th1-centric cluster. 
4.2.2 Molecular determinants of the co-ordinate immune response cluster 
 
Two-dimensional hierarchical clustering (Figure 4.5) was performed for the entire 
gene list (Table 4.1) incorporating expression data together with molecular and 
clinical characteristics (KRAS, BRAF, NRAS, TP53, PIK3CA & PTEN mutations; 
microsatellite status, methylation subtype, tumour stage, tumour site & recurrence 
data).  The microsatellite status of the total patient population was as follows: 11.8% 
were MSI-H, 15.9% were MSI-L (microsatellite-low) and 71.8% were MSS.  6.7% of 
patients were BRAF mutant (MT)/MSI-H, and 3.1% were BRAF MT/MSS.  The 
mutational status of the cohort was as follows - KRAS MT (39.5%), NRAS MT (8.2%), 
BRAF MT (9.7%), PIK3CA MT (18.4%) and TP53 MT (51.8%).  38.5% of patients 
were quadruple wild type (BRAF WT, KRAS WT, NRAS WT and PIK3CA WT).  I also 
investigated mutations in the novel genes POLE (7.2% of patients) and POLD1 
(2.6% of patients), which have recently been highlighted as key drivers of colorectal 
carcinogenesis for a minority of CRC patients [132].  As in MSI-H tumours, the 
mutational burden in POLE and POLD1 mutant tumours is high.  In the case of POLE 
and POLD1 mutants, this is due to a defect in the correction of mispaired bases 
inserted during DNA replication [132]. 
Hierarchical clustering delineated four distinct patient groups (Figure 4.5, Table 4.4)
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Figure 4.5 Two-dimensional hierarchical clustering delineates distinct immunological CRC patient groups. Gene expression (yellow, high 
expression; black, intermediate; blue, low expression) was clustered together with mutation data of key genes (TP53, KRAS, BRAF, NRAS, PI3KCA 
and PTEN (yellow, mutant; blue, wildtype)) and clinical data (microsatellite status (yellow, MSI-H; black, MSI-L; blue, MSS), recurrence data (yellow, 
recurred/progressed; blue, disease-free), tumour site (yellow, left sided; blue, right sided), tumour stage (yellow, stage III/IV; blue, stage I/II), 
methylation subtype (yellow, CIMP-H;  black, CIMP-L; blue, CIMP-negative). Clustering was performed by genes/mutations/clinical data (rows) and 
patients (columns) using the Pearson algorithm.  Red boxes indicate groups of patients with strong clustering of the co-ordinate immune response 
cluster.  Patients were delineated into four distinct groups (A to D) on the basis of the dendrogram and the cluster expression.   
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 Group A Group B Group C Group D 
Microsatellite 
status 












Right (82%) Left (63%) Left (94%) Left (82%) 
Stage I+II  73% 55% 72% 49% 
TP53 MT 35% 65% 62% 48% 
BRAF MT 50% 4% 3% 1% 
KRAS MT 18% 47% 22% 49% 
NRAS MT 0% 4% 9% 13% 
PIK3CA MT 39% 14% 9% 18% 
Quadruple 
WT 
18% 39% 69% 33% 
Percentage 
of patients 








    
 
Table 4.4 Characteristics of patient groups.  For microsatellite status, methylation 
and tumour side, the most frequent result is stated.  Tumour side refers to the right or 
left side of the colon.  The cluster expression pattern displays the expression pattern 





Group A patients (Table 4.4) demonstrated strong CIRC expression (mean 
expression 0.98).  Notably, all of the MSI-H patients were included in this group, who 
constituted 82.1% of all group A patients, whereas only 10.7% were MSS and 7.1% 
were MSI-L. Across the entire cohort, expression of the CIRC signature was 
significantly higher in the MSI-H cancers versus MSS (p<0.001) and MSI-L cancers 
(p<0.001).  Multivariate analysis revealed that expression of HLAA, HLAB and HLAC 
were all significantly less in MSI-H than MSS cancers (p=0.027, p=0.017 and 
p=0.018 respectively for HLA-A, B and C), consistent with previous observations 
[133].  Group A was characterised by the CpG island methylator phenotype (CIMP-H) 
(67.9%), right-sided tumour site (82.1%), TP53 wild type (65%) and KRAS wild type 
(82.1%).  50% of patients in this group were BRAF mutant and of these BRAF 
mutants, 92.9% were MSI-H.  Notably, POLE and POLD1 mutant tumours were 
associated with higher expression of the CIRC (p<0.05). 42.9% of patients in group A 
were either POLE or POLD1 MT, and 70.6% of all patients with POLE or POLD1 
mutations were found in group A; 100% of POLD1 mutants were assigned to group 
A.  Of the non-MSI-H patients in group A, 3/5 were POLE mutant, two of which were 
MSS and one MSI-L.  
 
I then analysed patient groups B, C and D (Table 4.4), which displayed lower 
expression of the CIRC signature than group A, to determine whether any molecular 
characteristics were associated with low CIRC expression. Group D comprised 
cancers with the lowest expression of the cluster (mean expression -0.62) and 
represented 43% of the entire patient population; group B had a lower mean cluster 
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expression (0.13) than group C (0.50). Significantly, RAS mutation (KRAS/NRAS), 
occurring in 47.7% of patients, was associated with lower CIRC expression 
(p<0.001).  This was confirmed in the provisional TCGA dataset, in which mutation 
and expression data for a further 30 patients (225 total) was available (p<0.001).  
The frequency of RAS mutation was significantly higher in group B and D than other 
patient groups (p=0.01), with group D having the highest frequency (D (61.9%)>B 
(51.0%)>C (28.1%)>A (21.4%)) (p=0.01).  Consistent with these observations, within 
MSS cancers (enriched in groups B-D), there was a strong trend for RAS mutation to 
be associated with low CIRC expression (p=0.076).  Furthermore, in the MSS group, 
NRAS mutant cancers had significantly lower CIRC expression than RAS wild type 
cancers (p<0.05).  In group A, 83.3% of RAS mutations were MSI-H and 16.7% were 
MSS.  In RAS mutant MSI-H patients, the expression of HLA-DRA was lower (0.518) 
than in RAS wild types (1.027) but this difference did not reach significance 
(p=0.209).  Finally, multivariate analysis indicated that KRAS and NRAS mutation, as 
well as PIK3CA and PTEN mutation, were associated with decreased CD4 










BRAF CD247 Down <0.001 
 CD80 Up 0.017 
 GNLY Up 0.031 
 HAVCR2 Up 0.039 
 HLAA Up 0.004 
 HLAB Down 0.003 
 HLADOA Down 0.017 
 LAG3 Up <0.001 
KRAS CD4 Down 0.008 
NRAS CCL5 Up 0.002 
 CD247 Down 0.007 
 CD4 Down 0.036 
 CXCL10 Down 0.037 
PIK3CA CD4 Down 0.001 
 HAVCR2 Up 0.005 
 STAT3 Up 0.002 
TP53 CD274 Up 0.028 
 CD276 Down 0.001 
 CD4 Up 0.005 
 CX3C11 Down 0.012 
 CXCL10 Up 0.008 
 HLAB Up 0.024 
 HLADQ2 Down 0.002 
 IFNG Down 0.004 
 IL7R Down 0.018 
PTEN CD4 Down 0.003 
 CTLA4 Up <0.001 
 HLADMB Up <0.001 
 HLADRA Down 0.027 
 IL7R Down 0.004 
 STAT1 Down 0.001 
 STAT3 Up 0.026 
 VTCN1 Up 0.017 
 
Table 4.5 Multivariate analysis of gene expression changes in key mutation 
groups.  p-values are derived from multivariate linear regression analysis.  This 




The association of low expression of the cluster and RAS mutation was particularly 
strong in the case of NRAS mutation where 76.9% of these cancers were in group D 
and over 90% of these tumours clustered in the two lowest expression groups (B and 
D).   
Thus RAS mutation, unless linked with microsatellite instability, was commonly 
associated with low levels of Th1 infiltration and activation, class II expression and 
inhibitory checkpoint expression in this dataset.  This depletion appeared to be 
stronger in NRAS cancers in particular.  Table 4.6 shows the distribution of key 
mutations.   
Expression of the CIRC correlated inversely with tumour stage.  Stage IV cancers 
had significantly lower CIRC expression than stage I (p< 0.05) or stage II (p<0.001) 
cancers.  In analysis of MSS patients alone, stage IV cancers had lower expression 
than stage II (p<0.05). 
CIRC expression was higher in disease-free patients than those with progressive or 
recurrent disease (p<0.05). This is despite the fact that only 22.2% of disease-free 
patients were MSI-H.  Formal survival analysis on a per-stage basis was not possible 






% of total 
patient 
population 
% of total in 
patient 
group A 
% of total in 
patient 
group B 
% of total in 
patient 
group C 
% of total in 
patient 
group D 
TP53 MT 51.8% 6.9% 32.7% 19.8% 40.6% 
BRAF MT 9.2% 72.2% 11.1% 5.5% 11.1% 
KRAS MT 41.0% 7.5% 30% 10% 52.5% 
NRAS MT 6.7% 0% 15.4% 7.7% 76.9% 
KRAS/NRAS 
MT 
47.7% 6.5% 28.0% 9.7% 55.9% 
PIK3CA MT 4.1% 50% 37.5% 0% 12.5% 
Quadruple 
Wildtype 
39.0% 6.6% 26.3% 28.9% 38.2% 
 
Table 4.6 Frequencies of mutations in total patient population and distribution 
of mutations across patient groups A to D.   
To prevent overlap of patients, in this analysis patients were classified initially on the 
basis of KRAS status, followed by NRAS, BRAF, and finally PIK3CA.  According to 
these criteria, KRAS mutations may also have NRAS, BRAF and PIK3CA mutations 
(KRAS MT +/- NRAS MT +/- BRAF MT +/- PIK3CA MT).  NRAS mutations are KRAS 
wildtype but may have mutations in BRAF and PIK3CA (KRAS WT + NRAS MT +/-
BRAF MT +/- PIK3CA MT).  BRAF mutants are KRAS and NRAS wildtype but may 
have mutations in PIK3CA (KRAS WT + NRAS WT + BRAF MT +/- PIK3CA MT).  
PIK3CA mutants are wildtype for KRAS, NRAS and BRAF.  Quadruple wildtype 
patients are KRAS, NRAS, BRAF and PIK3CA wildtype.  TP53 mutation status is 








4.2.3 MEK activation signature 
To determine how RAS mutation impacts on immunity, I wanted to investigate the 
contribution of the RAS-RAF-MEK-ERK pathway on immunosuppression.  To do this, 
the MEK activation signature characterised by Dry and colleagues was utilised [16].  
This signature was initially developed to predict responses to the MEK inhibitor 
selumetinib in vitro, and has been validated in multiple tumour types including colon 
cancer.  It comprises 18 genes that are upregulated by MEK activation, and this 
upregulation is a strong indicator of MEK and ERK phosphorylation, which occurs 
downstream to both RAS and RAF.  The signature’s authors also characterised a 5-
gene CRC optimised MEK signature (MEK CRC), comprising DUSP6, PHLDA1, 
SPRY2, DUSP4 and ETV4, which was used in this analysis.  
In the TCGA dataset, NRAS and KRAS mutant tumours had significantly higher 
expression of the MEK CRC signature than RAS wild type tumours (p<0.05 for both).  
The expression of the signature in NRAS mutants was borderline significantly higher 
compared with KRAS mutants (p=0.055).  The NRAS mutant group therefore served 
as a group where any MEK driven effects were likely to be most obvious.  Indeed, the 
expression of the CIRC was significantly lower in the NRAS mutants compared with 











MEK CRC signature 0.089 0.251 -0.096 
CIRC -0.187 -0.604 -0.011 
Class II HLA -0.104 -0.625 0.013 
IL-12 -0.128 -0.513 0.322 
CXCL9 -0.203 -0.646 -0.029 
CXCL10 -0.075 -0.724 0.025 
 
Table 4.7 Mean MEK signature, CIRC, and other selected immune genes in 
NRAS mutant, KRAS mutant, and RAS wild type patients.  Values represent 
mean microarray z-scores. 
 
Class II HLA expression is an important component of the CIRC and the differences 
in class II expression mirrored that of the MEK signature where expression was 
significantly lower in NRAS cancers compared with wild type (-0.625 vs 0.013, 
p<0.05) and borderline significantly lower in NRAS compared with KRAS mutant 
tumours (-0.625 vs -0.104, p=0.067).  Another key molecule in Th1 immunity is IL-12, 
which is the key cytokine in the decision of CD4 cells to polarise towards Th1 and is 
produced by DCs, monocytes and macrophages.  IL-12 expression was significantly 
lower in both NRAS and KRAS mutant cancers compared with wild type (p<0.05 for 
both).  There was a high degree of negative correlation between IL-12 expression 
and expression of the MEK signature (R = -0.359, p<0.00001) and a positive 
correlation between IL-12 expression and expression of the CIRC (R = 0.217, 
p<0.01), in all patients and in MSS patients only.  When KRAS mutant MSS cancers 
were considered, there was a highly significant difference in IL-12 expression 
between those with MEK signature expression in the top and bottom quartiles 
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(p<0.0001).  These data show strong correlations and suggest the possibility that 
RAS mutation could inhibit Th1 immunity through inhibition of IL-12.    
 
4.2.4 RAS mutant subtype analysis 
It is established that the degree of RAF/MEK/ERK pathway activation following KRAS 
mutation is dependent on the specific amino acid substitution that occurs [134].  For 
example, G12D/G13D KRAS mutations have low affinity for RAF and a fast 
hydrolysis rate, which should lead to relatively low levels of RAF activation. 
Consistent with this, G12D/G13D mutations have been shown to signal through the 
PI3K/Akt pathway, with no activation of RAF [135].  In contrast, G12V KRAS 
mutations, which are associated with more aggressive tumours, strongly signal 
through the canonical RAF/MEK/ERK pathway [135].  As a strong inverse 
relationship between the Dry MEK activation signature and CIRC expression was 
observed, I hypothesised that differing subgroups of KRAS mutants would also vary 
in immune profile.  Table 4.8 shows the CIRC expression in each KRAS and NRAS 















NRAS Q61L 0.556 1 1.45 
G12R 0.146 1 1.45 
G12D 0.007 20 28.99 
G13D -0.084 6 8.70 
A146T -0.087 6 8.70 
R68S -0.170 1 1.45 
A146V -0.286 1 1.45 
G12V -0.368 14 20.29 
G12F -0.428 1 1.45 
G12S -0.511 3 4.35 
NRAS Q61K -0.521 6 8.70 
Q22K -0.541 1 1.45 
Q61L -0.667 2 2.90 
G12C -0.724 4 5.80 
NRAS Q61H -1.100 1 1.45 
NRAS G13R -1.763 1 1.45 
 
Table 4.8 Mean CIRC expression within each RAS mutation subtype, and 
number and percentage of patients per group.  Mutations are ordered from 
highest to lowest CIRC expression.   
 
It was clear that KRAS G12D/G13D mutants made up a large proportion of the KRAS 
mutants, but these patients had relatively high immunity.  KRAS mutant patients were 
therefore divided into G12D/G13D and non-G12D/G13D mutants.  Table 4.9 shows 
the expression of the CIRC and other key parameters in the RAS subgroups of MSS 















KRAS expression -0.177 0.706 -0.083 -0.327 
NRAS expression 0.014 -0.543 0.369 0.222 
CIRC -0.014 -0.374 -0.604 -0.018 
CXCL9 -0.009 -0.485 -0.646 -0.040 
CXCL10 0.246 -0.421 -0.724 0.030 
IL12A -0.076 -0.167 -0.513 0.288 
IL18 -0.104 -0.026 0.108 -0.071 
IL6 -0.286 -0.533 -0.046 -0.139 
 
Table 4.9 Expression of key genes by RAS subtypes in MSS POLE+POLD1 WT 
patients.  KRAS mutants are divided into G12D/G13D mutants and other KRAS 
mutants.  Values represent mean microarray z-scores. 
 
These data suggest that G12D/G13D KRAS mutants are very similar to RAS wild 
type in terms of immune profile, whereas the non-G12D/G13D KRAS mutants have 
significantly lower CIRC expression than RAS wild type cancers (-0.374 vs -0.018, 
p<0.05).  This may be due to the lower RAF/MEK/ERK activation seen in 
G12D/G13D KRAS mutants, and also lower KRAS expression than in non-
G12D/G13D mutants.  Therefore, it is likely that subcategorization of KRAS mutants 





4.2.5 Consensus Molecular Subtypes (CMS) analysis 
Several groups have identified molecular subtypes of colorectal cancer based on 
expression data.  In an effort to create consensus and to facilitate clinical translation, 
and in parallel with my efforts to create an immunological classification, the colorectal 
cancer subtyping consortium (CRCSC) created an integrated classification - 
consensus molecular subtypes (CMS) [136].   This consortium of groups utilised data 
from six independent CRC transcriptional subtyping systems to create a consensus 
classification which focussed on the core transcriptional groups in CRC (Table 4.10). 
Group Typical Clinical Features Common Pathological features 
CMS1 Females, older age, right 
colon 
MSI-H, hypermutation, BRAF MT 
CMS2 Left Colon Epithelial, MSS, high CIN, TP53 MT, WNT/MYC 
pathway activation 
CMS3  Epithelial, heterogeneous CIN/MSI, KRAS MT, 
IGFBP2 overexpression 
CMS4 Younger age, 
Stage III/IV 
Mesenchymal, CIN/MSI, TGFβ/VEGF activation, 
NOTCH3 overexpression 
 
Table 4.10 Characteristics of each CMS group. Adapted from Guinney et al [136]. 
 
To investigate how closely my CIRC patient groupings (based predominantly on 
immunological gene expression) correlated with the CMS classifications, I retrieved 
CMS data for the TCGA dataset.  Table 4.11 shows the distribution of CMS 





















CMS1 13.8% 81.5% 7.4% 3.7% 7.4% 1 
CMS2 40.0% 0.0% 15.4% 23.1% 61.5% 4 
CMS3 10.3% 0.0% 30.0% 20.0% 50.0% 3 
CMS4 18.5% 5.6% 63.9% 13.9% 16.7% 2 




 1 3 2 4  
 
Table 4.11 Distribution of Consensus Molecular Subtype (CMS) groups across 
CIRC patient groups. 
The cells show the percentage of each CMS group that fall within each CIRC patient 
group, and the respective rank for Th1 infiltration from high to low (1=highest Th1 
immunity, 4=lowest Th1 immunity), by CIRC expression for CIRC groups and Th1 
infiltration gene set enrichment for CMS groups [136].  5.1% of TCGA patients did not 
have CMS classification data available.   
 
As expected, CMS1, which is a group comprised of mostly MSI-H and BRAF MT 
tumours with strong immunity, falls predominantly within Group A.  Interestingly, 80% 
of CMS3 tumours, which are mostly epithelial with KRAS mutations, fall within patient 
groups B and D, similar to my KRAS distribution data (Table 4.6).  This reinforces the 
hypothesis that KRAS mutant tumours are immunologically impoverished.  A large 
proportion of CMS4 tumours, which are predominantly mesenchymal with a poor 
prognosis, were found in patient group B (63.9%), and a large proportion of CMS2 
tumours, which are epithelial with high CIN and WNT/MYC pathway activation, fall 
within patient group D (61.5%).   This demonstrates that patient groups B and D are 
distinct despite both groups having low CIRC expression levels.  
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4.2.6 The CIRC compared to other immune signatures 
To determine whether the observed immunosuppression in RAS mutant cases was 
specific to my particular immune metagene/signature (CIRC), or whether it was 
observable with other immune signatures, I retrieved expression data from the TCGA 
CRC dataset for a variety of published immune metagenes and determined how well 
their expression correlated with the CIRC [49, 137-139].  These metagenes 
overlapped little with each other, with only 14.8% of genes replicated in two or more 
separate metagenes.  Strong correlations were found between the CIRC and the 
Nagalla T/NK (T cell and NK cell) and M/D (macrophage and dendritic cell) 
signatures, as well as the class II-centric 14-gene Fehlker signature (p<0.0001 for 
all).  The expression of several of these immune signatures were significantly lower in 
NRAS mutant CRC compared to RAS wild type (Table 4.12), providing further 
evidence that RAS mutant tumours appear to be immunologically depleted relative to 
RAS wild type in this dataset.  In addition, the expression of the signatures were 




 KRAS MT NRAS MT RAS WT 
CIRC signature -0.135 -0.646 0.157 
Lym signature (3 gene version) -0.149 -0.715 0.173 
Fehlker signature (14 gene version) -0.098 -0.538 0.132 
Nagalla T/NK signature -0.128 -0.528 0.096 
Nagalla M/D signature -0.132 -0.635 0.136 
 
Table 4.12 Expression of various immune signatures/metagenes by RAS 
mutation status. Values represent mean microarray z-scores. 
 
In MSS patients, when KRAS mutants were further subcategorised into G12D/G13D 
and non-G12D/G13D mutants, it was clear that non-G12D/G13D KRAS mutants had 







NRAS MT RAS WT 
CIRC  -0.014 -0.291 -0.604 -0.011 
Lym signature (3 gene version) 0.014 -0.309 -0.598 -0.015 
Fehlker signature (14 gene version) 0.065 -0.226 -0.529 0.045 
Nagalla T/NK signature -0.008 -0.271 -0.455 -0.008 
Nagalla M/D signature 0.063 -0.274 -0.635 0.003 
 
Table 4.13 Expression of immune signatures by RAS subtype in MSS patients.  
KRAS has been divided into G12D/G13D KRAS mutants and other KRAS mutants. 




4.2.7 The relationship between immunity and total mutation rates 
MSI-H tumours, which have high mutational burden, had strong CIRC expression, 
whereas MSS tumours had lower CIRC expression generally.  However, the degree 
of variability in immunity within the MSS group, as well as the reasons for this 
variability, is poorly understood. Oncogenic signalling by pathways such as RAS, as 
explored previously, may partly contribute.  Neoantigens, which derive from non-
synonymous mutations, are another possible contributor to this variability.  Kandoth 
and colleagues determined mutation rates in 12 major cancer types using TCGA 
data, and made this data freely available [96].  To determine how mutation rate 
relates to immunity, I retrieved mutation rate (mutations per megabase pair (Mbp)) 
and total mutation (mutations per tumour) data for the colorectal TCGA patients and 
assessed their relationship with the CIRC.  Overall, CIRC expression did not 
correlate with mutational rate (R2=0.0026, p=0.48).  However, those tumour types 
with high mutational load (MSI-H and POLE/POLD1 mutant), had higher CIRC 










Figure 4.6 Mutation rate by Microsatellite status.   
The boxes represent the 25th and 75th percentile values.  The lines within the boxes 
represent median values.  The lines emerging from the boxes represent the 









Figure 4.7 CIRC expression by microsatellite status. 
The boxes represent the 25th and 75th percentile values.  The lines within the boxes 
represent median values.  The lines emerging from the boxes represent the 









Figure 4.8 Relationship between mutation rate and CIRC expression, by 





All MSS POLE and POLD1 WT patients had relatively low mutation rates (<15/Mbp) 
(Figure 4.9).  In this group, there was no significant correlation between mutation rate 
and CIRC expression, and yet the CIRC expression was highly variable, with the 
patients with the highest CIRC expression in this group having similar expression to 
patients in the MSI-H group.  Conversely, many patients in this group had very low 
CIRC expression.  In figure 4.9, MSI-H patients above the horizontal blue line have a 
CIRC expression within the top 75% of all MSI-H patients.  The box highlights MSS 
POLE+POLD1 wild type patients (orange dots) with a CIRC signature equal to or 
above this cut off, representing 20.7% of this patient group.  These patients could be 
classed as ‘MSS-CIRC-high’.  Like MSI-H patients, these immune-rich MSS patients 








Figure 4.9 Variability of CIRC expression in the MSS POLE+POLD1 wild type 
patient group.  MSI-H patients above the horizontal blue line have a CIRC 
expression within the top 75% of all MSI-H patients.  The box highlights MSS 
POLE+POLD1 wild type patients (orange dots) with a CIRC signature equal to or 
above this cut off, representing 20.7% of MSS POLE+POLD1 WT patients that could 




To further investigate how mutation rate correlates with the CIRC, the analysis was 
extended to a further 8 cancer types that had TCGA mutation rate data available 
(head and neck cancer, lung squamous cell cancer, lung adenocarcinoma, bladder 
cancer, glioblastoma, uterine cancer, ovarian cancer and breast cancer) [96]. 
When analysing mutation rate groups, it became clear that the majority of patients 
with these tumour types had mutation rates below 15/Mbp (Figure 4.10).  However, 
when correlating mutation rate with CIRC expression, CIRC expression only began to 
rise markedly when the mutation rate proceeded above 15 mutations/Mbp (Figure 
4.11).  
Similar results were observed when total numbers of mutations were analysed rather 
than mutation rate (Figure 4.12).  In this case, the CIRC only increased significantly 



















Figure 4.11 CIRC expression in each mutation rate group. 













Figure 4.12 CIRC expression in relation to number of mutations per tumour.  







Since the vast majority of patients had a mutation rate below 15/Mbp (Figure 4.10), 
and a fraction of these patients had high immunity, only a small percentage of 
patients with high CIRC expression had high mutation rates (above 15/Mbp) (Figure 
4.13).  This suggests that in the majority of these patients’ cancers, mutational rate 
was not the dominant determinant of intra-tumoural immunity.  Mutation type may be 
important – patients with low mutation rate with high immunity may have particularly 
















4.2.8 Neoantigen prediction analysis 
 
As the majority of patients in the TCGA CRC dataset had relatively low mutation 
rates but variable CIRC expression, I wanted to investigate the factors that 
determined the immune profile in these patients.  One factor likely to have 
contributed, as shown above, is mutational profile and the effect of driver mutations.  
Another important possibility is that both the quality (in terms of antigenicity) and 
quantity of neoantigens were important.  Certain mutations are likely to be more 
immunogenic than others, partly due to the strength of binding to the patient’s 
particular class I and II HLA molecules.  To explore this idea further, I collaborated 
with the Sahin Group at TRON (Translational Oncology, University of Mainz, 
Germany).  This group had previously utilised Next Generation Sequencing (NGS) 
and RNAseq technology to predict the neoantigens present in individual cancers, and 
were using this approach in a personalised cancer vaccine trial [16].  In addition, they 
had performed a parallel analysis on the TCGA CRC dataset, and therefore had 
neoantigen data available.  To perform the analysis the number of non-synonymous 
single nucleotide variations (nsSNVs), which are responsible for the alteration of the 
protein amino acid sequence, was determined for each patient.  Then, using RNAseq 
data, the number of reads per mutation was calculated to determine whether the 
neoantigen was expressed.  Highly expressed neoantigens are more likely to 
produce immune responses [16].   Finally, HLA-type was predicted from RNAseq 
data using seq2HLA, and HLA-binding predictions were made using the IEDB MHC 
binding prediction algorithm v2.9, “consensus” method [97, 98].  A cut-off for strong 
binding (and thus “likely immunogenic”) was below 1.0. This approach was used to 
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determine how the strength of neoantigen binding to HLA and the total number of 
neoantigens related to CIRC expression in TCGA patients. 
In addition, I wanted to explore how the neoantigen profile varied between patients 
and patient groups.  A recent study demonstrated that there is little overlap in 
neoantigen profile between CRC patients and that individual neoantigens are rarely 
shared [140].  This group suggested that 70 peptides would be required in a generic 
vaccine to cover 50% of MSS CRC patients.   However, what had not been explored 
is how the profile of neoantigens varies in key patient subgroups, such as RAS 
mutant patients.  Increasing this understanding could be key to stratified vaccine 
approaches targeting such groups, which could have a key role in the window before 
personalised treatments are produced for patients. 
Initially, the number of genomic, expressed and predicted to be presented nsSNVs 
were determined for each patient and were grouped by microsatellite status (Figure 
4.14).  As expected, MSI-H patients were predicted to present significantly more 
nsSNVs than MSI-L or MSS patients.  However, the difference was larger than 
expected, with MSI-H tumours predicted to present a median of 359 nsSNVs, and 







Figure 4.14 Number of total presented Class I neoepitopes per patient by MSS 
status.  The top panel shows the total number of non-synonymous single nucleotide 
variations (nsSNVs) in each patient (red dots).  The middle panel shows the number 
of these nsSNVs that were expressed (at mRNA level) in each patient.  The bottom 
panel shows the number of these expressed nsSNVs that were predicted to be 
presented on that particular patient’s predicted class I HLA type.  Boxes represent 
median, 25th and 75th percentile of each group. 





In the overall population, patients with stronger binding Class I neoepitopes (in terms 
of the single strongest binder) had significantly higher CIRC scores than those with 
weaker binders (p<0.001), which was consistent with the quality of neoantigens 
impacting significantly on the overall immune phenotype (Figure 4.15).  This was also 
observed in relation to total number of neoantigens.  However, in the MSS group 
alone, this correlation was not observed for neoantigen binding strength or quantity, 
suggesting that in the majority of patients with low mutation rates, strongest binding 
neoantigen or neoantigen number was not the main determinant of immune 
response.  The same result was observed for Class II-binding neoantigens (Figure 
4.15).  Furthermore, the number of mutations in each sample did not correlate with 
CIRC expression within the MSS or MSI-H groups (though MSI-H patients had both 
higher mutation numbers and CIRC than MSS patients) (Figures 4.16 and 4.17).  
This is consistent with my findings above regarding mutation rates and immune 
responses across 8 tumour types.  It is possible that the immune response only rises 
substantially with mutation rate above a certain level.  This highlights the need for 
further work to explore and fully understand the determinants of immune response in 



















Figure 4.15 CIRC score in patients with top binding neoantigens versus 
patients with bottom binding neoantigens, for both Class I and II neo-epitopes in 
all patients and MSS patients only.  The single strongest binding neoantigen in each 
case was considered.   
Figure courtesy of Sebastian Boegel, TRON. 





P < 0.001 P > 0.4  



































Figure 4.16 Class I neoantigens analysis.  Correlation between CIRC and total number of expressed nonsynonymous single nucleotide variations 
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Figure 4.17 Class II neoantigens analysis. Correlation between CIRC and total number of expressed nonsynonymous single nucleotide variations 
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In addition to investigating quality and quantity of neoantigens, and the association 
with the CIRC, I also wanted to investigate the antigenicity of RAS-associated 
neoantigens. This analysis demonstrated that approximately 94% of TCGA CRC 
RAS mutant patients were predicted to express a RAS-associated neoantigen on 
Class I HLA (Table 4.14).  Approximately 23% of all KRAS mutant patients were 
predicted to present a ‘likely immunogenic’ strong-binding KRAS-associated 
neoantigen.  When considering that MSS patients were only predicted to present a 
median of 26 Class I neoepitopes each, this represents strong overlap within this 
patient group.  Furthermore, within certain RAS mutant subgroups (Table 4.15), such 
as the common G12V subgroup, 50% of patients were predicted to present an 
immunogenic KRAS-associated neoantigen (Figure 4.18).  These analyses took into 
account the predicted HLA-types of the patients.  Certain HLA and neoantigen 
combinations were recurrent (Table 4.16).  The identification of recurrent RAS-



























neoantigen (rank <1) 
Percentage of group 
predicted to present a 
KRAS associated 
neoantigen (any rank) 
Percentage of group 
predicted to present 
'likely immunogenic’ 
KRAS associated 
neoantigen (rank <1) 
A146T 6 6 0 100.00 0 
A146V 1 1 1 100.00 100 
A155D 1 0 0 0.00 0 
G12A 5 5 0 100.00 0 
G12C 3 3 1 100.00 33.33 
G12D 19 19 0 100.00 0 
G12R 2 2 1 100.00 50 
G12S 5 5 3 100.00 60 
G12V 16 14 8 87.50 50 
G13C 1 1 0 100.00 0 
G13D 17 17 0 100.00 0 
K117N 1 1 0 100.00 0 
L19F 1 1 1 100.00 100 
P34L 1 1 1 100.00 100 
Q22K 1 1 1 100.00 100 
Q61H 2 2 1 100.00 50 
Q61K 2 0 0 0.00 0 
Q61P 1 1 1 100.00 100 
Q61R 1 1 1 100.00 100 
All KRAS 
mutants 
86 81 20 94.19 23.26 
 










Percentage of group with 'likely 
immunogenic’ KRAS associated 
neoantigen (rank <1) 
A146T 6 0 
G12A 5 0 
G12C 3 33.33 
G12D 19 0 
G12S 5 60 
G12V 16 50 
G13D 17 0 
 
Table 4.15 KRAS subtype neoantigens predicted to present on HLA A and B – 
selected mutations. 
 
Predicted class I HLA 




(substitution in red) 
Percentage of total KRAS 
G12V mutant patient group 
(n=16) 
B*49:01 TEYKLVVVGAV 6.25% (n=1) 
B*40:02 TEYKLVVVGAV 6.25% (n=1) 
B*18:01 TEYKLVVVGAV 18.75% (n=3) 
A*03:01 VVGAVGVGK 18.75% (n=3) 
 
Table 4.16 Analysis of HLA-restriction and presentation frequency of predicted 
strong binding KRAS G12V-derived neoantigens. Notably, this analysis predicts a 
promiscuous HLA-B-restricted neoepitope (TEYKLVVVGAV), as well as HLA-A 
derived G12V presentation by HLA-A*03 (VVGAVGVGK). In addition, it highlights the 
potential for presentation of some form of KRAS G12V-based neoantigen in up to 








Figure 4.18 Neoepitope prediction for recurrent KRAS mutations.  
All KRAS mutation subtypes (frequency indicated by the blue bars) were predicted to 
give rise to class I MHC epitopes (red bars). However the proportion of predicted 
strong-binding (score ≤1) KRAS-derived neoantigens (green bars) was highest for 







In this chapter, I have identified a group of tightly co-regulated immune-related genes 
that was termed the Coordinate Immune Response Cluster (CIRC), and used this to 
assess differences in the intra-tumoural immune response in a molecularly 
characterised cohort of CRC patients.  The CIRC signature I defined stems from the 
work of Galon and colleagues, who first established the prognostic impact of T cell 
infiltration in CRC, initially highlighting 7 co-modulated genes principally associated 
with Th1-associated immunity that correlated with outcome [37].  Subsequently, they 
demonstrated that the Th1 genes, TBX21, IFNG, IRF1 and STAT1 were all 
individually associated with outcome [42].  Other independent immune gene 
predictors in that analysis were IL18RAP, ICOS, PD-L1, PD-L2 and PD-1.  I 
extended this gene list by adding the class I and class II genes, further immune 
checkpoint genes and a number of other genes related to innate immune recognition 
and T cell activation, generating an initial gene list of >50 genes.  Hierarchical 
clustering then highlighted a core cluster of 28 tightly co-regulated genes comprising 
the CIRC signature.   Importantly, 20 of the 28 genes had previously been highlighted 
by Galon and colleagues [37, 42, 141] as either prognostically or predictively 
relevant, including 5 of the original prognostic 7 gene cluster (with only CD8A (for 
which microarray data was unavailable) and GZMB not represented).  In contrast, 
genes associated with Th2 and Th17 profiles were excluded from the cluster. Thus, 
applying a different approach to an independent dataset my analysis verified the high 
level of correlation of a number of genes based on Th1-associated immunity, and 




An important feature of the CIRC signature is that it includes essentially all class II 
MHC loci, as well as CD4, whereas in contrast, expression of class I MHC molecules, 
CD8B and also GZMB are all excluded from the signature.  In addition to the critical 
role of T helper cells for CD8 cell priming [142, 143] and expansion [144, 145], CD4 
cells have also been suggested to be major mediators of immunological tumour cell 
death [146-148].  Adoptive CD4 T cell transfer has been found to up-regulate class II 
expression on tumour cells mediating protection from tumour progression [147].  
Class II up-regulation was mediated via IFNγ and protection was attenuated using 
anti-IFNγ antibodies.  Recent adoptive transfer approaches involving autologous 
CD4+ T cells have met with clinical success.  A durable complete response was 
obtained in a patient with melanoma after infusion of NY-ESO-1 specific CD4+ cells 
recognizing an HLA-DP4 restricted epitope [149].  Additionally, a durable response 
was obtained in a patient with cholangiocarcinoma on infusion of autologous 
mutation-specific CD4+ cells which adopted a poly-functional Th1 phenotype [27].  
These studies highlight the potential for CD4 cells to mediate clinically potent anti-
tumour responses via Th1 mechanisms.  The CD4-centric nature of the CIRC 
highlights that CD4 T cells may be important in CRC anti-tumour immunity.  
 
The CIRC included the major immune checkpoint molecules.  Not only PD-L1, PD-L2 
but also LAG3, TIM3 and CTLA4 were all represented in the CIRC and there was a 
high degree of correlation between inhibitory checkpoint gene expression.  This is 
consistent with the expected feedback sequelae of a pronounced Th1 infiltrate.  IFNγ 
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is the canonical cytokine associated with Th1 T helper cells and expression of PD-L1 
is significantly augmented by IFNγ [150].  IRF1 is of primary importance in the 
constitutive expression of PD-L1 and in IFNγ-driven up-regulation [151].  In animal 
models, significant percentages of infiltrating CD4+ and CD8+ cells co-express high 
levels of both PD-1 and LAG-3 [152].  Dual anti-LAG3/anti-PD-1 immunotherapy 
strikingly enhanced survival in the MC38 colon cancer model compared with animals 
treated with single antibodies alone [152].  My data provide justification for trialling 
combinations of checkpoint blockade agents in CRC.  
 
One of the key aims of this study was to investigate the somatic factors associated 
with the immune response in CRC. Group A, which exhibited strong expression of 
the CIRC signature, was dominated by MSI-H tumours, all of which fell in this 
grouping.  This complements very well the work of Biossière-Michot and colleagues, 
who revealed that MSI-H tumours have a high density of Tbet-positive Th1 T cells 
relative to MSS tumours, and higher expression of the chemokines CCL5, CXCL9 
and CXCL10, all of which are found in the CIRC [50].  The Th1 response may be 
driven through activation of the CXCL9/CXCL10 signalling axis [50].   Previous 
studies have also shown that MSI-H phenotype is highly associated with class II 
expression [153].  Strongly DR positive tumours had a significantly higher TIL density 
than those with absent or weak staining and survival was significantly better in 
patients with high DR expression.  Consistent with this, Bindea and colleagues 
demonstrated that the expression of several class II genes, including HLA-DRA, are 
individually associated with improved disease-free survival [141].  High DR 
expression in MSI-H CRC contrasts with that of class I molecules, which are 
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completely lost in 60% of sporadic MSI-H cases and only 16.7% of right sided MSS 
cancers [133].  Thus, the immune landscape of MSI-H CRC, which is characterised 
by a high mutational burden including frameshift mutations [48], is dominated by T 
helper cell infiltration and activation, class II expression and co-ordinated up-
regulation of a range of immune checkpoint genes.  My data suggested that these 
patients may be more responsive to checkpoint blockade – a hypothesis which has 
since been confirmed [154].  Similarly, POLE/POLD1 mutant tumours, which also 
have a high mutational burden whether microsatellite stable or unstable [132], were 
also associated with high CIRC expression.  This association has also now been 
confirmed in a retrospective clinical study [155].  These data in combination support 
the hypothesis that high mutational burden may translate into a strong immune 
response, possibly due to neoantigen presentation, leading to better outcomes.  The 
finding that the gene encoding TGFβR undergoes frameshift mutation in 90% of MSI-
H CRC, giving rise to a highly immunogenic promiscuous class II peptide, is entirely 
in keeping with this hypothesis [156].  Though FOXP3 was not in the hierarchical 
clustering due to an absence of microarray data, I separately analysed RNA 
sequencing data which showed that FOXP3 expression is highest in patient group A 
and lowest in group D, suggesting that the immune enrichment in MSI-H patients 
may include suppressive Tregs.  However, the ratio of effector T cells to regulatory T 
cells, which was not determined in this analysis, may be important [157] and may 
differ between MSI-H and MSS patients. 
  
A further aim of this work was the investigation of mutation rates and CIRC.  I found 
that overall, the CIRC was higher in patients with high mutation rates, both in CRC 
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and across eight tumour types.  Increased mutation rate is likely to increase the 
probability of immunogenic mutations, such as missense mutations.  However, this 
relationship was not linear, and the CIRC only increased significantly above a certain 
level (15 mutations/Mbp, or 500 total mutations).  MSI-H and MSS differed in both the 
number of neoantigens, as well as the strongest binding neoantigens. The frameshift 
mutations seen in MSI-H lead to multiple changes in amino acid sequence, whereas 
single point mutations may lead to single amino acid substitutions.  It is likely that 
multiple amino acid changes are more immunogenic than single amino acid 
alterations, due to the higher number of neoantigens (each with potentially multiple 
amino acid changes) that will be derived from these mutated proteins.   Factors 
related to this are likely to explain the difference in immunity between these two 
groups, as well as the difference in clinical outcomes.  However, within both the MSS 
and MSI-H groups, there were no correlations between total mutations, total 
predicted neoantigens, or strongest-binding neoantigen and the CIRC.  Therefore, it 
is possible that other undetermined factors may explain the differences between 
MSS patients.  Specific immunogenic mutations may be important.  Another 
possibility is that the cumulative strength of neoantigen binding is significant – this 
analysis was superficial as it only considered the single strongest binder.  In addition, 
strong HLA-binding may not necessarily produce strong immune responses [20].  
Other important factors may include tumour factors (including cell signalling, tumour 
antigen expression, microenvironmental factors), host factors (including germ line 
genetics, single nucleotide polymorphisms (SNPs), expression quantitative trait loci 
(eQTLs [158]), general health), and environmental factors (such as bowel flora [159, 
160]).  Determining how each of these factors and possibly as-yet-unknown factors 
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contribute to the overall immune phenotype is likely to be crucial to the appropriate 
targeting of existing therapies such as checkpoint blockade, as well as for the 
development of novel approaches that adjuvantise the microenvironment.  As 
discussed, checkpoint blockade therapy is most effective in patients with high 
mutation load (MSI-H) [154]. This is likely to be due to the strong infiltration of 
exhausted T cells within these tumours, which are retained in the tumour by 
neoantigens presented on HLA molecules.  Therefore, measures that can alter the 
immune environment to induce immune infiltration may improve efficacy of 
checkpoint blockade.   
 
Interestingly, approximately 20% of MSS POLE+POLD1 wild type patients had CIRC 
scores that fell within the top 75% of CIRC scores for MSI-H patients.  These patients 
could be classified as ‘MSS CIRC-high’.  These patients, who have strong immune 
infiltration through an unknown mechanism, could, like MSI-H patients [154], be 
responsive to checkpoint blockade therapies.  Potentially responsive patients could 
be identified by PD-L1 expression (which is a biomarker used to predict anti-PD1 
mAb responses [14]), or high RNA or protein expression of various other molecules 
found within the CIRC, such as CD4 or Class II HLA, as my data suggest that these 
are upregulated in a co-ordinated fashion.  This should be a priority for further clinical 
study, as MSS patients make up over 80% of CRC cases.   
 
RAS mutation was significantly associated with lower CIRC expression, with over 
60% of cancers in the group exhibiting very low expression (group D) being RAS 
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mutant.  KRAS and NRAS mutant CRC had significantly lower levels of CD4+ T cells 
on multivariate analysis.  Although 21.4% of cancers in group A were RAS mutant, 
over 80% of these were MSI-H.  This is the first analysis to my knowledge to clearly 
define the immunological landscape of RAS mutant CRC.  Ogino and colleagues 
examined the interaction between T cell infiltration and KRAS, BRAF and PIK3CA 
mutation status and found no significant associations with KRAS mutation [161], but 
this study was limited to the density of CD3+, CD8+, CD45RO+ and FoxP3+ cells.  
Morris and colleagues demonstrated that transfection of mutant KRAS into fibroblasts 
abrogated the IFNγ-mediated up-regulation of class II expression: effects on class I 
expression were minimal [162].  RAS transfection into fibroblasts inhibited 
proliferation and IFNγ production of alloreactive T cells, an effect mediated by loss of 
class II expression on target cells [163].  These data suggest that abrogation of IFNγ 
related signalling may be a possible mechanism for my observed paucity of class II 
expression and hence Th1-related gene expression in RAS mutant CRC.  My data 
complement previous studies demonstrating widespread abnormalities of class I 
presentation in RAS mutant CRC [164].  Of the RAS subtypes, the less common 
NRAS mutant tumours had the lowest CIRC expression, potentially due to increased 
MEK activation.  NRAS and KRAS mutant tumours had significantly higher 
expression of the Dry et al. MEK signature than RAS wild type cancers, as expected, 
and the expression of the MEK signature was borderline significantly higher in NRAS 
mutants compared with KRAS mutants, and thus served as a mutation set where any 
MEK driven differences would be likely most evident. I further investigated MEK 
signature expression and immune expression by the exact amino acid substitution 
that occurred.  Certain KRAS mutations, such as G12D and G13D, have low affinity 
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for RAF and a fast hydrolysis rate, which leads to low levels of RAF activation [134].  
G12D/G13D KRAS mutants had CIRC expression very similar to RAS wild type.  The 
finding that RAS-associated immunosuppression is strongest in the non-G12D/G13D 
mutants, which have the highest MEK signatures, is consistent with the hypothesis 
that the immunosuppression is MEK-driven.   
 
In MSI-H tumours, it is likely that any inhibitory effect of RAS mutation is overcome by 
the strong immunity resulting from neoantigens linked to mutations induced by 
microsatellite instability. Thus MSI-H RAS mutant tumours retain strong Th1 
immunity, despite having numerically lower HLA-DRA expression than MSI-H RAS 
wildtype tumours.   In sum, these data suggest that the micro-environment of MSS 
RAS mutant CRC is relatively immunologically unfavourable to conventional  T cell 
responses.  
 
The identification of recurrent and commonly presented strong-binding neoantigens 
derived from mutant RAS raises the possibility of utilising these antigens in 
vaccination approaches.  Currently,  RAS-associated neoantigens are frequently 
amongst the strongest identified, and are being targeted in personalised vaccine 
approaches [16].  However, the frequency of RAS-associated neoantigens in certain 
mutation groups, such as the G12V group, raises the possibility of stratified 
vaccination for patients with particular mutations. This is discussed further in the 




The CIRC molecular associations relate to the CRCSC consensus molecular 
subtypes and their immune and molecular characteristics [136].  The majority of 
CMS1 patients (MSI high and immune activated) fall within CIRC group A.  82.5% of 
KRAS mutated patients were in CIRC groups D and B (the lowest two CIRC 
expression groups) and almost the same percentage of CMS3 patients, 
characterised by KRAS mutations and no significant immune infiltration and 
activation, were present in CIRC groups D and B.  The relationship between CMS, 
RAS mutation and immunity is explored further in the next chapter.  
 
The development of the CIRC provides a useful tool with which to explore the 
immunobiology of different cancers.  As an example, I investigated CIRC expression 
in the TCGA head and neck squamous cell cancer dataset, in a study exploring the 
relationship between immunity and hypoxia.  This revealed an inverse correlation 
between immunity and hypoxia signatures, and the combination of these two factors 
had a significant impact on patient survival.  Those patients with high hypoxia and 
low immunity had significantly poorer survival than those with low hypoxia and high 
immunity.  Patients with both low hypoxia and low immunity had intermediate 
survival. This work is now being prospectively validated, and has potential 
implications for the targeting of hypoxia modulators and immunotherapies to specific 
patient groups.  Hypoxia and immunity could conceivably be combined into a new 
scoring system (for example, a ‘hypoximmunoscore’), which could potentially be 






















The RAS genes were the first identified oncogenes [165, 166], and encode a family 
of tyrosine kinases that includes KRAS, NRAS and HRAS.  RAS is downstream of 
EGFR in the EGFR-RAS-RAF-MEK-ERK pathway, and its activation can mediate 
both RAF phosphorylation and PIK3CA phosphorylation [134].  RAS is therefore 
capable of activating two key oncogenic signalling pathways.  After RAS mutation, 
which occurs in approximately 40% of CRC [91, 119], the RAS protein becomes 
constitutively active.   
 
Patients with RAS mutant CRC have poorer outcomes than those with wild type RAS, 
and receive no benefit from EGFR inhibitors [167]. The outcome of RAS mutant CRC 
matches that of advanced non-small cell lung cancer [10, 168].  Although KRAS 
mutant tumours are critically dependent on intact MEK pathway signalling, clinical 
efforts to target this pathway either with or without parallel pathway inactivation of 
PI3K/AKT/mTOR signalling, through which mutant RAS can also signal [134], have 
been disappointing [169, 170].  Therefore, RAS mutant patients are a key group of 
unmet need in CRC.  In addition to CRC, RAS mutation occurs in a range of common 
cancer types, with some, including pancreatic cancer, being predominantly RAS 
mutant [134].   
 
Following my in silico transcriptomic analyses in the TCGA CRC dataset that 
revealed a link between RAS mutation and low expression of immunity related 
genes, I wanted to investigate the relationship between RAS and immunity further in 
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a separate, independent local sample.  The TCGA analyses were based on 
transcriptomics, and, though RNA expression and protein expression are correlated, 
this association is not always linear or reliable.  The correlation depends on multiple 
factors which vary according to the specific gene, including mRNA transcription and 
degradation, and protein translation and degradation [171, 172].  Therefore, for the 
analysis of the independent local sample set, in addition to transcriptomics, I wanted 
to investigate protein expression.  Protein expression is not only more functionally 
relevant than RNA, but its quantification through immunohistochemistry is more 
clinically aligned, and allows the assessment of the tumour microenvironment. 
 
In addition, I wanted to investigate how RAS mutation affects immunity within the key 
molecular subgroups of CRC.  The recently published CMS analysis, introduced in 
the previous chapter, demonstrated that the classification of CRC could be 
significantly refined beyond one based on common single mutations [136]. The 
authors showed that RAS mutations are heterogeneous, being observed across all 
CMS groupings to varying extents and with these groupings displaying very different 
underlying biology.  Secondly, although under-representation of a Th1 immune 
signature is observed in CMS3, which is the RAS-enriched sub-type, low Th1 
signature expression is also seen in CMS2, characterised by high WNT and MYC 
pathway signalling and a lower RAS mutation rate.  Indeed CMS2 is globally 
immunologically impoverished, with under-expression of multiple signatures of innate 
and adaptive immunity and to a much greater extent than CMS3.  In this chapter, I 
show that the immunological impact of RAS mutation is dependent upon the 




5.2.1 Cohort characteristics 
To determine the required sample size, a power calculation was performed using 
Altman’s nomogram.  This confirmed that a total of 100 samples (50 RAS mutant, 50 
RAS wildtype) were required for a power of 80%, a significance level (α) of 0.05 and 
a minimum detectable standardised difference between the two groups of 0.55.   This 
power provided an 80% probability of detecting a difference between the RAS mutant 
and wildtype groups if one existed.  The significance level represented the threshold 
below which the null hypothesis (that there was no difference between the RAS 
mutant and wildtype groups) would be rejected, in this case corresponding to a p 
value <0.05.   
The specimens were selected to represent the range of RAS mutations observed in 
the original TCGA microarray data set.  The final cohort comprised 28 RAS 
G12D/G13D mutants (24.3%), 38 RAS non-G12D/G13D mutants (33.0%), and 49 
RAS wild types (42.6%).  Therefore, there were 66 RAS mutants and 49 RAS 
wildtypes (total = 115), which closely matched the requirements determined by the 
power calculation. 
As microsatellite instability is associated with high immune infiltration [5], the 
microsatellite status for each tumour was confirmed by extracting total DNA from 
formalin-fixed paraffin-embedded (FFPE) tumour scrolls and performing fragment 
analysis (details in methods).  This confirmed that 7 tumours (6.09%) were MSI-H.  
Of these 7 tumours, 3 were RAS mutant (2 G12D/G13D MT, 1 non-G12D/G13D 





To determine the relationship between RAS mutation status and protein expression 
of key markers of immune infiltration, IHC was performed targeting CD4, CD8, Tbet, 
Class II HLA, STAT1, PD-L1 and CXCL10 on the cohort of 115 primary CRC 
specimens.  Clinically validated (IVD-CE) antibodies were chosen where available.  
Otherwise, knockdown/knockout validated antibodies were chosen.  If these were not 
available, in-house antibody validation was performed (details in methods).  Stained 
slides were digitally scanned, and were analysed using Definiens Tissue Studio 
software.  Tumour regions were segmented into tumour epithelium and stroma 
regions during analysis, and percentages of cells or pixels with high, medium, low or 
no immunoreactivity were quantified in both regions.  This produced either 
histological scores for cell-based scoring (Figure 5.1), which is a function of the 
number and intensity of immunoreactive cells, or percental scores for pixel-based 
scoring (Figure 5.2), which is a function of the number and intensity of positive pixels 
in the scanned specimen.  The results for each slide were grouped by RAS mutant 
and RAS wild type, as well as by RAS mutant subtype.  H-scores were compared for 
RAS mutant and RAS wild type across the entire sample set.  To align the results 
with previous studies [153, 173], for PD-L1, STAT1 and Class II HLA, each patient 
was additionally categorised into expression groups according to the percentage of 
cells/pixels that were positive for the marker in each region.  Finally, I calculated the 
number of Tbet positive cells in each group normalised by area (mm2), to enable 
comparisons with existing literature [174].  A separate correlation of immune markers 










Figure 5.1 Cell-based IHC scoring algorithm.   
Identification of CD8 immunoreactive cells using trained Definiens Tissue Studio cell-
based scoring algorithm.   
 
a) Tumour region of a CD8-stained CRC slide (20x magnification) 
b) Image A, after analysis with cell identification and scoring algorithm.  In this 
image, white cells are negative, yellow cells are lightly stained, orange cells 
are moderately stained, and dark red cells are heavily stained.  This image is 










Figure 5.2 Pixel-based IHC scoring algorithm.   
Identification of Class II HLA positive cells and pixels using trained Definiens Tissue 
Studio pixel-based algorithm.   
 
a) Tumour region of a Class II HLA-stained CRC slide (20x magnification) 
b) Image A, after analysis with cell identification and pixel scoring algorithm.  In 
this image, blue represents cell nuclei.  Yellow areas represent pixels with light 
staining, orange areas represent pixels with moderate staining and dark red 






In the epithelial compartment, STAT1 protein expression was significantly lower in 
RAS mutant cancer cells compared with their wild type counterparts thus 
recapitulating at the protein level the findings at the transcriptional level in the TCGA 
dataset (Table 5.1).  This was the case whether samples were analysed by H-scores 
(p=0.016 in the epithelial compartment) or by analysing samples according to 
percentage of cells positive for STAT1 (Chi squared p=0.033 in the epithelial 
compartment).  However, there were no significant differences in Tbet positive cells, 
CD4 positive cells, CD8 positive cells, PD-L1 reactivity or CXCL10 reactivity in either 
the epithelial or stromal compartments (Table 5.1 and 5.2).  In the stromal 
compartment, class II HLA reactivity was borderline higher (p=0.051) in the RAS 
mutant group, contrary to my previous in silico findings.  Just over 50% of both RAS 
mutant and RAS wild type tumours were negative for class II HLA and only 6.35% 
RAS mutant tumours had >50% class II HLA positive cells.  Strikingly, more than 
95% of both RAS mutant and RAS wild type cancers were cancer cell PD-L1 
negative although stromal PD-L1 positivity was seen in greater than 50% of both sub-
types.  The median number of Tbet positive cells in the epithelial compartment of 
RAS mutant cancers was 146/mm2 compared with 163/mm2 in RAS wild type 
cancers (p=0.46) and in the stromal compartment 96/mm2 and 104/mm2 respectively 
(p=0.98).  Figures 5.3 to 5.9 demonstrate staining in the tumours with the lowest, 
median and highest reactivity for each marker in the RAS mutant and wildtype 
groups (in stromal regions for CD8, CD4 and Tbet, and in epithelial regions for 




No significant differences were observed in protein expression of any of the markers 
between MSI-H and MSS cases, likely reflecting the small number of MSI-H samples.  
In addition no significant differences were seen between G12D/G13D RAS mutant 
cases and non-G12D/G13D RAS mutant cases in terms of IHC scoring, though this 







CD8 3 6 0.633 
CD4 1 0 0.462 
Tbet 2 3 0.308 
STAT1 180 238 0.016 
PD-L1 0 0 0.960 
CXCL10 270 224 0.175 
Class II HLA 125.16 136.79 0.260 
 
Table 5.1 Median Histological scores or Percental scores in epithelial regions.  
Class II HLA reactivity is represented by percental scores.  All other markers are 








CD8 10 11 0.986 
CD4 5 6 0.984 
Tbet 5 5 0.897 
STAT1 88 122 0.086 
PD-L1 1 1 0.741 
CXCL10 70 55 0.290 
Class II HLA 143.87 135.82 0.051 
 
Table 5.2 Median Histological scores or Percental scores in stromal regions. 
Class II HLA reactivity is represented by percental scores.  All other markers are 










Figure 5.3 Stromal CD8 staining. Representative images (20x magnification) of the 
tumours with the lowest, median and highest stromal CD8 reactivity in the RAS 







Figure 5.4 Stromal CD4 staining. Representative images (20x magnification) of the 
tumours with the lowest, median and highest stromal CD4 reactivity in the RAS 









Figure 5.5 Stromal Tbet staining. Representative images (20x magnification) of the 
tumours with the lowest, median and highest stromal Tbet reactivity in the RAS 









Figure 5.6 Epithelial CXCL10 staining. Representative images (20x magnification) 
of the tumours with the lowest, median and highest epithelial CXCL10 reactivity in the 








Figure 5.7 Epithelial PD-L1 staining. Representative images (20x magnification) of 
the tumours with the lowest, median and highest epithelial PD-L1 reactivity in the 












Figure 5.8 Epithelial Class II HLA staining. Representative images (20x 
magnification) of the tumours with the lowest, median and highest epithelial Class II 










Figure 5.9 Epithelial STAT1 staining. Representative images (20x magnification) of 
the tumours with the lowest, median and highest epithelial STAT1 reactivity in the 




5.2.3 Targeted RNAseq panel 
 
 
In addition to IHC analysis, targeted RNAseq analysis was performed using RNA 
extracted from FFPE scrolls from the same patient cohort.  This exploratory study 
took advantage of RNAseq’s ability to sequence relatively degraded RNA that would 
not be suitable for microarray-type analysis, such as the RNA extracted from 
archived FFPE tissue.  If this technique was found to be robust, it would provide the 
opportunity to perform transcriptomics on samples collected retrospectively, without 
the need for prospective collection of fresh tissue.  Targeted sequencing was 
performed for all genes from the CIRC signature, as well as several other key 
immune genes and the Dry et al. CRC-optimised MEK signature as a positive control 
(full list of genes in methods) [175]. 
 
On logistic regression analysis of all included genes against RAS mutation status, 
several genes were significantly differentially expressed in RAS mutant versus wild 
type tumours (Table 5.3). This analysis suggested that the expression of key genes 
including CD4, CCL5, CXC10 and PDCD1 were significantly lower in RAS mutant 
cases.  However, genes including CD8A, GZMH and CXCL11 were significantly 
higher in RAS MT cases on multivariate analysis.  The CIRC metagene itself was not 
significantly differentially expressed.  The Dry et al. CRC-optimised MEK signature 
was higher in RAS mutant tumours than RAS wild type tumours on univariate 











Z P value 





ALOX5AP 9.362858 6.825728 3.07 0.002 2.243179 39.07986 
BNIP3 2.130329 0.626167 2.57 0.01 1.197439 3.790007 
CCL5 0.331359 0.138236 -2.65 0.008 0.146284 0.750587 
CD4 0.560019 0.14001 -2.32 0.02 0.343079 0.914138 
CD48 0.654067 0.1225 -2.27 0.023 0.453108 0.944154 
CD74 2.449633 0.701375 3.13 0.002 1.397611 4.293541 
CD80 1.592431 0.361971 2.05 0.041 1.019944 2.486251 
CD8A 1.853823 0.435369 2.63 0.009 1.169942 2.937461 
CSF1R 0.562262 0.115678 -2.8 0.005 0.375678 0.841516 
CXCL10 0.615967 0.152273 -1.96 0.05 0.379431 0.999959 
CXCL11 1.663005 0.408575 2.07 0.038 1.027464 2.691664 
DOCK2 0.459117 0.10747 -3.33 0.001 0.290184 0.726394 
ETV4 0.571134 0.147028 -2.18 0.03 0.344835 0.945942 
EVI2B 2.839844 0.805265 3.68 <0.001 1.629026 4.950636 
GNLY 0.158137 0.069613 -4.19 <0.001 0.066731 0.374748 
GZMH 4.898323 3.359166 2.32 0.021 1.277354 18.7838 
HLAB 2.676023 1.187708 2.22 0.027 1.12124 6.38677 
KANK1 3.559602 1.110757 4.07 <0.001 1.931025 6.561678 
LAT2 2.231394 0.597264 3 0.003 1.320505 3.770617 
LCP2 0.395805 0.101685 -3.61 <0.001 0.239222 0.65488 
LGALS3 0.458636 0.124752 -2.87 0.004 0.269115 0.781627 
LST1 1.667267 0.415677 2.05 0.04 1.02279 2.71784 
PDCD1 0.048851 0.037932 -3.89 <0.001 0.010665 0.223773 
 
Table 5.3 Logistic regression of RAS mutant versus wild type tumours using a 
custom targeted TRUSEQ RNAseq panel.  Odds ratio>1 indicates higher 
expression in RAS mutant cases, and odds ratio<1 indicates lower expression in 




5.2.4 Survival analysis 
Clinical data, including age, gender, ethnicity, clinical stage and overall survival were 
retrieved for all the patients in the clinical cohort.  Cox regression analyses were 
performed to determine which factors associated with survival.  On multivariate 
analysis, patients with higher stage disease had significantly poorer survival, as 
expected (Figure 5.10A).  Furthermore, patients with NRAS mutant tumours had 
significantly poorer survival than KRAS or RAS wild type patients (Figure 5.10B).  In 
addition, there was a clear trend towards KRAS mutant patients having poorer 
survival than RAS WT, consistent with the literature [176].  After 5 years post-
resection, 80.7% of RAS wild type patients survived, compared to 56.5% of KRAS 
mutant patients.  This did not reach statistical significance, most likely because this 
study was insufficiently powered to detect smaller changes in overall survival.  In 
addition, when RAS mutation was categorised according to mutational subtype, there 
were no significant differences in survival between the RAS G12D/G13D mutant 
group, the non-RAS G12D/G13D mutant group and the RAS wild type groups.  
Furthermore, there were no significant differences between MSI-H and MSS patients 
in survival.  Protein expression of CD4, CD8, Tbet, STAT1, Class II HLA, PD-L1 or 
CXCL10, in epithelium or stroma, as determined by IHC above, were not predictive 






Figure 5.10 Kaplan-Meier curves for overall survival, by: 
d) Clinical Stage 




5.2.5 Cancer Cell Line Encyclopaedia analysis 
To investigate whether the effect of RAS mutation on immunity was due to a cell 
autonomous effect, independent of the tumour microenvironment, I calculated 
expression of key immune genes in multiple CRC cell lines from the Cancer Cell Line 
Encyclopaedia [93].   This analysis revealed that the MEK signature was significantly 
higher in RAS G12D/G13D mutant (n=11), RAS non-G12D/G13D mutant (n=20) and 
BRAF mutant (n=13) cell lines versus the RAS/RAF/PIK3CA wildtype (n=7) cell lines 
(p<0.001 for all). BRAF mutants, which are known to have the strongest MEK 
activation [175], had the highest MEK signature, as expected.  However, with only 7 
RAS/RAF/PIK3CA wildtype lines, this study was insufficiently powered to detect 
smaller effects.  There were no significant differences found in expression of potential 
mediators of a RAS-associated immunological effect such as STAT1 or IRF1, or 
class I and class II HLA (Table 5.4).  STAT1 expression was lowest in BRAF 
mutants, then non-G12D/G13D RAS mutants, then G12D/G13D RAS mutants, and 
was highest in wild type cell lines, as would be expected if its expression was 
suppressed by MEK signalling.  However, this was not statistically significant.  In 
addition, the expression of genes including CD4 and PDCD1 (PD1) were not 
significantly different in RAS mutant and wild type cell lines, but this was expected, 
as the cell line analysis excluded the tumour microenvironment, and therefore 
microenvironmental cells such as CD4 positive lymphocytes.  However, despite the 
lack of statistical power, this analysis did provide indications that MEK pathway 
activation may have an impact on STAT1 expression, though this requires further in 














MEK signature 0.347 0.420 0.400 0.026 
CCL5 -0.001 -0.102 -0.497 -0.531 
CD247 -0.363 -0.325 -0.380 -0.292 
CD274 -0.318 -0.208 0.107 0.129 
CD276 -0.049 -0.068 -0.056 0.450 
CD3E -0.317 -0.222 -0.102 -0.102 
CD4 -0.198 -0.279 -0.314 -0.139 
CD8A -0.166 0.017 -0.131 0.054 
CD8B -0.066 0.047 -0.060 -0.166 
CTLA4 -0.239 -0.150 -0.147 -0.201 
CXCL10 0.168 0.069 -0.337 -0.009 
CXCL9 -0.220 -0.210 -0.094 -0.329 
GZMB -0.104 0.814 0.807 0.206 
HAVCR2 -0.235 -0.283 -0.211 -0.223 
HLA-A 0.036 0.506 -0.199 0.333 
HLA-B 0.257 0.322 -0.288 -0.056 
HLA-C 0.353 0.447 -0.165 -0.053 
HLA-DMA -0.179 -0.246 -0.348 -0.446 
HLA-DMB -0.415 -0.362 -0.549 -0.546 
HLA-DOA -0.304 -0.354 -0.328 -0.328 
HLA-DPA1 -0.525 -0.575 -0.503 -0.587 
HLA-DQA1 -0.278 -0.297 -0.281 -0.345 
HLA-DRA -0.359 -0.473 -0.502 -0.599 
IFNG -0.254 -0.194 -0.182 -0.116 
IL12B -0.173 -0.142 -0.128 -0.127 
IL12RB2 -0.076 -0.262 -0.309 -0.187 
IL18RAP -0.220 -0.105 -0.276 -0.339 
IRF1 -0.152 0.039 -0.240 -0.125 
LAG3 -0.183 -0.176 -0.201 -0.217 
PDCD1 -0.186 0.368 0.193 0.020 
PDCD1LG2 -0.490 -0.494 -0.267 0.662 
STAT1 0.038 -0.105 -0.382 0.373 
STAT3 -0.138 -0.272 -1.007 0.209 
TBX21 -0.201 -0.304 -0.242 -0.289 
 
Table 5.4 Cell line encyclopaedia analysis.  Mean expression of key immune 




5.2.6 Consensus Molecular Subtypes analysis 
In view of the lack of significant differences in expression of key proteins including 
CD4 and CD8 between RAS mutant and wild type cancers in my IHC analysis, and 
the discrepancy with my previous TCGA transcriptomic analysis, I investigated 
possible reasons for the difference.  One hypothesis was that the significance of RAS 
mutation could be related to biological context, and in particular, the transcriptional 
subgroup of CRC in which the mutation occurs.  RAS mutation occurs in all of the 
Consensus Molecular Subtype groupings to varying degrees, even though each of 
them differ biologically [136].  Therefore the immunosuppressive effect of RAS 
mutation could be restricted to particular CMS groups.  When I investigated the 
impact of RAS mutation within specific CMS groupings in the original 195 patient 
TCGA microarray dataset [91], there was a trend towards CMS2 RAS mutants having 
lower CIRC expression than CMS2 RAS wild types (Figure 5.11).  To explore this 









Figure 5.11 CIRC expression z-scores in each CMS grouping by RAS mutation 
status (original 195 patient TCGA microarray dataset). 
The boxes represent the 25th and 75th percentile values.  The lines within the boxes 
represent median values.  The lines emerging from the boxes represent the 




The TCGA dataset was first reinvestigated.  190 of the 195 original TCGA 
microarray-based samples have subsequently been analysed by RNAseq and were 
included in an expanded TCGA dataset totalling 291 samples.  We initially wanted to 
confirm whether RAS mutation was associated with lower CIRC expression in this 
expanded dataset.  Table 5.5 shows that the expression of the CIRC was indeed 
significantly lower in RAS mutant samples than in wild types (p=0.0117).  In a 
separate validation set, using transcriptional data from the Koo Foundation Sun-Yat-
Sen Cancer Center dataset ((KFSYSCC), n=289) [177], again there was a 
significantly lower expression of the CIRC in RAS mutant cancers (p=0.00376).  This 
therefore confirmed that RAS mutation is associated with reduced expression of the 
CIRC metagene in CRC.  In both datasets, as expected, expression of the Dry et al. 
CRC MEK activation signature was significantly higher in RAS mutants than 
wildtypes. 
 
The original CMS study demonstrated that the CMS groups clearly have different 
levels of the transcription of a range of immune-related genes [136]. The RAS-
directed IHC analysis had not taken CMS sub-type into account and left open the 
question as to whether the observed transcriptional differences between RAS mutant 
and RAS wild type cancers might be particular to certain molecular sub-types.  This 
could explain why differences were not seen in my local cohort.  Thus CIRC 
expression of RAS mutant cancers was compared with RAS wild type cancers in 
each individual CMS in both the extended RNAseq TCGA and the KFSYSCC 






CMS1 CMS2 CMS3 CMS4 
Extended 
TCGA dataset      
CIRC 0.0117 0.816 0.000193 0.268 0.855 
MEK 2.20E-13 0.0758 4.03E-09 0.163 0.000235 
T cells 0.434 0.792 0.0156 0.563 0.570 
Cytotoxic cells 0.162 0.566 0.00227 0.198 0.758 
iDC 0.0993 0.699 0.0133 0.930 0.570 
KFSYSCC 
dataset      
CIRC 0.00376 0.494 0.0256 0.696 0.0774 
MEK 1.76E-17 0.614 2.59E-08 3.06E-05 1.24E-06 
T cells 0.576 0.614 0.582 0.207 0.522 
Cytotoxic cells 0.0202 0.243 0.206 0.171 0.241 
iDC 0.460 0.157 0.907 0.665 0.141 
 
Table 5.5 CIRC, MEK, T cell, cytotoxic cell and iDC signatures by CMS 
grouping.  p-values of differences in expression of signatures in all patients and by 
CMS groups between RAS mutant and RAS wild type colorectal cancers.  
 
Cell colour relates to whether mean expression was higher in RAS mutant or wild 
type cases.  Pink cells = higher in RAS wild type samples, but not significant.  Red 
cells = significantly higher (p value <0.05) in RAS wild type samples.  Light blue cells 
= higher in RAS mutant samples, but not significant.  Dark blue cells = significantly 
higher (p value <0.05) in RAS mutant samples. 
  
 
In the TCGA dataset there was no difference in the expression of the CIRC between 
RAS mutant and RAS wild type cancers in CMS1, CMS3 and CMS4.  CMS2 is the 
most immune suppressed MSS subtype [136]: expression of the CIRC was 
significantly lower in RAS mutant CMS2 tumours compared with wild type tumours 
(p=0.000193).  This finding was confirmed in the KFSYSCC dataset where 
expression of the CIRC was lower in RAS MT tumours in CMS2 (p=0.0256), but 




A range of different immune transcriptional signatures, characterised by Bindea et al. 
[100], were also utilised in this analysis.  In the TCGA dataset only, T cell, cytotoxic 
cell and immature dendritic cell (iDC) signatures, like the CIRC, were significantly 
lower in CMS2 RAS mutant cancers compared with CMS2 RAS wild type cancers 
(Table 5.5).  This suggests that at the microenvironmental level the possible Th1 
suppressive effect of RAS mutation may manifest itself in cancers that are already 
relatively immune impoverished whereas this effect may be functionally insignificant 
in CRCs that are more immunologically activated such as CMS4 and especially 
CMS1.  It also suggests that the relationship between RAS mutation and immunity in 
CMS2 patients may go beyond the Th1 phenotype. 
 
To determine the relative impacts of RAS mutation and CMS groupings on immunity, 
the most immunosuppressed MSS CMS subtype (CMS2) and the least suppressed 
MSS subtype (CMS4) were compared.  CIRC expression was significantly lower in 
CMS2 RAS mutants compared to CMS4 RAS mutants in the TCGA (p=2.76x10-8) 
and KFSYSCC (p=0.00042) datasets.  CIRC expression was also significantly lower 
in CMS2 RAS wild type cancers compared with CMS4 RAS wild type cancers in both 
datasets (p=9.90x10-7 (TCGA) and 4.30x10-6 (KFSYSCC)).  Importantly, in the TCGA 
dataset, CIRC expression was significantly lower in CMS2 RAS wild type cancers 
compared with CMS4 RAS mutant cancers (p=0.000588) in spite of the fact that, as 
expected, the Dry et al. 5-gene MEK signature was significantly higher in the CMS4 
RAS mutants (p=1.90x10-5).  Finally, in the TCGA dataset, expression of the CIRC 
was significantly lower in CMS2 RAS mutants (p=0.00832) compared to RAS mutant 
CMS3 tumours, highlighting that CMS2 is the most immunosuppressed group.  Thus, 
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the CMS status of the patient appears to govern the immunological impact of RAS 







The work in this chapter focussed on the impact of RAS mutation on immunity.  RAS 
mutant patients form a critical group of unmet need in CRC as well as in a range of 
other cancer types.  Therefore it was important to confirm whether the RAS-
associated immunosuppressive effect observed in the previous chapter could be 
replicated in an independent dataset and at a protein level.  The TCGA, though large 
and comprehensive, with 195 patients in the published CRC dataset [91], is 
nevertheless only a single dataset and it was possible that the RAS correlation with 
immunity was a cohort-specific finding. 
 
A range of experimental approaches were used to attempt to validate this finding.  
Firstly, digital IHC approaches were used to investigate the effects of RAS mutation 
at a protein level in a local, independent sample set, using digital pathology software.  
In parallel, exploratory RNAseq was performed from RNA extracted from FFPE 
tissue.  Next, to supplement the in silico analyses previously performed, and to 
investigate the cell autonomous effect of RAS mutation, the cell line encyclopaedia 
was interrogated.  Finally, in view of the findings from the above experiments, 
additional in silico analyses were performed on the expanded RNAseq TCGA dataset 
and the KFSYSCC dataset to investigate the impact of CMS groupings and RAS 
mutation status together on immunity.  This variety of approaches proved invaluable 
in investigating the hypothesis (that RAS mutation is associated with 
immunosuppression) and took advantage of the strengths of different techniques.  
The advantage of publically available datasets are in accessibility, the speed of 
analysis, and the data-rich nature of the sample set, with a quantity of data that could 
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not be easily replicated locally.  However, the functional and clinical importance of 
changes in DNA and RNA depend on the effect on protein expression and structure, 
as well as changes to the tumour microenvironment.  IHC, a clinically aligned 
approach, is best placed to investigate protein expression and the microenvironment. 
 
The IHC studies analysed the impact of RAS mutation on the protein expression of 
key molecules represented in the CIRC using digital pathology.  Digital pathology is 
emerging as a key technique in the research setting, and attempts are being made to 
validate and standardise the approach for clinical usage [38].  The advantage that 
digital pathology provided for this study was that, with pathologist input and 
validation, I was able to create computer-based learning algorithms that could 
objectively analyse whole CRC sections, producing data on a per region and cell 
basis.  This approach eliminates the subjective variation that occurs in the scoring of 
different specimens.  However, it cannot completely eliminate user-dependent 
variation, as the segmentation and setting of scoring thresholds is partly subjective.  
However, this was minimised by close pathologist collaboration.  In addition, any 
small scoring errors would have been spread equally between the two groups (RAS 
mutant and wildtype), and therefore the effect on the inter-group analysis would have 
been minimal.  
 
In addition to careful creation of the scoring algorithms, particular efforts were made 
to ensure that the antibodies used were validated.  Antibodies that do not target the 
correct antigen or that are non-specific are a particular problem in laboratory and 
clinical studies, leading to a lack of reproducibility of published findings [178].  
Therefore, clinically validated antibodies (conforming to In Vitro Diagnostics 
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Conformité Européenne (IVD-CE) standards) were chosen where possible (CD4, 
CD8).  These antibodies go through robust validation before they are approved for 
clinical use [178].  If these were not available, antibodies that were carefully validated 
by the vendor, using techniques including gene knockout/knockdown and peptide-
blocking, were chosen (Tbet, STAT1, PD-L1).  Where these were not available, in-
house in vitro validation was performed (CXCL10, Class II HLA).  This, alongside 
careful optimisation, ensured robust and reliable staining.  In addition, the use of an 
autostainer and digital analysis reduced the likelihood of inter-batch variability. 
 
The IHC analysis revealed that there were no differences in the expression of class II 
or PD-L1 between RAS mutant and RAS wild type cancers in spite of significantly 
reduced protein expression of STAT1.  CIITA is the master transcriptional activator of 
the class II molecules and along with PD-L1 is a STAT1 target gene.  Half of all CRC 
tumours analysed were class II negative in the epithelial component in agreement 
with previous data [179] and I found that this negative fraction was very similar in 
RAS mutant and RAS wild type cancers.  Membranous PD-L1 expression was very 
low again in agreement with recent data [180], using the same antibody as used 
herein which critically only stains membranous (and hence biologically relevant) PD-
L1 [181]. This suggests that CRC at the protein level is generally significantly 
immunosuppressed independently of RAS mutation status.  As I was not aware of 
the possible importance of CMS status on the effect of RAS mutation at this stage, I 
did not perform IHC specifically in CMS2 samples.  This would have required full 
transcriptomics to accurately classify the CMS grouping of each case, but could have 
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enabled investigation of the CMS-RAS interaction at a protein level.  This will be 
crucial future work. 
 
The targeted RNAseq for transcriptomics from FFPE tissue was a novel approach, 
and was used as it enabled transcriptomic analysis using degraded RNA from 
archived FFPE tissue.  This work was performed to both investigate this method for 
transcriptomic analysis, to determine whether it is a robust and feasible approach 
warranting further evaluation, and to ascertain whether the transcriptomic results 
observed in the TCGA could be replicated locally, albeit with a different experimental 
approach (in the TCGA analysis, microarray and RNAseq were performed from fresh-
frozen tissue derived RNA).  This approach makes the presumption that degraded 
RNA in FFPE samples is comparable between cases, despite possible differences in 
the lengths of time samples have been stored prior to RNA extraction.  Ideally, a 
more established method would have been used, such as full transcriptomics (total 
RNAseq) from fresh resection tissue.  However, this approach would take a 
considerable amount of time to accrue the necessary number of samples.  In view of 
the additional transcriptomics analysis subsequently performed on the extended 
TCGA and KFSYSCC datasets, this analysis may not have been necessary, as the 
transcriptomic finding from the previous chapter was validated on the second 
dataset.  The key local analysis was on the protein IHC level.  The findings of the 
targeted panel were not consistent with the TCGA dataset, as univariate analysis 
failed to show expression differences between key immune genes in RAS mutant 
versus wildtype cases.  However, multivariate logistic regression analysis did reveal 
changes in key genes such as CD4.  However, though useful to discern biological 
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interactions, the multivariate analysis in this case does not represent the clinical 
scenario where absolute differences in gene expression between groups will likely be 
more meaningful.  Regardless of this, the finding that the Dry et al. MEK signature 
did not differ significantly between RAS mutant and RAS wildtype cases (though 
there was a trend in the expected direction) suggests that the data and technique 
require further evaluation, as this signature has proven robust and has been 
validated in multiple datasets [175], and by us in the TCGA and KFSYSCC datasets.  
This lack of significance may have been due to a small number of outliers in the 
analysis, or a small amount of contamination during tissue processing, rather than an 
inherent problem with the technique.  However, for validation of the FFPE targeted 
RNAseq approach, firstly a comparative RNAseq analysis of fresh-frozen and FFPE 
tissue should be performed, to determine whether FFPE analysis aligns with the 
results obtained from fresh-frozen tissue.  This could be performed using fresh tissue 
obtained at resection, and then with corresponding FFPE tissue blocks at various 
time points, to determine whether there is a time limit after which the RNA is too 
highly degraded for analysis.  Additionally, established positive and negative controls 
are needed for the analysis, which may include tissue from tumours with known high 
and low immune infiltrate in this case.  Finally, to ensure that the quantification is 
accurate, parallel quantitative real-time PCR (qPCR) analysis could be performed for 
selected targets from the same cDNA. 
 
Despite the lack of significance in the RNAseq analyses, my previous TCGA 
transcriptomic analyses did reveal a significant association between RAS mutation 
and reduced STAT1 expression, which I have now also observed at the protein level.  
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There are several potential mechanisms through which RAS mutation could 
potentially suppress immunity, including direct tumour cell mediated effects and 
indirect effects.  In terms of direct effects, a reduction in STAT1 expression in RAS 
mutant tumours may lead to a reduction in IFNγ signalling.  CRC cell lines bearing 
activating mutant KRAS have been found to downregulate levels of numerous IFNγ 
responsive genes, and studies in isogenic HCT116 cell lines have shown that 
abrogation of KRAS signalling pathways elevate basal and IFNγ stimulated 
expression of IFN-responsive genes, including class II MHC [182].  In addition, such 
approaches have suggested that mutant RAS signalling decreases basal and IFNγ 
induced expression of STAT1, the critical Th1-associated transcription factor [182], 
and negatively influences IFNγ induced activation of IRF1 [182, 183], which plays a 
central role in activating STAT1 expression [184].  Both IRF1 and STAT1 are 
components of the CIRC.  CIITA, which is activated by STAT1, is the master 
transcriptional activator of class II expression, and also effects class I expression 
[185, 186].  Therefore RAS mutation may have an immunosuppressive effect by 
reducing IRF1 activation and STAT1 expression, which then suppresses IFNγ 
signalling, thereby reducing CIITA activation and therefore HLA Class I and II 
expression. 
 
A potential indirect mechanism of RAS-associated immunosuppression is a reduction 
in the cytokine IL-12.  IL-12, produced by dendritic cells, is a key cytokine 
determining Th1 development and IFNγ production by T cells [187, 188].  I have 
shown in the previous chapter that IL-12 expression is significantly reduced in both 
NRAS (p=0.016) and KRAS mutant CRC (p=0.011) compared with RAS wild type.  In 
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the TCGA dataset, there was a negative correlation between IL-12 expression and 
expression of the Dry et al. MEK signature [175], and a positive correlation between 
IL-12 expression and expression of the CIRC.  The mechanism by which tumour cell 
RAS mutation would decrease IL-12 expression is currently unclear, but a reduction 
in class II expression and therefore DC activation could be contributory factor.    
 
IL-12 production by DCs could also be suppressed by immunosuppressive cytokines 
produced by RAS mutant tumour cells.  In vitro expression of RAS G12V in HEK cells 
has been found to result in tumourigenicity that is dependent on production of the 
immunosuppressive cytokine IL-6 that acts in a paracrine fashion [189].  In addition, 
melanoma cells bearing mutations in BRAF, immediately downstream of RAS, have 
been shown to produce IL-6 [190], which could decrease maturation of, and IL-12 
production by, monocytic dendritic cells [190, 191].  MEK inhibition not only 
decreases immunosuppressive cytokine production by BRAF mutant melanoma cells 
[190], but also affects DCs, abrogating the effects of immunosuppressive cytokines 
on IL-12 induction, and promoting Th1 induction [191].  Therefore there are multiple 
potential mechanisms for RAS-induced immunosuppression, which warrant further 
investigation in in vitro studies.  
 
The limitations of cancer cell line data from the CCLE were in fact useful for this 
study as the effects of the microenvironment were excluded, which allowed me to 
assess if RAS-mediated autonomous effects were evident.  However, though the 
MEK signature was associated with RAS mutation as expected, there were no 
significant differences in the expression of key genes such as STAT1 (though there 
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was a trend towards lower STAT1 expression in RAS mutant lines), perhaps 
reflecting the small number of wild type cell lines in this analysis.  Ideally, to 
determine the effect of RAS mutation in cell lines, local in vitro studies would be 
performed using an isogenic cell line system, with specific RAS mutations generated 
with for example CRISPR-Cas9 gene editing, to determine the effect on possible 
expression of key genes such as STAT1 or CIITA.  This would be important future 
work for determining whether there is a causal relationship between RAS mutation 
and immune response in CRC. 
 
After finding that RAS mutation did not appear to be associated with low immunity at 
the protein level in the local sample set, I considered possible reasons for the 
discrepancy with the TCGA data, which included the established variability in the 
correlation between RNA and protein expression in CRC [171, 172].  However, 
another possibility was that the relationship between RAS and low immunity was 
restricted to particular subgroups of CRC that only comprised a subset of my cohort.  
The CMS classification (a consensus classification based on six independent 
classification systems), introduced in the previous chapter, classifies tumours by their 
transcriptional profile, and therefore separates them by key biological subtypes rather 
than by single driver mutations such as RAS.  As the CMS classification is based 
upon transcriptomics, rather than genomics, it is more closely linked with tumour 
phenotype and clinical behaviour, and each CMS group includes tumours with a 
variety of different mutations that lead to the same phenotype [136].  As key 
mutations such as KRAS are distributed across all four CMS groups, this suggests 
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that CMS is a more accurate classifier of key biological groupings than a system that 
uses mutation status alone.  
  
My previous finding that RAS mutation was associated with reduced transcription of 
the CIRC metagene was confirmed in two large bioinformatics datasets.  However, in 
addition, it was found that the net impact of RAS mutation was dependent upon the 
CMS in which the mutation was found. CMS2 is the most immunosuppressed 
subtype and in this subtype alone the addition of RAS mutation appeared to deepen 
that immunosuppression at least at the level of immune-related gene transcription.  
As previously discussed, RAS mutation is associated with a reduction in STAT1 
expression [182], which I have observed at RNA (in the TCGA) and protein level.  
There are potential reasons why a reduction of STAT1 expression in RAS mutant 
CRC would only cause a concomitant reduction in the transcription of its target genes 
in CMS2.  The previously discussed in vitro data demonstrated that RAS mutation 
dampens the STAT1 response to IFNγ and the level of STAT1-driven transcription in 
CRC cells but does not abolish it [182].  My work has demonstrated that 
membranous PD-L1 expression is very low across MSS CRC suggesting that MSS 
CRC in general lacks sufficient immune reactivity to elicit adaptive PD-L1 up-
regulation.  It is possible that in immune impoverished environments (such as CMS2) 
RAS mutation’s effect on STAT1 may be a limiting factor on immunity, whereas in 
more enriched environments (such as CMS4), RAS mutation is not a limiting factor.  
The analysis showed that the level of STAT1 expression is significantly lower in 
CMS2 wild type tumours compared with CMS4 wild type tumours in the TCGA.  The 
addition of a possible RAS mutation-mediated STAT1 decrease in CMS2 cancers is 
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likely to have a greater impact on the downstream transcriptional network than that 
same change in tumours where STAT1 levels are less close to the lower limits of the 
functional range.  Furthermore, in somewhat less immune impoverished tumours 
such as those in CMS4, there may be at least sufficient microenvironmental IFNγ 
production to partially abrogate the decrease in STAT1 expression and hence 
STAT1-driven transcription due to RAS mutation.    
 
Thus, prediction of the effect of RAS mutation on immune-related 
microenvironmental gene transcription may be impossible without knowledge of the 
CMS group in which that mutation is found.  Therefore IHC is of limited relevance 
unless the CMS group can be assigned, which is not currently feasible in the clinical 
setting, as it requires full transcriptomic analysis.  Manipulation of the specific 
pathways activated by RAS mutation in order to up-regulate immune gene 
transcription may mainly be of therapeutic relevance in CMS2.  However, this alone 
is unlikely to significantly immune activate these cancers.  CMS2 RAS wild type 
tumours have lower expression of the CIRC than CMS4 RAS mutant tumours. 
Hence, attention to the underlying biological effect limiting the immune infiltration in 
each particular CMS group is required.  
 
In view of the potential CMS2-specific effect of RAS mutation, it would be interesting 
to consider the biology of CMS2.  This CMS group, termed the ‘canonical’ CRC 
subgroup as it is characterised by high activation of the classical CRC-initiating Wnt 
and MYC pathways, includes 37% of all CRC patients.  It includes a substantial 
proportion of the microsatellite stable group of patients, who I have previously shown 
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have almost universally low mutation rates, and is associated with a high number of 
somatic copy number alterations (SCNAs) due to chromosomal instability (CIN) [136].  
There is evidence that Wnt signalling is immunosuppressive.  Activation of WNT/β-
catenin signalling in melanoma significantly reduces T cell infiltration into the tumour 
microenvironment as a result of decreased ingress of BATF3-lineage DCs [192]. 
These findings of the immunosuppressive effect of WNT/β-catenin signalling have 
been generalized across other cancer types including CRC [193].   The apparent 
restriction of RAS-associated immunosuppression to CMS2 suggests that the 
interaction of Wnt signalling and RAS mutation warrants further investigation to 
determine whether there is a synergistic effect.  If so, dual inhibition of these 
pathways could be a route to improving immunity in this CMS grouping. 
 
If RAS mutation is causatively linked with immunosuppression, inhibition of 
downstream signalling may be a route towards increasing intra-tumoural immunity.  
Recent clinical data have shown that combining the MEK inhibitor cobimetinib with 
the anti-PD-L1 antibody atezolizumab results in a durable 17% response rate in 
KRAS mutant MSS CRC patients [194].  This approach was based on the pre-clinical 
observation of synergy between MEK inhibition and PD-L1 blockade, driven by a 
reduction in antigen-driven T cell exhaustion mediated by activated MEK signalling in 
microenvironmental T cells and by class I up-regulation [195].  Interestingly therefore, 
in this case, the MEK activation within T cells, not tumour cells, was crucial.  A 
worthwhile therapeutic avenue to explore may be a combinatory approach utilising 
the previously discussed neoantigen-directed or tumour antigen-directed  vaccination 
or adoptive cell therapies to increase anti-tumour T cell responses, followed by MEK 
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inhibition to reduce antigen-driven T cell exhaustion and checkpoint blockade to 





















This thesis has explored the role of EPCR, a γδ T cell receptor ligand, in colorectal 
tumourigenesis and the genetic factors that impact on the immune microenvironment. 
The EPCR study investigated the mechanism of its upregulation in tumourigenesis 
and whether this has functional significance in CRC.  I found that EPCR is 
consistently upregulated in CRC and can mediate intra-cellular signalling via ERK 
phosphorylation.  However, the results of my in vitro assays did not suggest that 
EPCR has any positive impact on CRC cell survival.  In fact, perturbation of EPCR 
reduced chemosensitivity and increased cell migration in HCT116 cells. In addition, 
EPCR expression was not predictive for patient survival, chemotherapy response or 
cetuximab response.  These results, together with my bioinformatics analyses, 
suggest that EPCR may be upregulated as a bystander gene as a component of 
chromosome 20q amplification, rather than due to it conferring a selective advantage 
per se.  Previous studies have confirmed EPCR expression in breast cancer, ovarian 
cancer and lung cancer, but these studies have not related EPCR expression to 
wider abnormalities such as chromosomal amplification or hypomethylation [78, 80, 
86].  Significantly, all of these tumour types are associated with 20q amplification to 
varying degrees.  A limitation of previous studies, and of approaches highlighting 
both beneficial and detrimental effects of EPCR perturbation in animal models [78, 
79, 83, 114] is that they primarily address EPCR-intrinsic effects on cancer 
development, and typically focus on one or a small number of cell lines. This study 
has utilised a broader approach, and investigated the wider context of EPCR 
dysregulation, highlighting that the effects of EPCR upregulation on cancer cells may 
be heavily dependent on biological context, including the exact cancer cell line (even 
within a single cancer type) and potentially upregulation of functionally important 
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neighbouring genes co-amplified on chromosome 20q.  Therefore studies that focus 
on cell lines or animal models may not accurately recapitulate the clinical scenario.  
EPCR expression may be clinically useful as a marker of 20q amplification and as a 
marker of thrombotic risk in a range of tumours, potentially in serum or urine as 
sEPCR.  This has not been determined in this study and would be important future 
work.   In CRC, amplification of chromosome 20q occurs mostly in the progression of 
adenomas into carcinomas, and increases further in metastatic disease [117, 125].  
EPCR could be a useful biomarker of 20q amplification, and therefore of progression. 
 
EPCR upregulation in CRC may provide an example of how γδ T cells can recognise 
cellular stress in different settings.  This aspect of EPCR, and whether it is directly 
recognised by γδ T cells within colorectal cancer is an area which is being explored 
by our group and others.  γδ T cells may respond to stress ligands, and as these 
cells are not MHC restricted, they do not require Class I expression on tumour cells 
and are traditionally thought to have an innate-like function similar to NK cells, with 
pre-expanded γδ T cells able to respond rapidly to stress stimuli in an innate-like 
fashion [52].  However, work within our group has shown that the γδ repertoire 
appears to be private to each individual, and therefore the LES clone, which 
recognises EPCR, appears unlikely to be present in many patients.  The discovery of 
private repertoires and selective expansions of individual T cell receptors (TCRs) 
suggest that γδ T cells may also play an adaptive role.  Despite this, a group from 
Freiburg (Germany) have claimed to have identified the LES clone in breast cancer 
tissue from multiple patients [196].  If true, this suggests that the γδ TCR repertoire is 
larger, or not as private, as it appears and that cells capable of recognising EPCR, 
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which is upregulated during tumourigenesis, may be enriched in the tumour 
microenvironment.  Importantly, highly sensitive in-situ hybridisation (ISH) 
approaches have now been developed to explore this issue further.  Nevertheless, 
EPCR may fit a general theme of dysregulation of stress ligands.  While LES was 
expanded in CMV infection [53], the dysregulation of EPCR in cancer suggests the 
possibility that known γδ T cell ligands may signal stress in different scenarios, and 
via different mechanisms.  As my work was focussed mainly on the mechanism and 
biological significance of EPCR expression, the significance of EPCR expression with 
regards to γδ T cell recognition in CRC still needs exploration. 
 
In addition to investigating EPCR, I also studied the impact of tumour genetics on the 
immune microenvironment of CRC.  My bioinformatics studies revealed important 
links between genetics and immunity, allowing the stratification of CRC patients into 
groups based on immunogenomics.  This has implications for patient care, and has 
led to several predictions which have subsequently been confirmed.  Firstly, this work 
suggested that MSI-H patients, who have high mutation rates and immune infiltration, 
would likely respond to checkpoint blockade therapy.  This has since been confirmed 
in a clinical study [154].   
 
Secondly, I hypothesised that combination checkpoint blockade would be beneficial, 
due to the co-ordinate upregulation of several of these molecules as part of the 
CIRC.  Combination therapy has now been shown to be effective in melanoma, 
where a combination of CTLA4 and PD-1 inhibition had an additive beneficial effect 
beyond the effect of each individual drug [197].  Currently, it is unclear whether this 
235 
 
benefit is directly related to the co-upregulation of these checkpoint molecules.  
However, such a combination approach warrants investigation in MSI-H CRC 
patients, as well as potentially MSS patients with strong immune infiltration, who, like 
MSI-H patients, have co-upregulation of immune checkpoints.  Such combination 
therapy is associated with higher toxicity.  However, the toxicity levels, whilst 
occasionally severe and life threatening, compare favourably to existing 
chemotherapeutics regimens [15].                      
 
Third, I showed that POL mutant cancers are associated with increased immune 
infiltration.  This has recently been confirmed in a retrospective clinical study, which 
demonstrated that POLE mutant CRCs display increased CD8+ lymphocyte 
infiltration and expression of cytotoxic T cell markers and effector cytokines, similar to 
the immune infiltration seen in MSI-H cancers [155].   
 
Finally, another key prediction was that MEK inhibition and checkpoint blockade 
could be synergistic, and this has been partially confirmed in a phase I clinical study 
that revealed that combining the MEK inhibitor cobimetinib with the anti-PD-L1 
antibody atezolizumab resulted in a durable 17% response rate in KRAS mutant 
MSS CRC patients [194].  Clearly, this requires further assessment in phase II and III 
studies.  Interestingly, rather than a tumour cell effect, this response appears to be 
due to inhibition of MEK signalling within microenvironmental T cells.  TCR signalling 




A further key prediction would be that the subset of MSS patients who have a similar 
immune profile to MSI-H patients (the ‘MSS CIRC-high’ group) could also respond to 
checkpoint blockade therapy.  This would be a crucial clinical study, as MSS patients 
make up over 80% of sporadic CRC cases, and therefore responses in even a small 
subset of the MSS group could benefit a large number of patients.  In such a trial, 
MSS patients could be treated with checkpoint blockade therapy based on protein 
expression of key immune markers, such as PD-L1 (the current biomarker for anti-
PD-1 mAb therapy), CD4, CD8 or class II HLA.  This study would be important even if 
the mechanism underlying the variability in immunity in MSS is not yet understood, as 
responses are likely to depend on the immune phenotype itself, rather than the 
factors determining the immune phenotype. 
 
To investigate one of the factors determining immune phenotype, the relationship 
between overall tumour mutation rate/number and immunity was explored.  This 
demonstrated that immune infiltration was linked to overall mutation rate and number, 
but this relationship was weak when intra-group analysis was performed within either 
MSS or MSI-H patients.  This seemed to suggest that the quality and type of 
mutation may have been the key determinant of immunity, perhaps in relation to 
certain host genes, e.g. HLA.  However, investigation of neoantigen binding using 
binding prediction algorithms did not show any clear association between the 
strongest binding neoantigen and CIRC expression, though, as only the strongest 
single neoantigens was considered, this analysis was superficial.  However, it 
suggests that neoantigen number and strongest binding neoantigen, whilst clearly 
being highly significant and likely being responsible for the high immune infiltration in 
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MSI-H tumours, cannot reliably predict the strength of intra-tumoural immunity in 
MSS POLE+POLD1 wild type patients, who all have relatively low mutation rates 
(<15/Mbp).  Whilst in MSI-H patients the high neoantigen load may override other 
factors, in MSS patients other tumour, host and environmental factors may be the 
key determinants of immune response.  As such, there are many possible 
contributors which are currently poorly understood, including tumour-extrinsic factors 
such as bowel flora and host genetics, both of which warrant further investigation.   
Bowel flora have previously been linked to colorectal tumourigenesis [159], with 
particular microbiota such as Fusobacterium enriched in CRC patients [160].  In 
addition, lipopolysaccharide (LPS), a gram-negative bacterial antigen present in 
primary CRC due to breakdown of epithelial integrity, has been implicated in cell 
migration, metastases and immune response in CRC [200-203].  If bowel flora have 
an immunosuppressive effect in CRC, this could contribute to the low immune 
infiltration seen in many patients, and modifying the microbiome could conceivably be 
a route to improving immunity.  Host genetics, and in particular expression 
quantitative trail loci (eQTLs), which are genomic loci which contribute to the 
expression of nearby (cis eQTLs) or distant (trans eQTLs) genes [158], have been 
linked with immune response in the infectious and inflammatory disease settings 
[204-206].  It is possible that eQTLs could also affect immunity in the tumour setting.  
It is now established in melanoma that tumour regression after PD-1 blockade 
depends on pre-existing CD8 T cells and PD-1/PD-L1 expression in the invasive 
margin and inside the tumour [207]. Understanding the determinants of immunity in 
MSS patients could lead to the development of new therapeutic approaches that 
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could ‘adjuvantise’ the microenvironment, and then enable the effective use of 
checkpoint blockade in MSS CRC patients.   
 
The frequency and predicted immunogenicity, based on HLA-binding prediction 
algorithms, of RAS-associated neoantigens were also investigated.  The prediction of 
recurrent and commonly presented strong-binding neoantigens derived from mutant 
RAS raises the possibility of utilising these antigens in vaccination or other 
immunotherapeutic approaches, such as cell-based therapies.  In comparison to 
personalised vaccination, a stratified vaccination approach would have the 
advantage of being usable at diagnosis, as determination of RAS mutation status is 
now routine in clinical practice, after biopsy or resection.  The patient’s HLA-type 
would likely need to be determined, as certain HLA/neoepitope combinations were 
recurrent.  However, full genetic sequencing would not be necessary.  In the longer 
term, it is feasible to envisage an approach where off-the-shelf stratified vaccines are 
given to patients very soon after biopsy or surgery, potentially bridging the time gap 
before personalised vaccines can be developed and complementing more costly 
personalised approaches.  Currently, personalised vaccination requires a significant 
amount of time to be produced following tumour resection [16].  Furthermore, the 
vaccines could be applicable to multiple patients, and could therefore result in 
production scale cost savings.  As RAS is a key cancer driver mutation, it could 
potentially be less susceptible to immune escape, which is desirable for a potential 
target antigen [29].  The RAS-associated neoantigen could be combined with highly 
expressed tumour antigens to increase efficacy.  MSS KRAS mutant patients tend to 
have low mutation rates, and therefore have a limited number of targetable 
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neoantigens (a median of 26 class I presented neoepitopes were predicted per 
patient).  KRAS mutant as a group makes up 40% of all CRC patients, who do not 
respond to current targeted therapies such as EGFR monoclonal antibodies [10].  
Therefore novel therapeutic options are needed.   
 
The success of such a vaccine programme would have significant implications.  It 
could improve survival in a patient group with very poor survival outcomes.  Crucially, 
the approach focusses the vaccine development on tumour groups with low 
mutational burden, where immunotherapies such as up-front checkpoint blockade are 
unlikely to work as single therapies.  If successful in generating potent anti-tumour 
responses, it could increase the effectiveness of such checkpoint blockade 
approaches, through the ‘adjuvantisation’ of the microenvironment.  Such stratified 
vaccine approaches could be applied to a wide range of tumour types other than 
CRC, as driver mutations such as KRAS are highly commonplace throughout all 
tumours.  Stratified vaccination warrants further study in preclinical and clinical 
models. 
 
One of the key findings from my in silico studies was that RAS mutation was 
correlated with reduced immune infiltration.  In the TCGA dataset, this correlation 
was most marked in those RAS mutants with highest MEK signatures – the non-
G12D/G13D subtypes.  However, my local IHC analysis did not show any association 
between RAS mutation and CD4, CD8, Class II HLA, CXCL10, PD-L1 and Tbet 
density, although STAT1 was significantly reduced in RAS mutants, suggesting that 
RAS signalling may reduce STAT1 expression, which mediates IFNγ receptor 
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signalling.  However, this did not appear to produce significant reductions in immune 
infiltration in this sample set. 
 
As I did not see a clear association between RAS mutation and immune protein 
expression, the TCGA data was revisited and in collaboration with Justin Guinney, I 
found that the association of RAS mutation with immunity depended on CMS 
groupings.    RAS mutation did not have a significant association with immunity within 
all CMS groupings – only within CMS2.  This group is associated with left sided 
colonic tumours that have high WNT/Myc pathway activation.  CMS2 is relatively 
immunosuppressed, and it is possible that in an immunosuppressed group, RAS 
mutation has a further suppressive effect.  However, the fact that CMS2 RAS wild 
types have lower immunity than CMS4 RAS mutants suggests that the CMS 
groupings, which are based on overall transcriptional profiles, are more significant in 
terms of immune impact than individual driver mutations such as RAS.  Though 
understanding the key mechanisms and mutations driving tumours may be of benefit 
if they can be affected (such as with targeted therapies), targeting of 
immunotherapies based on transcriptional profiles such as CMS or immune 
phenotype may be more appropriate than mutational subtype alone, as discussed 
above.  It is possible that different factors limit immunity within the three MSS CMS 
groups (2, 3 and 4), and specific therapies may need to be developed for each 
subgroup to improve immune infiltration.  For example, dual MEK and Wnt pathway 
inhibition may be warrant further exploration in CMS2 RAS mutant patients, both to 





This study has shown the value of recently developed bioinformatic approaches, 
which can utilise large publically available databases that include clinical, mutation 
and transcriptomic data.  These large databases could not be produced locally 
without great time, effort and cost, and enable a ‘reverse translation’ approach, 
whereby clinical and scientific hypotheses can be investigated with patients as the 
starting point.  Important findings can then be explored and validated in the 
laboratory and a local patient set, and then, finally, could impact on patient 
management.    
 
Overall, this work has increased the understanding of the factors that determine 
immunity in CRC, and it is a step towards implementing successful immunotherapy in 
CRC, which though showing great promise in a range of cancer types, has only been 
successful in MSI-H CRC thus far.  CRC is a useful model for the tumour 
immunology field in general, due to the established relationship between immune 
infiltration and patient outcome, the variety of well characterised molecular subtypes 
with both high and low mutational burdens, and the identification of different patient 
groups in which checkpoint blockade therapy has been both effective and ineffective.  
It is likely that immunotherapies can succeed in MSS CRC once the factors that 
determine immune infiltration are better understood, and once existing and emerging 
immunotherapies are targeted appropriately and are used in intelligent combinations.  
The future of immunotherapy in CRC and other cancers will likely involve the use of 
synergistic combinations of immunotherapies, such as combination checkpoint 
blockade, or vaccination in low immune profile patients followed by checkpoint 
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blockade.  In addition, it is likely that immunotherapies will increasingly be combined 
with other therapy types including targeted therapies, chemotherapy, radiotherapy 
and surgery.  Several such combinations are being investigated in studies worldwide 
[20].  My work has provided strong indications as to how immunotherapies should be 




Appendix. Association of immunity in paired CRC biopsy and resection 
specimens 
 
In a window-of-opportunity clinical trial, patients may be given a drug or intervention 
between the time of cancer diagnosis (biopsy) and surgical resection.  To investigate 
how immunity within colonic tumour biopsies (obtained endoscopically) correlates 
with immunity in full colonic surgical resection samples, resected several days after 
the biopsy, I collected FFPE sections from 15 CRC biopsy/resection pairs.  IHC 
staining revealed relatively weak correlations between CD8, STAT1 and PD-L1 
protein expression in the biopsies and resections.  In epithelium, Spearman 
correlations were 0.369 (p=0.175) and -0.322 (p=0.243) for CD8 and STAT1 
respectively.  All biopsy sections were negative for PD-L1 in epithelium.  In stroma, 
Spearman correlations were 0.316 (p=0.251), -0.018 (p= 0.952) and 0.261 (p= 
0.347), for CD8, STAT1 and PD-L1 respectively.  Though analysis of further samples 
is required to confirm this finding, if confirmed this potentially has significant 
implications for the design of windows-of-opportunity studies.   In such a study, 
biological differences between the biopsy and the resection sample may be 
measured to determine the effect of a drug or intervention on the tumour 
microenvironment.  However, this result suggests that biopsy and resection sample 
immune infiltrations are not closely correlated, which would need to be considered in 
a window study design.  It is possible that immune infiltration changes during the 
period between biopsy and resection, leading to potential bias according to when the 
resection occurs.  Furthermore, heterogeneity in different areas of the tumour could 
lead to sampling bias depending on which areas of the biopsy and resection are 
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analysed.  However, despite this, this study design may be useful if an intervention or 
drug has a substantial impact on the microenvironment of the resection sample, 







All work in this thesis was my own other than:  
Initial confirmation of EPCR expression on CRC cell lines (Carrie Willcox). 
Confirmation of EPCR expression on mast cells (Peter Bradding and Aarti Shikotra). 
Validation of Class II HLA and CXCL10 antibody (Ghaleb Goussous). 
 
In addition, the neoantigen studies were in collaboration with Sebastian Boegel, who 
performed the neoantigen prediction.  The CMS grouping studies were in 
collaboration with Justin Guinney, who performed the statistical analyses on the 
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